Document:

EX-10.23

 Exhibit 10.23 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 MASTER
SERVICES AGREEMENT 
 This MASTER SERVICES AGREEMENT (the
“Agreement”) is entered into effective as of March 2, 2009 (“Effective Date”) by and between SVTC TECHNOLOGIES, LLC, a Delaware limited liability company, with
principal offices at 3901 North First Street, San Jose, CA 95134, USA, (“SVTC”) and BioNanomatrix, Inc., a Delaware Corporation, with principal offices located at 3701 Market St, 4th Floor, Philadelphia, Pennsylvania 19104, USA
(“Customer”). 
 RECITALS 

WHEREAS, SVTC including its facilities located in San Jose, CA and Austin, TX, own and operate semiconductor manufacturing, research and
development facilities, offers semiconductor-process engineering development and related services, and also licenses related intellectual property; and, 

WHEREAS, Customer desires to engage SVTC to provide certain of the above services or to licenses SVTC intellectual property, 

NOW THEREFORE, for valuable consideration, the parties hereby agree as follows: 

 

	 	1.	DEFINITIONS 

1.1    “Affiliate” shall mean any entity that controls, is controlled by or is
under common control with SVTC or Customer. For purposes of this definition, “control” shall mean beneficial ownership of (i) more than fifty percent (50%) of the shares of the subject entity entitled to vote in the election of
directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority); or (ii) such lesser percentage as is the maximum control or ownership right permitted in the country where
the subject entity exists. A “Wholly Owned Affiliate” shall mean an entity that is at least eighty percent (80%) controlled by a party to this Agreement. 

1.2    “Confidential Information” shall mean information that is disclosed
between the parties under this Agreement conspicuously marked or confirmed in writing if oral, that the disclosure is confidential, including the disclosure of any Technology, intellectual property or other documentation or any product plans,
business, financial or personnel information. “Confidential Information” shall not include information which: (i) is publicly disclosed by the receiving party with the prior written approval of the disclosing party; (ii) is
independently developed by the receiving party without use of the disclosing party’s Confidential Information; (iii) is intentionally disclosed by the disclosing party to a third party without restriction on disclosure; (iv) is
rightfully received by the receiving party from a third party without a duty of confidentiality; or (v) is disclosed pursuant to any judicial or governmental order, provided that the receiving party gives the disclosing party sufficient prior
written notice to contest such order. 
 1.3    “Customer
Personnel” shall mean all employees, contractors, agents and any others brought onto SVTC premises by or at the behest of Customer, who are therefore subject to provisions of this Agreement. 

1.4    “Intellectual Property Rights” shall mean those rights emanating from
forms of intellectual property as defined by applicable laws including any or all of the following and all rights in, arising out of, or associated therewith: (i) all patent rights and all reissues, renewals,
re-examinations, continuations, continuations in part, divisions and extensions thereof or foreign counterparts thereto, and all applications for any of the foregoing; (ii) all trade secrets and
other rights in know-how and confidential or proprietary information; (iii) all copyrights, copyrights registrations and related applications and all other rights in or to works of authorship
corresponding thereto throughout the world; (iv) all mask works, mask work registrations and applications, and any equivalent or similar rights in semiconductor masks, layouts, architectures or topology; (v) all trademarks, service marks,
trade names, service names, trade dress, domain names and similar rights; and (vi) any corresponding or equivalent rights to any of the foregoing now known or hereafter recognized anywhere in the world. 

  
 

 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 1.5     “Line” or
“Pilot Line” shall mean semiconductor wafer processing facilities, which also may be referred to as the “fab” or “foundry” and that are operated by SVTC. 

1.6    “Start Date” shall mean the mutually agreed date that SVTC will begin
providing services under this Agreement and the attached Schedules. 

1.7    “Schedule” means one or more documents attached to this Agreement,
spelling out the details of Customer projects and the specific terms and conditions that will apply to the provision of SVTC services for those projects; exhibits may be attached to Schedules. By way of example, A “Statement of Work” or
“Scope of Work” or “SOW” may be attached. 
 1.8    “SVTC
Personnel” shall mean all employees, contractors or agents of SVTC. 

1.9    “Technology” means embodiments of Intellectual Property Rights,
whether in electronic, written or other media, including technical documentation, specifications, designs, bills of material, build instructions, test reports, schematics, algorithms, user interfaces, routines, formulae, process libraries or recipe
books, test vectors, IP cores, net lists, photomasks, reticles, databases, lab notebooks, processes, prototypes, samples, studies, wafers, chips, know-how, or other works of authorship. 

1.10    “Term” means the period commencing on the Effective Date and ending
on the date that this Agreement expires or is terminated. 
  

	 	2.	SERVICES AND SUPPORT 

 2.1    Services. SVTC will
provide Customer the services described in Schedules and other attachments to this Agreement, which are incorporated by reference. In the event of a conflict between the terms and conditions of any attachment and this Agreement, the terms and
conditions of this Agreement shall govern unless explicitly superseded in such attachment. 
 2.2    Premises
Support for Customer Personnel. Customer may request support or facilities for Customer Personnel on SVTC premises such as that provided to Resident Partner customers, as defined and described in applicable attachments. Unless agreed in writing
otherwise, SVTC shall not make available for Customer, clerical, administrative or infrastructure support or any physical space on its premises. 

2.3    Equipment. Except as otherwise set forth herein or in a Schedule, as between the parties, SVTC will
own all equipment in the fab or elsewhere on SVTC’s premises and Customer will acquire no rights or interest in or to any equipment at SVTC premises as a result of this Agreement. If it is agreed in an attachment that Customer may bring
equipment into the fab or elsewhere on SVTC premises, whether to be operated by SVTC or by Customer, such equipment must be pre-approved by SVTC, is subject to being located or relocated during the term of
this Agreement if required by SVTC, and must be promptly removed on the termination of this Agreement. Customer shall have no right to any particular space on the premises and the space that is assigned may expand or contract as required or as
mutually agreed for specific projects pursuant to this Agreement. 
 2.4    Legal Status While On
Premises. The legal status of Customer Personnel while on SVTC premises is that of an invitee. In the event that any individual who is an employee of Customer, or anyone else who is on the SVTC premises at the invitation of Customer, fails
to comply with the safety, security, confidentiality, or other applicable conditions in this Agreement, its attachments, or in other mutually agreed documents, then SVTC may order such individuals off the premises and their continued presence will
be considered that of a trespasser. 
 2.5    Wafer/Silicon Reclamation and Recycling. SVTC supports the
reclamation and recycling of discarded wafers and scrap silicon. If applicable to Customer, it is acknowledged that if any is not removed by Customer, it will be destroyed, reclaimed, or recycled at SVTC’s sole discretion. 

  
 

 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 2.6    Hazardous Materials. No hazardous or toxic materials
may be brought onto SVTC premises without SVTC’s prior written consent. All materials to be used in the fab, whether or not toxic or otherwise hazardous, must be pre-approved by SVTC. 

 

	 	3.	CUSTOMER PAYMENT ARRANGEMENTS 

 3.1    Fees and Costs.
All information on prices, fees, and costs to be paid by Customer shall be listed in attached Schedule[s]. Unless otherwise specifically stated in the applicable Schedule, the payment terms shall be as described below in Section 3.4. 

3.2    Taxes. All fees stated herein or otherwise provided by SVTC pursuant to this Agreement are exclusive
of taxes. Customer shall be responsible for and shall pay any applicable sales, use, excise, withholding or similar taxes, including value added taxes (VAT) and customs duties, that may be due for the provision of services and licenses under
this Agreement, or for the purchase of wafers or other deliverables hereunder, excluding any taxes based on SVTC’s net income. Customer will make all payments hereunder free and clear of, and without reduction for, any withholding taxes; any
such taxes imposed on payments of the fees to SVTC will be Customer’s sole responsibility. Customer will provide SVTC with official receipts issued by the appropriate taxing authority, or such other evidence as SVTC may reasonably request,
to establish that such taxes have been paid. No tax shall be billed to Customer if Customer provides SVTC with either (i) an exemption certificate provided in good faith and in accordance with applicable law, or (ii) a direct pay
permit number provided in accordance with applicable law. 
 3.3    Extraordinary Expenses. To the extent
that Customer intends to use raw materials that are different or more expensive than those used by SVTC, or to take any other action that it or SVTC expects (or should expect in the exercise of prudent technical and commercial judgment) will
increase expenses above those in the normal course (any expense so incurred, an “Extraordinary Expense”), SVTC will invoice Customer in accordance with Section 3.4 or as otherwise specified in the applicable Schedule.
Extraordinary Expenses will not be incurred without the prior written approval of Customer, and no activities that might result in such Extraordinary Expenses will be conducted by SVTC absent Customer’s agreement to bear such Extraordinary
Expenses. 
 3.4    Payment Terms. 

(a)    Customer will be invoiced monthly for all services and deliverables provided by SVTC during the previous month. All
other payments required hereunder shall be invoiced on a monthly basis at the beginning of each calendar month and shall be paid within [...***...]. Each SVTC invoice hereunder shall be accompanied by a detailed report containing supporting
information, as Customer may reasonably request, used to determine the amounts due hereunder. 
 (b)    Except as may
be agreed otherwise in writing, all payments due to SVTC under this Agreement shall be made by bank wire transfer to a designated bank account. All payments shall be made in U.S. dollars unless otherwise agreed by the parties. If any payments
are more than [...***...] late, Customer will pay SVTC, in addition to any other remedies that may be available to SVTC, a late payment of the lower of [...***...] per month or the highest rate allowed by law for all past due amounts
until paid. 
  

	 	4.	INTELLECTUAL PROPERTY RIGHTS 

 4.1    Joint
Development. Unless otherwise expressly set forth in a Schedule attached hereto, SVTC and Customer do not plan any joint development at the time of this Agreement. Any joint development activities intended by the parties must be agreed to in
writing and ownership of any resulting Technology and Intellectual Property Rights shall be as set forth therein. If Technology and Intellectual Property Rights are created or invented jointly, unless expressly agreed in writing otherwise, such
Technology and Intellectual Property Rights shall be jointly owned in accordance with US intellectual property laws but without any right of accounting, except that it is agreed that any jointly created patent improvements or copyright derivatives
shall be assigned to the owner of the underlying Technology. 

  
 

 
 ***Confidential Treatment Requested 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 4.2    New Technology and Related Intellectual Property
Rights. Any Technology and related Intellectual Property Rights, invented, created, or authored solely or independently by either party shall be owned by that party, except that it is agreed that all rights in any patent improvements or
copyright derivatives to the other party’s Technology shall be assigned to the other party subject to a license back for use solely in connection with the purposes of this Agreement. The creating party agrees to promptly notify the other party
and to cooperate in any government filings undertaken. 

4.3    Pre-existing Technology and Ownership. Any Technology and any
related Intellectual Property Rights, pre-existing this Agreement shall stay with the owning party and is no ownership rights are assigned or otherwise transferred by this Agreement, save and except for
license rights granted by each party to the other necessary to perform the obligations of this Agreement or as otherwise provided in section 5, below. For purposes of clarity, SVTC agrees that the chip design, composition, layout, topology,
fabrication process flow, process selection and material selection described in Exhibit D is Customer Technology and all related Intellectual Property is the property of the Customer. 

4.4    Trade Secrecy. SVTC shall treat all knowledge of Customer’s projects and development work
pursuant to this Agreement, including by way of example process flows and recipes, whether or not subject to protection under other intellectual property laws, as Customer’s trade secrets subject to the confidentiality provisions of section 10,
below, and/or other agreements between the parties; SVTC agrees to scrupulously prevent other customers of SVTC or third parties from gaining knowledge of such Customer trade secrets. 

4.5    Intellectual Property Prosecution. To avoid a flawed prosecution, Customer agrees that if it decides
to file for a patent or to otherwise perfect ownership through any other government registration for Technology created pursuant to the performance of this Agreement that is related to or is an improvement of SVTC Technology, Customer
agrees to notify SVTC before filing to confirm whether the subject matter of the intended filing has not previously become part of SVTC’s intellectual property program or whether it has been previously disclosed by SVTC to other customers or is
already intellectual property owned by others. 
  

	 	5.	LICENSES 

 5.1    License from Customer. Customer
grants no rights to SVTC except for a non-exclusive, non-transferable, royalty-free license under Customer’s applicable Intellectual Property Rights, to use any of Customer’s Technology,
products or processes as necessary for SVTC to provide the services requested by Customer pursuant to this Agreement, for the purposes of this Agreement. 

5.2    License from SVTC. Subject to the terms and conditions of this Agreement, SVTC grants Customer a
non-exclusive, perpetual, irrevocable, royalty free and paid up right and license, under all applicable SVTC Intellectual Property Rights (including any Technology developed by SVTC pursuant to activities under this Agreement) (the
“Licensed Technology”) for the manufacture of Customer’s products (including any unique equipment configurations and modifications used therein and any unique semiconductor or integrated circuit structures resulting from
such modules). Subject to the terms and conditions set forth herein, such right and license shall include (i) the right to have Customer products made by third party manufacturers, and (ii) the right to sublicense such rights to third
parties solely as a part of a license to such party for the manufacture of a Customer product. 
 5.3    No
Other Rights. Except as expressly provided in this Section or the applicable Schedule, neither party grants to the other party any license, right, title or interest in or to any Intellectual Property Rights or Technology, whether by implication,
estoppel or otherwise. All rights not specifically granted herein are reserved by the Party owning the respective Technology and Intellectual Property Rights. 
  

	 	6.	INDEMNIFICATION 

 6.1    SVTC Indemnification
Obligations. SVTC shall defend, indemnify, and hold Customer harmless from 

  
 

 
 ***Confidential Treatment Requested 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 
and against any claim of liability, loss, damage, cost or expense (including reasonable attorneys’ fees and other legal expenses) (collectively, “Losses”)
resulting from any third party claim that (i) is based upon any act or omission of SVTC or any SVTC Personnel, (ii) based upon any material breach by SVTC of any obligation imposed by this Agreement (iii) use of Customer
equipment by SVTC Personnel or (iv) Licensed Technology infringes or misappropriates the Intellectual Property Rights of any third party. This indemnity shall not apply to the extent that any such claim is based upon (i) modification
to the Licensed Technology made by or on behalf of Customer, (ii) Customer’s use of the Licensed Technology outside of the scope of the license granted pursuant to this Agreement, or (iii) a claim that is subject to Customer’s
indemnification obligations pursuant to Section 7.2. SVTC’s obligation under this paragraph shall expire as to any claim that Customer has not provided written notification of to SVTC within one year after receipt by Customer or becomes
known by Customer. 
 6.2    Customer Indemnification Obligations. Customer shall defend, indemnify, and
hold SVTC or any Affiliate of SVTC harmless from and against any Losses (as defined in the preceding paragraph) resulting from any third party claim (i) that any Customer Personnel is an employee of SVTC (such Losses including any employee
benefit that any such person claims to be entitled to from SVTC as an employee of SVTC), (ii) based upon any act or omission of any Customer Personnel (such Losses including but not limited to any fire or other catastrophic loss to the Line or any
significant portion of the Line that is attributable to any such act or omission), (iii) based upon any breach by Customer or any Customer Personnel of any obligation imposed by this Agreement, (iv) relating to Customer equipment in the
event that customer equipment fails to perform as designed, (v) relating to Customer’s implementation or use of Customer’s Technology at the SVTC premises, including claims related to bodily injury, damage or loss of tangible
property, and (vi) that Customer equipment, Customer processes or Customer Technology infringes or misappropriates the Intellectual Property Rights of any third party. Customer shall not be obligated to defend, indemnify, or hold SVTC harmless
to the extent that any such claim is based upon a modification to the Customer equipment or Customer’s Technology made by SVTC, if such modification was not made at the instruction or on behalf of Customer. Customer’s obligation under this
paragraph shall expire as to any claim that SVTC has not provided written notification of to Customer within one year after receipt by SVTC or becomes known by SVTC. 

6.3    Procedure. Each party seeking indemnification under this Section 6 (i) agrees to provide the
indemnifying party prompt written notice of an indemnifiable claim, (ii) agrees to provide control of the defense or settlement of such claim to the indemnifying Party, provided that the indemnifying party shall not settle or compromise a claim
in a manner that does not unconditionally release the indemnified party from liability and that does not adversely affect the Intellectual Property Rights owned by the indemnified party unless the indemnifying party obtains the indemnified
party’s prior written consent; and (iii) agrees to provide assistance in the defense or settlement of a claim at the indemnifying Party’s request and reasonable expense. 

6.4    Insurance. During the term of this Agreement, each party will, for its respective liability, secure
and maintain a comprehensive general liability insurance policy providing sufficient coverage for personal injury (including as a result of product liability) and property damage, at the level as is usual and customary in the industry to
procure, provided, that in the event that Customer Personnel is actually working on the Line and using SVTC equipment, then such insurance shall be in accordance with Exhibit C. 

 

	 	7.	REPRESENTATIONS AND WARRANTIES 

 7.1    SVTC Limited
Warranties. SVTC represents and warrants that (i) SVTC has the full right and authority to enter into this Agreement and grant the rights and licenses granted herein; (ii) SVTC has not previously granted and will not grant any rights
that prevent SVTC from fulfilling its obligations under this Agreement; and (iii) SVTC will comply with all applicable laws and regulations in connection with its performance under this Agreement. SVTC warrants that it will use commercially
reasonable efforts to provide the services contracted for in this Agreement. Due to the research and development nature of the services to be provided, and in particular, any services that are novel or unprecedented, no warranty is offered or made
that all services performed by SVTC 

  
 

 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 
will be successful or that the goals of the Customer will be achieved. 

7.2    Customer Limited Warranties. Customer represents and warrants that (i) Customer has the full
right and authority to enter into this Agreement and grant the rights and licenses granted herein; (ii) Customer has not previously granted and will not grant any rights that prevent Customer from fulfilling its obligations under this
Agreement; and (iii) Customer will comply with all applicable laws and regulations in connection with its performance under this Agreement. Customer warrants that it has fully disclosed information to SVTC in advance regarding any hazardous or
toxic materials. Customer further warrants that none of the wafers or other materials processed by SVTC will be used in or on human subjects, experimental or otherwise, without SVTC’s prior written consent. 

7.3    Disclaimer of Warranties. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT OR IN A SCHEDULE ATTACHED
HERETO, SVTC AND CUSTOMER EACH EXPRESSLY DISCLAIM ANY AND ALL REPRESENTATIONS, WARRANTIES OR CONDITIONS, RELATING TO ANY TECHNOLOGY OR SERVICES PROVIDED UNDER THIS AGREEMENT, WHETHER EXPRESS, IMPLIED, OR STATUTORY, INCLUDING ANY WARRANTIES OF TITLE,
NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
  

	 	8.	LIMITATION ON LIABILITY 

 8.1    Damages Waiver. EXCEPT
FOR THE BREACH OF A CONFIDENTIALITY OBLIGATION, AND EXCEPT FOR AN INDEMNIFICATION OBLIGATION UNDER THIS AGREEMENT, AND EXCEPT FOR MISCONDUCT OR NEGLIGENT ACTS OF CUSTOMER PERSONNEL THAT INTERFERE WITH THE NORMAL OPERATIONS OF THE FAB, IN NO EVENT
SHALL EITHER PARTY BE LIABLE TO THE OTHER, OR TO ANY THIRD PARTY CLAIMING THROUGH OR UNDER SUCH PARTY, FOR ANY LOST PROFITS, LOSS OF DATA, EQUIPMENT DOWNTIME OR FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN ADVISED
OF THE POSSIBILITY THEREOF. 
 8.2    Liability Cap. EXCEPT FOR CLAIMS BASED ON BREACHES OF A
CONFIDENTIALITY OBLIGATION, AND EXCEPT FOR AN INDEMNIFICATION OBLIGATION UNDER THIS AGREEMENT, , AND EXCEPT FOR MISCONDUCT OR NEGLIGENT ACTS OF CUSTOMER PERSONNEL THAT INTERFERE WITH THE NORMAL OPERATIONS OF THE FAB, IN THE EVENT THAT ANY LIABILITY
IS IMPOSED ON EITHER PARTY HEREUNDER, THE AGGREGATE AMOUNTS PAYABLE BY EITHER PARTY TO THE OTHER BY REASON THEREOF SHALL NOT EXCEED THE AMOUNT PAID OR PAYABLE BY CUSTOMER TO SVTC DURING THE TWELVE (12) MONTHS PRECEDING THE CLAIM TO WHICH SUCH
LIABILITY RELATES. 
 8.3    Acknowledgement. Each party acknowledges that the foregoing limitations are
an essential element of the Agreement between the parties and that in the absence of such limitations the pricing and other terms set forth in this Agreement would be substantially different. Customer acknowledges that the risk of its acts may
interfere with the normal operations of the Line and that it has been advised to exercise special caution in its activities in the fab. 
  

	 	9.	CONFIDENTIALITY 

 9.1    Obligations. All Confidential
Information exchanged between the parties pursuant to this Agreement shall not be disclosed by the recipient to anyone except its own employees, consultants or subcontractors or those of its Affiliates, who have a need to know such Confidential
Information consistent with the purposes of this Agreement and who have been advised of the confidential nature and who have been contractually obligated to observe the terms and conditions hereof; nor shall Confidential Information be used by the
receiving party for any purpose other than exercising its rights or fulfilling its obligations under this Agreement. Parties shall not disclose confidential information of third parties without the owner’s prior consent. Parties shall at all
times and notwithstanding any termination or expiration of this Agreement hold received Confidential Information in strict 
  

  
 

 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 
confidence with at least the degree of care it uses for its own confidential information and with not less than a legally reasonable degree of care. Recipient’s obligations to maintain
confidentiality shall survive termination of the Agreement and shall be binding upon the Recipient’s heirs, successors and assigns. Upon request of the disclosing party, copies and embodiments of the disclosing party’s Confidential
Information shall be promptly returned to the disclosing party by the receiving party, unless such copies are required to fulfill the terms of this Agreement. Upon termination of this Agreement for any reason, each party shall promptly return to the
other party all Confidential Information provided by the other party, including all copies, except that a receiving party may keep one copy solely for archival purposes. If either party becomes an unauthorized disclosure, even if not confirmed,
it shall promptly notify the original disclosing party and promptly take reasonable actions to mitigate the effects of the unauthorized disclosure. 

9.2    Independent Development. The disclosing party acknowledges that the receiving party may currently or
in the future be developing information internally, or receiving information from other parties, that is similar to provided Confidential Information. Nothing in this Agreement will prohibit the receiving party from developing or having developed
for it products, concepts, systems or techniques that are similar to or compete with the products, concepts, systems or techniques contemplated by or embodied in the Confidential Information, provided that no Confidential Information is referenced,
accessed or used and the receiving party does not violate its obligations under this Agreement. Parties shall have no obligation to limit or restrict the assignment of its employees or consultants as a result of their having had access to
Confidential Information. 
 9.3    Terms of Agreement; Publicity. Parties shall not to disclose to any
third party the financial terms of this Agreement without the prior written consent of the other party, except to its advisors, independent accountants, investors and others on a
need-to-know basis under circumstances that reasonably ensure confidentiality, or to the extent required by law. Any press release relating to this Agreement that is
issued by one party and which mentions the other party shall be jointly released and mutually agreed upon by the parties or, if released by one party, approved by the other party. Notwithstanding the foregoing, SVTC may disclose that Customer
is a customer of SVTC and Customer may disclose that it is a customer of SVTC. Notwithstanding the foregoing, either party may disclose the terms of this Agreement to existing or potential acquirers or merger candidates; investment
bankers, existing or potential investors, venture capital firms or other financial institutions or investors solely for purposes of obtaining financing, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use no less stringent than those set forth in this Agreement. 
  

	 	10.	NON-SOLICITATION 

10.1    Non-solicitation. During the term of this Agreement and for
one (1) year after expiration or termination of this Agreement, neither party shall, directly or indirectly, without the prior written consent of the other party solicit, encourage, or take any other action which is intended to induce or
encourage, any employee of the other party to terminate his or her employment with the other party. Customer shall not directly or indirectly, without prior written consent of the other SVTC customer solicit, encourage, or take any other action that
is intended to induce or encourage, any employee of another customer working on the SVTC premises to terminate his or her employment with the other customer. 
  

	 	11.	TERM AND TERMINATION 

 11.1    Initial Term. Unless
terminated earlier pursuant to the terms and conditions of this Agreement, this Agreement shall commence on the Effective Date and shall remain in force for two (2) year(s) from the Start Date. The Agreement will automatically renew thereafter
for additional one (1) year terms, unless either party notifies the other party in writing at least thirty (30) days prior to the expiration of the then-current term of its intent not to renew the Agreement for any further additional term.

  

	 	11.2	 Early Termination 

 (a) Customer may terminate this Agreement or any Schedule after
the Start Date upon giving SVTC at least 

  
 

 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 
thirty (30) days written notice. At the same time as giving notice of termination for convenience, SVTC shall invoice and Customer shall make a
non-refundable payment to SVTC for all Services provided under this proposal up to and including the date of final termination net 30. 

(b) Either party may terminate this Agreement upon written notice as set forth in Section 12.4 below in the event of a Force Majeure
event. 
 11.3    Termination for Breach. Either party to this Agreement may terminate this Agreement in
the event the other Party materially breaches this Agreement and does not cure such breach within thirty (30) days after written notice thereof by the non-breaching party. 

11.4    Customer Equipment and Personnel. If applicable, then no later than the date of termination or
expiration of this Agreement, Customer shall remove all of its equipment and shall cause all Customer Personnel to have removed all of their personal property from the SVTC premises. After that date, no such persons shall have any right to
access the SVTC premises, except such reasonable access as SVTC and Customer shall agree in advance in writing in furtherance of the purposes hereof. Unless otherwise agreed, access badges and passwords will be disabled on the date of
termination or expiration of this Agreement. 
 11.5    Survival; Effect of Termination. Sections 1, 4,
5.2 (unless Customer materially breachs an obligation under this Agreement), 6, 7, 8, 9, 10 (for one year following expiration or termination of the Agreement), 11.5 and 12 shall survive any termination or expiration of this Agreement. Except
for purposes of exercising continuing license rights hereunder, upon termination or expiration of this Agreement, each party shall return or destroy any Confidential Information of the other party then in its possession. 

 

	 	12.	MISCELLANEOUS 

 12.1    Governing Law. The rights and
obligations of the parties under this Agreement shall not be governed by the provisions of the 1980 United Nations Convention on Contracts for the International Sale of Goods or the United Nations Convention on the Limitation Period in the
International Sale of Goods, as amended. This Agreement and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, without reference to
conflicts of laws provisions. 
 12.2    Assignment. This Agreement shall not be assigned by either party,
whether voluntarily or involuntarily or by operation of law, in whole or in part, to any other entity without the prior written consent of the other party, which consent shall not unreasonably be withheld, conditioned or delayed. Notwithstanding the
foregoing, either party may assign this Agreement to an Affiliate, without the other’s prior consent, subject to providing written notice of such assignment. Further, upon written notice to the other party, either party may assign this
Agreement to a successor in interest, upon a merger, acquisition, reorganization, change of control, or sale of all or virtually all of the assets of the assigning party, and any such assignment shall not require the consent of the non-assigning party. Any assignment in violation of this Section 13.3 shall be null and void from the beginning, and shall be deemed a material breach of this Agreement. 

12.4    Force Majeure. Neither party shall be liable to the other in any way whatsoever for any failure or
delay in performance of any of the obligations under this Agreement (other than obligations to make payment), arising out of any event or circumstance beyond the reasonable control of such party (including, war, rebellion, civil commotion,
strikes, lock-outs or industrial disputes; fire, explosion, earthquake, acts of God, flood, drought or bad weather; the unavailability of deliveries, supplies, software, disks or other media or the requisitioning or other act or order by any
government department, council or other constituted body). If either party’s performance is prevented by a force majeure event for a period of more than forty-five (45) days, the other party may terminate this Agreement without
further obligation or liability, subject to any payment amounts due and payable immediately prior to the commencement of such force majeure event. 

  
 

 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 12.5    Compliance with Law. In performing its duties under
this Agreement, each party shall at all times comply with all applicable international, federal, state and local laws and shall not engage in any illegal or unethical practices. Without limiting any of the foregoing, each party agrees to comply with
all applicable US and foreign export control laws and regulations. 
 12.6    Waiver. Failure or neglect
by either party to enforce at any time any of the provisions hereof shall not be construed nor shall be deemed to be a waiver of such party’s rights hereunder nor affect the validity of the whole or any part of this Agreement nor prejudice such
party’s rights to take subsequent action. 
 12.7    Independent Contractors. It is agreed and
understood that neither party is the agent, representative or partner of the other and neither has the authority or power to bind or contract in the name of or to create any liability against the other party in any way or for any purpose. It is
understood that each party is an independent contractor. Each party expressly reserves the right to enter other similar agreements with other parties on the same or on different terms. 

12.8    Notices. All notices, requests and other communications hereunder shall be in writing and shall be
(a) personally delivered or (b) sent by facsimile and registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to
the other party hereto: 
  

					
		 	To SVTC:	  	
			
		 		  	SVTC, LLC
		 		  	3901 North First Street
		 		  	San Jose, CA 95134
		 		  	Attn: [...***...]
		 		  	cc: Legal Department
			
		 	To Customer:                	  	
			
		 		  	BioNanomatrix, Inc.
		 		  	3701 Market St, 4th Floor
		 		  	Philadelphia, PA 19104
		 		  	Attn: Michael Boyce-Jacino, President and CEO

 Notices shall be deemed received on the earlier of the following: (i) notices delivered by hand or sent by fax shall
be deemed received the first business day following such delivery or sending; and (ii) notices which have been posted or sent via courier shall be deemed received on the date of the courier’s delivery receipt. 

12.9    Modification. No amendment or modification of any provision of this Agreement shall be effective
unless in writing signed by both parties hereto. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and
signed by both parties. 
 12.10    Severability. In the event that any clause, sub-clause or other provision contained in this Agreement shall be determined by any competent authority to be invalid, unlawful or unenforceable to any extent, such clause,
sub-clause or other provision shall to that extent be severed from the remaining clauses and provisions, or the remaining part of the clause in question, which shall continue to be valid and enforceable to the
fullest extent permitted by law. 

  
 

 
 ***Confidential Treatment Requested 

			
	

	 	 BioNanomatrix

MSA462393-001

  

 
  

 12.11    Headings; Construction. The headings to the
clauses, sub-clause and parts of this Agreement are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement. The terms
“this Agreement,” “hereof,” “hereunder” and any similar expressions refer to this Agreement and not to any particular Section or other portion hereof. The Parties hereto agree that any rule of construction to the effect
that ambiguities are to be resolved against the drafting Party will not be applied in the construction or interpretation of this Agreement. As used in this Agreement, the words “include” and “including,” and variations thereof,
will be deemed to be followed by the words “without limitation.” 
 12.12    Counterparts. This
Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 

12.13    Entire Agreement. This Agreement, together with the Schedules and any exhibits attached to the
Schedules, listed below, all of which are hereby incorporated into this Agreement by reference, supersedes any arrangements, understandings, promises or agreements made or existing between the parties hereto prior to or simultaneously with this
Agreement and constitutes the entire understanding between the parties hereto. It is acknowledged that the terms of this Agreement have been negotiated between the parties. 

LIST OF ATTACHMENTS. Following is a list of attachments to this Agreement, including all Schedules and Exhibits. Each future added attachment must
include a dated Amendment cover page or provision referencing this Agreement and must be executed by all parties. 
 Customer Managed Project Services
Schedule 
 Exhibit A - Proposal 
 Exhibit B - Equipment List

 Exhibit C — Insurance Requirements 
 Exhibit D —
[...***...] — deliverables, timeline, details and specifications quoted are goals only and not binding on SVTC. Actual project work will be as specified in Exhibit A. 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered in duplicate originals as of the date first above written.

  

									
		 	SVTC Technologies, Inc.	 		 		 	BioNanomatrix, Inc.
					
	Signature:	 	 /s/ Jon Myers
	 		 	Signature:	 	 /s/ Michael Boyce-Jacino

	Printed Name:	 	Jon Myers	 		 	Printed Name:	 	Michael Boyce-Jacino
	Title:	 	Vice President, Global Sales	 		 	Title:	 	President & CEO
	Date:	 	February 19, 2009	 		 	Date:	 	March 23, 2009

  
 

 
 ***Confidential Treatment Requested 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

 CUSTOMER MANAGED PROJECT SERVICES SCHEDULE 

This Customer Managed Project Services Schedule (the “Schedule”) is entered into effective as of March
    , 2009 (“Effective Date”) between SVTC TECHNOLOGIES, LLC, and BioNanomatrix, Inc., (“Customer”) as an attachment to the Master Services
Agreement (“Agreement”), between the parties, dated March 2, 2009. Capitalized terms used but not defined herein have the meanings ascribed to them in the Agreement. All terms and conditions in this Schedule are in addition
to the terms and conditions set forth in the Agreement. In the event of any conflict between the provisions of this Schedule and the Agreement, the Agreement shall govern unless explicitly superseded in this Schedule. 

Customer desires access to the fab and other premises of SVTC in connection with the provision of services. Customer Personnel
may operate SVTC equipment and have other capabilities as provided in this Schedule. 
  

	1.	DEFINITIONS 

  

	 	1.1	 “Activity” or “Move” shall mean one wafer going through
one semiconductor wafer production process step as delineated by SVTC in its normal operating practice. A semiconductor wafer production process step constitutes the actions performed and processes, procedures or associated equipment used in a
single physical transformation of a wafer or one or more layers thereon, including: (i) [...***...] (ii) [...***...] (iii) [...***...] (iv) [...***...] (v) [...***...]; and (vi) [...***...]. 

 

	 	1.2	 “Activity Allocation” shall mean the allocation of Activities set forth in
Exhibit A attached hereto. 

  

	 	1.3	 “Customer Equipment” shall mean any equipment on the Line owned or installed by
Customer and shall include any upgrades thereto. 

  

	 	1.4	 “Engineering Services” means services performed by SVTC’s personnel,
agents or subcontractors. 

  

	 	1.5	 “Minimum Batch Size” shall mean the minimum total number of wafers in a Process
Batch. 

  

	 	1.6	 “Moves per Inventory” or “M/I” is defined as the
activities generated in a given day divided by the average Work In Progress (“WIP”) that is not on hold for engineering development or on problem lot for engineering evaluation. 

 

	 	1.7	 “Non-Hold WIP” shall mean semiconductor
wafers that can be processed and are not subject to any move restrictions by Customer. The current standard procedure for calculating Non-Hold WIP is as follows: 

 

			
	Daily Required Non-Hold WIP =	 	 [...***...]

	 	  
 [...***...]

 1.8 “Product” means a wafer manufactured by SVTC for Customer hereunder prior
to qualification by Customer per Customer’s qualification specifications, excluding all Prototypes. 

  
 

 
 ***Confidential Treatment Requested 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

	 	1.9	 “Prototype” means prototypes of Products provided to Customer by SVTC.

  

	 	1.10	 “Problem Lot” means a Process Batch that is not moveable due to unforeseen
issues that must be resolved by engineering. 

  

	 	1.11	 “Process Lot” or “Process Batch” shall mean a group of
wafers that are processed together as a group. 

  

	 	1.12	 “Production Product” means products or wafers ordered by Customer after
qualification and issuance of a prototype approval by Customer. 

  

	 	1.13	 “Standard Operating Procedure” or “SOP” shall mean
SVTC’s then current standard administrative operating procedure, including the standard operating manual, specifications, and other applicable documentation,. . SVTC may update the SOP from time to time in its sole discretion.

  

	 	1.14	 “Start-Up Costs” shall have the meaning
set forth in Exhibit A and which may include a separate “Library Access Fees” for the applicable process libraries. 

  

	 	1.15	 “Wafer Starts” shall mean the number of new wafers that will be allowed.

  

	2.	PROCESS OPERATIONS 

  

	 	2.1	 Activity Allocation to Customer. 

2.1.1    SVTC will allocate Wafer Starts on a weekly basis and review and assign Activities on a
daily basis, and shall provide the detail of its Activity Allocation in accordance with the process described in Exhibit A attached hereto. 

2.1.2    Subject to the terms and conditions set forth herein, the allocation of Activities to
Customer will be made by SVTC in its sole discretion and in accordance with SVTC’s SOP for the allocation of Activities among SVTC’s Customers, provided, that allocation of Activities to Customer for a specific period of time shall
not be less than the amount provided for such period in Exhibit A unless agreed to by Customer. 

2.1.3    Customer will have the responsibility for maintaining Customer’s Non-Hold WIP at levels defined by SVTC to ensure that it receives its Activity Allocation. SVTC will not be held accountable for Activity Allocations missed by Customer if Customer does not maintain the Non-Hold WIP level required by SVTC. The current standard procedure for calculating Non-Hold WIP is as set forth in this Schedule A, Section 1.7, above. 

2.1.4    The minimum Process Batch size is [...***...] wafers for wafers in the Pre-Prototype, Prototype and Production product Phases. Any process batch that is smaller than [...***...] wafers will be charged as if [...***...] wafers are in the Process Batch, thus the minimum
Activity charge is [...***...] for any step. The Maximum Process Batch size is [...***...]. 

2.2    Carry-forward. If for any reason whatsoever Customer does not use Activities or
engineering hours allocate to the Customer for the project (as defined in Exhibit A), Customer shall have the right to carry forward either the total unused Activities and total unused engineering hours, or up to [...***...] Activity
and engineering hour Allocation (as defined in Exhibit A), whichever is less, for a period of up to [...***...] beyond the termination date of the Agreement. If the Carry Forward is not used within the [...***...], any residual
of the Carry Forward Allocation will terminate. 
 2.3    Additional Allocations. Customer
may request to increase its Activity Allocation upon thirty (30) days’ prior written notice. Customer may request an increase in its Activity Allocation only up to an additional [...***...] per fiscal quarter. Any increased Activity
Allocation is subject to an increased payment as defined in attached Exhibits. Additional Allocations shall be provided at SVTC’s sole discretion. 

  
 

 
 ***Confidential Treatment Requested 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

	3.	PROCESS MANAGEMENT 

 3.1    SVTC shall
exercise day-to-day managerial authority over the semiconductor wafer fabrication facilities, referred to as the “Line,” including over the allocation
of Activities and all aspects of the operation, development and planning of the Line, consistent with the provisions of this Agreement. 

3.2    Customer shall appoint employees with decision-making authority to an operating committee
(“Operating Committee”) to work with SVTC. The Operating Committee shall meet in person or telephonically once every [...***...] at a regularly scheduled time to review operational results and approve future operational matters,
including changes to the Line operating procedures applicable to Customer; provided however, that SVTC shall retain ultimate control over any changes to the Line and its operating procedures. The Operating Committee shall attempt
to resolve by good faith negotiations any operating disputes that arise with respect to the Line, or any other disputes arising under this Agreement, except as specifically set forth herein. 

3.3    SVTC will hold a daily Line operations meeting in which the daily Activities on the Line are
reviewed, discussed and planned; a Customer representative is expected to attend all operations meetings. 

3.4    Customer shall submit for prior written approval to the Operating Committee or its designee,
a list of all proposed operations, including all equipment intended to be used. Failure to adhere to the approved list may be considered grounds for termination as provided in Section 12.3 of the Master Services Agreement. 

3.5    SVTC shall have no liability nor be responsible for any costs or damages arising out of or
related to the work of Customer Personnel including but not limited to results other than those desired by Customer in the wafers processed on the Line solely by Customer Personnel. 

 

	4.	EQUIPMENT 

 4.1    The Line. The Line
is equipped to run various process technologies utilizing the equipment listed in Exhibit B. SVTC may update this list from time to time in its sole discretion. 

4.2    Equipment Ownership on the Line. Except as may otherwise agreed in writing between
the parties, SVTC will own the Line including all its equipment and Intellectual Property Rights. Customer acknowledges that the Line including all of the equipment, is used by multiple customers and that Customer is obligated under this Schedule
and the Agreement to avoid misusing any equipment, causing any damages, or causing Line operations to be interrupted. 

4.2.1    If Customer damages any equipment other than it own, Customer agrees to indemnify SVTC
without limitation for the costs of repair, replacement, or extraordinary servicing. 

4.2.2    If Customer damages any equipment other than it own, or otherwise causes any disruption to
the Line, and if the forgoing results in lost revenue to SVTC, or if claims are made against SVTC by other customers for delays attributable to Customer, then Customer agrees to indemnify SVTC without limitation for all such claims and lost
revenue. 
 4.2.3    Sections 4.2.1 and 4.2.2 shall not apply if Customer has strictly adhered to
the operations approved by the Operating Committee, all Customer use of equipment was within normal or approved parameters, and all Customer Personnel involved had satisfactorily completed all required training. 

4.2.4    No Customer Personnel except those who have satisfactorily completed the required training
to the satisfaction of SVTC, whether or not paid for, shall be allowed into the fab or to operate SVTC equipment; SVTC reserves the right at its sole discretion, to determine if Customer Personnel have achieved sufficient knowledge and understanding
of the training materials to be considered having satisfactorily completed the training. If SVTC 

  
 

 
 ***Confidential Treatment Requested 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

 
reasonably determines that someone needs more or retraining, it may require such training to allow continued access and use privileges. 

 

	 	4.3	 Customer Equipment. 

4.3.1    Upon Customer’s request, SVTC will, in its sole discretion, permit Customer to install
Customer Equipment on SVTC premises. SVTC, in its sole discretion, may allow Customer to make modifications to the applicable SVTC premises reasonably necessary for the installation and operation of the Customer Equipment. Customer shall bear the
responsibility and cost of such installation, project management and clean room rental. Customer shall pay the applicable taxing authority any tax invoice with respect to Customer Equipment. Customer shall also pay all costs to upgrade such Customer
Equipment. Any such upgrade will be performed in accordance with Customer’s specifications, but all such specifications are subject to the pre-approval of SVTC in its sole discretion. Customer has the
right to remove any Customer Equipment at any time, provided that the removal minimizes disturbance to the Line and is done with reasonable advance written notice to SVTC and solely at Customer’s expense. Without limiting the foregoing,
Customer shall bear all costs of installation, deinstallation and removal of Customer Equipment and any damages resulting therefrom. 

4.3.2    Customer shall bear all costs associated with ownership of any Customer Equipment or
upgrade, including all sales or use taxes or property taxes imposed on or otherwise determined on the basis of any such Customer Equipment or upgrade, and all insurance costs associated with any Customer Equipment. 

4.3.3    SVTC shall have no responsibility to Customer for loss or damage to any Customer Equipment
unless such damage or loss is caused by SVTC. Customer shall be responsible for securing insurance for Customer Equipment on SVTC premises. Customer shall be responsible for installation, all maintenance and repairs for Customer Equipment unless
stated otherwise. Customer shall be responsible for maintaining Customer Equipment at a satisfactory working level defined by the equipment manufacturers listed uptime and operational quality specifications. 

4.3.4    Customer shall allow SVTC access to Customer Equipment for safety and maintenance purposes
as well as for other mutually agreed purposes. No SVTC Personnel except those who have satisfactorily completed the required training to the satisfaction of Customer, whether or not paid for, shall be allowed to operate Customer equipment; Customer
reserves the right at its sole discretion, to determine if SVTC Personnel have achieved sufficient knowledge and understanding of the training materials to be considered having satisfactorily completed the training. 

4.4    Use of Equipment. All equipment listed in Exhibit B may be used in
manufacturing the products of either Party without cost to Customer other than such amount payable under Section 4. Customer Equipment shall only be used to manufacture Customer products or otherwise for the benefit of Customer and for no other
purpose except during instances in which SVTC is the user of such customer owned equipment. 

4.5    Access of Equipment. Customer shall not have access to equipment that is not included
in Exhibit B under this Agreement unless the new equipment replaces a piece of equipment listed in Exhibit B or is otherwise added to Exhibit B by SVTC. Customer and SVTC may agree upon conditional access to SVTC-owned, non-replacement equipment as needed for newly added equipment. 

4.6    Maintenance Down Time. Although the Line generally operates 24/7/365, occasionally
the Line must be shut down in whole or in part for maintenance. Customer will be given notice of planned shut-downs in advance. If there is an unplanned shut-down, as may happen if there is an event beyond SVTC’s control, SVTC will use
commercially reasonable efforts to get the Line back up as soon as possible; Customer agrees that SVTC shall not 

  
 

 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

 
be liable for any damages resulting from the aforementioned shut-downs. 
  

	5.	EXPENSES 

 5.1    Training. Included in
the Start-Up Costs shall be the number of hours as defined in any Exhibits attached hereto for up to [...***...] from the Start Date of SVTC Engineering Services to be used for equipment training, wafer
management training and integration support. The number of Customer Personnel who will be trained and/or the number of hours allocated to training Customer Personnel is limited to that stated in the attachments, however, if Customer desires later to
train a greater number than agreed, SVTC shall provide such training at an additional charge. 

5.2    Non-Recurring Engineering Expenses. After the
initial set-up included in the Start-Up Costs, Customer will have the option to purchase from SVTC Engineering Services at a rate as defined in an attached Exhibits or
in other documents attached to the Agreement such an Engineering Services Schedule. SVTC may increase the hourly rate from time to time in its sole discretion upon advance written notice. Customer understands that Engineering Services may not always
be available due to staffing availability. The terms and conditions for such Engineering Services shall be set forth on a separate Schedule. 

5.3    Reticle and Analytical Laboratory Services Expenses. Customer will have the option to
purchase photomasks or to have analytical laboratory services through SVTC’s approved vendors subject to specifically applicable terms and conditions. 

5.4    Payment Terms. Customer will be invoiced monthly based upon Activities allocated as
described in Section 2.1. The invoice will be for at least the minimum number of Moves equal to the monthly Activity Allocation. If the actual Moves for the preceding month are more than the Activity Allocation, the total Moves will be
invoiced. Each SVTC invoice hereunder shall be accompanied by a detailed report containing Activity Allocation, actual Moves, quantity of Moves invoiced and other payment due and payable. Payment obligations under this Schedule shall survive any
termination or expiration of this Schedule. 
  

	6.	PREMISES SERVICES, SECURITY AND SUPPORT 

6.1    Limited Support for Customer Personnel. Customer acknowledges that SVTC will not be
providing support or facilities for Customer Personnel except as expressly set forth in the Agreement or it attachments, and in particular shall not make available clerical, administrative or technical support personnel other than for the limited
purposes explicitly referred to herein. If requested by Customer for a designated number of Customer Personnel, and as agreed by SVTC, then in addition to cubicle or office space that may be made temporarily available to Customer Personnel, SVTC may
make available office telephones and internet connectivity and may provide access to conference rooms (subject to allowing access to such rooms on an equal priority basis to other customers and SVTC needs), break rooms, printers, faxes, copiers, and
equipment for engineering-only time for recipe development or optimization (subject to allowing access to such equipment to other SVTC customers as determined by SVTC in its reasonable judgment). SVTC will ensure that all Customer Personnel are
provided prompt and unqualified access at all times to data and information residing on SVTC equipment and computers that is specific to Customer. 

6.2    Status of Personnel. Customer acknowledges that Customer is responsible for the
activities of all Customer Personnel on the SVTC premises and to assure compliance with all SVTC rules and guidelines. Customer has an affirmative duty to inform all Customer Personnel, including but not limited to agents, contractors or employees
of affiliates of Customer, of their obligations under this Agreement. Customer Personnel who are other than immediate employees of Customer, including but not limited to agents, contractors or employees of

  
 

 
 ***Confidential Treatment Requested 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

 
affiliates of Customer, shall not enter or work within SVTC fab facilities without SVTC’s prior written consent expressly naming each such individual. 

6.3    Security. 

6.3.1    Customer acknowledges that the security of SVTC’s facilities generally and of
SVTC’s computer systems and networks in particular is of paramount importance to SVTC and to all of SVTC’s customers, including Customer. Customer Personnel are not authorized to enter any zone of SVTC’s facilities other than the SVTC
premises specified in the applicable Schedule or the parking lot associated with such SVTC premises unaccompanied by an authorized employee of SVTC. For security purposes, SVTC will require each one of the Customer Personnel to wear a security badge
at all times that each is on SVTC property and to conform with all site policies and procedures, as updated from time to time by SVTC in its sole discretion. 

6.3.2    Customer Personnel shall not access any SVTC computer or networking equipment except as
agreed upon by SVTC on a case-by-case basis. If provided access, each one of the Customer Personnel shall be assigned his or her own individual password by SVTC in order
to obtain any such access, and such individual may not share that password with any other Customer Personnel or others. 

6.3.3    SVTC shall keep and maintain logs of access to its network and systems by Customer
Personnel, and in the event SVTC discovers that any Customer Personnel has gained unauthorized access to any portion of SVTC’s systems or network or has removed, used or disclosed any Confidential Information of SVTC or of any other SVTC
customer, or if any Customer Personnel have otherwise failed to comply with SVTC’s site policies and procedures, such persons may immediately have their access badge and passwords canceled and may be physically barred from SVTC premises; such
persons’ actions may be deemed a material breach of this Agreement by Customer. 

6.4    Safety. When using the SVTC premises, Customer shall at all times comply with all of
SVTC’s environmental, health, security and safety site policies, procedures, and programs, and to ensure that all Customer Personnel also comply. SVTC will provide Customer copies of any such policies, as updated from time to time by SVTC in
its sole discretion. It is Customer’s responsibility to understand all site policies, procedures and programs relating to site security, environmental protection, safety and health and to ensure that the Customer Personnel also understand and
comply with such policies, procedures, and programs. This includes chemical handling, lock-out-tag-out, EHS and OHS safety rules, and use of safety gear. Customer also
understands that all chemicals brought onto the SVTC premises or any SVTC location must be approved on a case-by-case basis by SVTC in advance in order to maintain
compliance with local, state and federal codes. The foregoing does not limit Customer’s responsibility for compliance with all applicable law. 

6.5    Insurance. Customer represents that it has procured, and at all times during the Term
shall maintain, levels of insurance as necessary or as may be specified by SVTC to cover the activities and obligations of Customer and Customer Personnel while working on the SVTC premises. Customer shall provide evidence of insurance to SVTC on
the Effective Date of this Agreement, and at other times upon request by SVTC. Depending upon the nature of Customer’s activities on the premises, SVTC may require specific insurance levels and certificates in an attachment to this Agreement.

 6.6    Third-Party Materials and Information. Except as otherwise set forth herein,
Customer shall not permit Customer Personnel, to knowingly use, remove or tamper with any equipment, materials or documents of other customers that may be on the SVTC premises. 

 

	7.	ENGINEERING SERVICES 

  
 

 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

 7.1    Work. Customer may request advanced
engineering services including but not limited process development. Depending upon the nature and complexity of the requested engineering services, additional documentation may be required such as an SOW, that would include the number and
qualifications of the desired engineers, the period of time needed, and what type of work is desired. SVTC will provide a written quote or proposal for such services and if mutually agreed, a written confirmation will be provided. SVTC will use
commercially reasonable efforts to render the mutually agreed services by the projected completion dates. The manner and means by which SVTC chooses to complete such services are in SVTC’s sole discretion and control. Unless otherwise agreed in
writing, all SVTC engineering services pursuant to this section of the Schedule will be during its normal local weekday business hours (not fab hours); services required outside normal hours (including after hours weekdays and/or on weekends) shall
be subject to SVTC staff availability and shall be charged at additional cost to Customer. 

  
 

 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

 Exhibit A 

Commercial Terms 
 For
BioNanomatrix, Inc.’s Nanochannel Array Development 
  

			
	START DATE: 04-07-2009	  	DURATION: Six (6) Months

 SVTC proposes the date above on which SVTC will begin providing the following services under the Master Services Agreement
(“Start Date”). Project Duration commences upon the (“Start Date”). 

1.0    DESCRIPTION OF SERVICES: 

SVTC shall provide access to SVTC’s Line for the defined Project Duration commencing upon the Start Date in order to process silicon
wafers in support of BioNanomatrix, Inc.’s Nanochannel Array Development. SVTC will use manufacturing processes that exist or are being developed by BioNanomatrix, Inc., and BioNanomatrix, Inc. will be allocated a specific number of Activities,
as well as other support and services, as described herein (“Services”). SVTC shall use commercially reasonable efforts to perform the Services requested by BioNanomatrix, Inc., subject to the ability of SVTC to perform these Services on
SVTC’s existing equipment and equipment contributed by BioNanomatrix, Inc. using standard materials and process recipes that are compatible with the equipment and resources of SVTC. 

2.0    SUMMARY OF SERVICES TO BE PROVIDED:

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  
 ***Confidential
Treatment Requested 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

 3.0    SVTC SERVICE FEES: 

 

					
	 Development
	  	 Fees
	  	 Frequency

	 Fab Access
  

•   Included Activities[...***...]

 

•   On-Site Workspace for 1 cube for 1 engineer

[...***...]
	  	[...***...]	  	[...***...]
			
	 Activity Fee for activities in excess of the included 600 activities
	  	[...***...]	  	[...***...]
			
	 Engineering Services - Fixed Fee Process Engineering Support

 
 •   Up to
[...***...]
  

•   Duration for 1 quarter
	  	[...***...]	  	[...***...]
			
	 Engineering Services for hours exceeding contracted hours per quarter
	  	[...***...]	  	[...***...]
			
	 Process Library Access
	  	[...***...]	  	[...***...]
			
	 Mask Design Services (including reticles) - Estimate
	  	[...***...]	  	[...***...]
			
	 Analytical Services - Estimate
	  	[...***...]	  	[...***...]
			
	 Prototype Production
	  	 Fees
	  	 Frequency

	 Prototype production - 2 months estimated duration

 
 - [...***...]
Activities
  
 - Excess Activities at
[...***...]
  
 - Minimum lot:
[...***...]
	  	[...***...]	  	[...***...]
			
	 Prototype production Engineering Support - 2 months

 
 -[...***...]

 
 - Excess Hours at
[...***...]
	  	[...***...]	  	[...***...]
			
	 Volume Production
	  	 Fees
	  	 Frequency

	 Volume Production
	  		  	
	 - 101-200 wpm:
	  	[...***...]	  	Per Wafer
	 - 201-300 wpm:
	  	[...***...]	  	Per Wafer
	 - 301-400 wpm:
	  	[...***...]	  	Per Wafer
	 - > 400 wpm:
	  	[...***...]	  	Per Wafer
			
	 [...***...]
	  		  	
	 [...***...]
	  		  	
	 [...***...]
	  		  	

  
 ***Confidential
Treatment Requested 

			
	

	 	 BioNanomatrix

SCED462694

  

 
  

 4.0     TERMS: 

 

	1)	Not withstanding herein or within related agreements and documents, SVTC agrees that if for any reason whatsoever Customer does not use Activities or engineering hours allocate to the Customer for the project (as
defined in Exhibit A), Customer shall have the right to carry forward either the total unused Activities and total unused engineering hours, or up to [...***...] Activity and engineering hour Allocation (as defined in Exhibit A),
whichever is less, for a period of up to [...***...] beyond the termination date of the Agreement. If the Carry Forward is not used within the [...***...], any residual of the Carry Forward Allocation will terminate.

  
 ***Confidential
Treatment Requested 

 EXHIBIT B 

Equipment List — BioNanomatrix Vision Corporation 

Table B1 — Equipment with Activity Multipliers and with Access Only Through SVTC 

Operation and/or Engineering — No Direct Hands-on Usage 

[...***...] 
  

  
 ***Confidential
Treatment Requested 

 Table B2, P1 — Equipment with Access Only Through SVTC Operation and/or Engineering

 — No Direct Hands-on Usage 

(Note – List includes tools both with and without activity multipliers.) 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Table B2, P2 — Equipment with Access Only Through SVTC Operation and/or Engineering

 — No Direct Hands-on Usage 

(Note – List includes tools both with and without activity multipliers.) 

[...***...] 
  

  
 ***Confidential
Treatment Requested 

 Table B2, P3 — Equipment with Access Only Through SVTC Operation and/or Engineering

 — No Direct Hands-on Usage 

(Note – List includes tools both with and without activity multipliers.) 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Table B2, P4 — Equipment with Access Only Through SVTC Operation and/or Engineering

 — No Direct Hands-on Usage 

(Note – List includes tools both with and without activity multipliers.) 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Exhibit C 

Insurance Requirements for SVTC Customers 

Within the timeframe specified in the Agreement stating insurance requirements or when requested by SVTC, Customer must provide Certificates
of Insurance verifying it has the following types of insurance (including an attachment specifying additional or named insureds and any waiver endorsements). If the Agreement requires limits other than those below, the limits stated in the Agreement
shall supersede those below. Customer agrees to maintain all such applicable insurance during its operations at SVTC. 
 Note that the
following insurance requirements apply only to Customers working on SVTC premises using SVTC equipment. If there will be no use of SVTC equipment, the below insurance requirements do not apply. If the nature of Customer’s work on SVTC premises
changes during the term of the Agreement, the insurance requirements below may be imposed, waived or re-imposed. By way of example, if a customer desires access to the fabs but does not actually use the
equipment , a lesser level of insurance may be acceptable, subject to the level being increased if the customer later starts directly using SVTC equipment. 

Commercial General Liability Coverage: Policy must name SVTC, Technologies LLC., (“SVTC”), as an additional insured and
include a waiver of subrogation in favor of SVTC; include Broad Form Property Damage, Blanket Contractual Liability (covering liability assumed by Supplier), Premises/Operations, and Products/Completed Operations. 

$    [...***...]    General Aggregate 

$    [...***...]    Products-Completed Operations Aggregate (as needed) 

$    [...***...]    Personal & Advertising Injury $ 1,000,000 Each Occurrence 

$    [...***...]    Fire Damage (Any one fire) 

$    [...***...]    Medical Expense (any one person) 

Excess/Umbrella Coverage: This policy must be in force in addition to the underlying coverage required above without any gaps and
subject to all of the same requirements as the underlying coverage so that the total amount of insurance coverage (underlying plus umbrella) equals the following: 

$    [...***...]    Each occurrence and general aggregate 

  
 ***Confidential
Treatment Requested 

			
	

	 	 BioNanomatrix

AMEND462693-001

  

 

 AMENDMENT 1 

This Amendment, (“Amendment”), dated July 13, 2009 (“Effective Date”) is to the Master Services Agreement dated March 2, 2009,
and Exhibit A - Commercial Terms dated April 7, 2009 (“Agreement”) between SVTC Technologies, LLC (“SVTC”), and BioNanomatrix, Inc. (“Company”). The Agreement mandates that all changes must be in a writing signed
by the parties. Except as provided below, all the provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 

 

	 	1)	Exhibit A states the Commercial Terms for development phase of the described six month Company project. Section 3.0 of Exhibit A states the Service Fees including the amount charged for Engineering Services which
currently provides that Engineering Services hours in excess of [...***...] will be billed at the rate of [...***...]. 

  

	 	2)	It is hereby agreed to amend the forgoing language to provide that Engineering Services hours in excess of [...***...] will be billed at the rate of [...***...]. It is also agreed that this reduction only
applies during the period of time ending September 25, 2009, when development is complete. 

 Effect of this Amendment. In the event of
any conflict between the Agreement and this Amendment, this Amendment shall control. Except as amended or otherwise set forth in this Amendment, all terms and conditions of the Agreement remain in full force and effect and shall apply to
this Amendment and the interpretation thereof. 
 With due authority from our respective companies, we hereby signify our consent to this
Agreement by signing below, 
  

			
		 	SVTC Technologies, LLC
		
	Signature:	 	 /s/ Brian A. Stein

	Printed Name:	 	Brian A. Stein
	Title:	 	CFO
	Date:	 	October 2, 2009
		
	Customer:	 	BioNanomatrix, Inc.
		
	Signature:	 	 /s/ Michael Boyce-Jacino

	Printed Name:	 	Michael Boyce-Jacino
	Title:	 	President and CEO
	Date:	 	  

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

	 	 BioNanomatrix

AMEND462693-002

  

 
  

 AMENDMENT 2 

This Amendment 2, (“Amendment”), dated October 21, 2009 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between SVTC Technologies, LLC (“SVTC”), and BioNanomatrix, Inc. (“Company”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement, including section 11, shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The Agreement included an Exhibit A which included specific commercial terms to cover the development phase of the ongoing project. The services and charges in Exhibit A were for work during the six month period
starting April 7, 2009. The parties are now ready to proceed to the next phase in the project . Note that an Amendment 1, dated July 13, 2009, was executed but is not relevant to this Amendment 2. 

 

	 	2)	Pursuant to Section 2.1 of the SVTC Agreement, the SVTC Agreement is hereby amended to include attached Exhibit A2 describing services that will be provided by SVTC to Company for the next phase. SVTC will provide
Company the services described in Exhibit A2 for the prices set forth therein, subject to any additional terms and conditions set forth therein. All work by SVTC for the project described in Exhibit A2 shall be pursuant only to the Agreement as
amended herein, and not pursuant to any other agreements. 

 Effect of this Amendment. In the event of any conflict between the Agreement and
this Amendment, this Amendment shall control. Except as amended or otherwise set forth in this Amendment, all terms and conditions of the Agreement remain in full force and effect and shall apply to this Amendment and the interpretation
thereof. 
 LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added
attachment must include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 Exhibit A2 

(signatures on next page) 

  
 

 

			
	

	 	 BioNanomatrix

AMEND462693-002

  

 
  

 With due authority from our respective companies, we hereby signify our consent to this
Agreement by signing below, 
  

			
		 	SVTC Technologies, LLC
		
	Signature:	 	 /s/ Brian A. Stein

	Printed Name:	 	Brian A. Stein
	Title:	 	CFO
	Date:	 	10/23/09
		
	Customer:	 	BioNanomatrix, Inc.
		
	Signature:	 	 /s/ Lorraine G. LoPresti

	Printed Name:	 	Lorraine G. LoPresti
	Title:	 	VP – Finance & Administration
	Date:	 	10/22/2009

  
 

 

			
	

	 	 BioNanomatrix

AMEND462693-002

  

 

 Exhibit A2 

Commercial Terms 
 For
BioNanomatrix, Inc.’s Revised Nanochannel Array Development Project 
  

			
	START DATE: 10-19-2009	 	DURATION: Six (6) Months*

 SVTC proposes the date above on which SVTC will begin providing the following services under the Agreement
(“Start Date”). *Project Duration commences upon the (“Start Date”) and shall continue for six months unless extended as provide in section 6, 2), below. 

1.0 DESCRIPTION OF SERVICES: 

SVTC shall provide services for the defined Project Duration in order to develop and process experimental prototype silicon wafers in support
of BioNanomatrix, Inc.’s Revised Nanochannel Array Development Project. SVTC will use manufacturing processes that are being developed and BioNanomatrix, Inc. will be allocated a specific number of Activities, as well as other support and
services, as described herein (“Services”). SVTC shall use commercially reasonable efforts to perform the Services requested by BioNanomatrix, Inc., subject to the ability of SVTC to perform these Services on SVTC’s existing equipment
and equipment contributed by BioNanomatrix, Inc. using standard materials and process recipes that are compatible with the equipment and resources of SVTC. 

2.0 SUMMARY OF SERVICES TO BE PROVIDED: 

 

	 	•	 	Fab Services for experimental prototype wafers 

  

	 	•	 	Engineering Services 

  

	 	•	 	Process Library Access 

 3.0 SVTC SERVICE DEFINITIONS: 

Fab Access Services: 
 1. [...***...] 

2. [...***...] 
 3. [...***...] 

4. [...***...] 
 5. [...***...] 

6. [...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

	 	 BioNanomatrix

AMEND462693-002

  

 
  

 Engineering Services: (in addition to those included within the Activities pricing) 

1. Contracted engineering time may be utilized for the following development tasks 
  

	 	a.	[...***...] 

  

	 	b	[...***...] 

  

	 	c.	[...***...] 

  

	 	d.	[...***...] 

  

	 	e.	[...***...] 

 2. These services are to be executed in collaboration with Company 

Process Library Services: 
 1. [...***...] 

4.0 ADDITIONAL SERVICES: 

Additional Services are subject to availability at SVTC’s sole discretion for additional fees 

 

			
	Reticles	  	[...***...]
	Analytical Services	  	[...***...]

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

	 	 BioNanomatrix

AMEND462693-002

  

 

 5.0 SVTC ESTIMATED SERVICE FEES: 

 

					
	BioNanomatrix Fees Summary	  	Cal Q4’09	  	Cal Q1’10
	 [...***...]
	  	[...***...]	  	
	 [...***...]
	  		  	
	 [...***...]
	  		  	
	 [...***...]
	  		  	[...***...]
	 [...***...]
	  		  	
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	[...***...]
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	[...***...]
	 Total Revised Prototype Wafers
	  	[...***...]	  	[...***...]
		  	  
	  	  

	 [...***...]
	  	[...***...]	  	[...***...]
	 - [...***...]
	  		  	
	 - [...***...]
	  		  	
	 - [...***...]
	  		  	
	 - [...***...]
	  		  	
	 - [...***...]
	  		  	
	 IP License Fee (actual - not estimated)
	  	[...***...]	  	[...***...]
	 Total Alpha2 Development
	  	[...***...]	  	[...***...]
		  	  
	  	  

	 Sub-Total (By Quarter)
	  	[...***...]	  	[...***...]
	 TOTAL
	  		  	[...***...]

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

	 	 BioNanomatrix

AMEND462693-002

  

 
  

 6.0 TERMS: 
  

	1)	The project summary in Section 5.0 represents a non-binding total estimated project cost and timeline. However, the Minimum Financial Commitment Fee for the
Duration is [...***...]. As part of this Amendment, Company commits to have [...***...] Prototype wafers constructed on the existing [...***...]
flow upon execution of this Amendment. 

	2)	Fees for all services actually provided by SVTC to Company. shall be invoiced at the end of each SVTC fiscal month and payment shall be due within 30 days. IP License fees shall be billed at the end the first month
of each quarter. Company will have the option to extend the Duration by up to three months, at the same rates as above, in the event that the above development services are not concluded within six months; to exercise the extension, Company must
notify SVTC in writing at least thirty days prior to the end of the initial six month Duration. Should the extension occur, SVTC will waive the associated quarterly IP License fee for the extension. 

	3)	All invoicing shall follow SVTC fiscal month start and end dates. 

	4)	Additional Activities, Engineering Hours, Additional Tool Training, access to additional equipment and resources, and other Extraordinary Expenses (“Additional Services) shall be made available at SVTC’s
sole discretion and shall be agreed to in writing prior to being performed by SVTC. Company shall pay for all Additional Services per the terms of the Agreement, with rates fixed at [...***...] and
[...***...]. 

	5)	No Company terms and conditions, including but not limited to any stated on Company’s Purchase Orders or other documents, shall apply to SVTC’s services. 

	6)	Outsourcing charges for any outsourced steps are estimates only and may be subject to additional fees and/or outsource non-reoccurring engineering charges. If outsourcing
occurs, [...***...]. 

 7.0 LICENSED TECHNOLOGY: 

The Services listed above and SVTC’s process technology, including recipes and steps, used in the performance of services shall be provided and
licensed to Company under the terms, conditions and limitations of the Agreement, which shall override and supersede any terms and conditions in any Company provided documents. 

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

	 	 BioNanomatrix

AMEND462693-002

  

 
  

 Table 1 

Process Flows 

[...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

	 	 BioNanomatrix

AMEND462693-002

  

 
  

 [...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

			
	 

  

 AMENDMENT 3 

This Amendment 3, (“Amendment”), dated July 9, 2010 (“Effective Date”) is to the Master Services Agreement dated March 2, 2009
(“Agreement”) between SVTC Technologies, LLC (“SVTC”), and BioNanomatrix, Inc. (“Company”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	Previous draft of Amendment 3, dated in November, 2009, which was not finalized or executed, is superseded and replaced with this version of Amendment 3. 

 

	 	2)	SVTC and Customer agree to again extend the expiration of the Commercial Terms in Exhibit A2 of Amendment 2 of the Agreement, which Customer previously extended, by exercising the option to extend the duration as stated
in Section 6, sub-paragraph 2 of Exhibit A2, for a prior revised expiration date of July 19, 2010. By this Amendment the parties agree that the Commercial Terms in Exhibit A2 shall now extended to
now expire on October 19, 2010. 

  

	 	3)	SVTC agrees to [...***...] for the duration of this extension. 

  

	 	4)	During the duration of this extension SVTC shall invoice Customer at the end of each SVTC fiscal month for actual services provided and payment shall be due within 30 days. 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as amended or otherwise
set forth in this Amendment, all terms and conditions of the agreement remain in full force and effect and shall apply to this Amendment and the interpretation thereof. 

With due authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 

 

					
		 	SVTC Technologies, LLC	  	
			
	Signature:	 	 /s/ Jeffrey E. Calvello
	  	
	Printed Name:	 	Brian A. Stein JEFFREY E. CALVELLO	  	
	Title:	 	Chief Financial Officer CORPORATE CONTROLLER	  	
	Date:	 	July 20, 2010	  	
			
	Customer:	 	BioNanomatrix, Inc.	  	
			
	Signature:	 	 /s/ Edward L. Erickson
	  	
	Printed Name:	 	Edward L. Erickson	  	
	Title:	 	President & CEO	  	
	Date:	 	7/19/2010	  	

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

  

 AMENDMENT 4 

This Amendment 4, (“Amendment”), dated September 23, 2010 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between SVTC Technologies, LLC (“SVTC”), and BioNanomatrix, Inc. (“Company”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The Agreement is hereby amended to include attached Exhibit A4 describing services that will be provided by SVTC for Customer starting on the Effective Date. SVTC will provide Customer the services described in Exhibit
A4 for the fees set forth therein, subject to any additional terms and conditions set forth therein. Starting September 23, 2010, attached Exhibit A4, including the service and fee provisions
therein, shall replace and supersede the provisions of prior Exhibit A2 to the Agreement in its entirety.             October 15 JC LL 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as amended or otherwise
set forth in this Amendment, all terms and conditions of the agreement remain in full force and effect and shall apply to this Amendment and the interpretation thereof. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 

 

Exhibit A4 - Commercial Terms 

With due authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 

 

					
		 	SVTC Technologies, LLC	  	
			
	Signature:	 	 /s/ Jeffrey E. Calvello
	  	
	Printed Name:	 	Brian A. Stein JEFFREY E. CALVELLO	  	
	Title:	 	Chief Financial Officer CORPORATE CONTROLLER	  	
	Date:	 	10/20/2010	  	
			
	Customer:	 	BioNanomatrix, Inc.	  	
			
	Signature:	 	 /s/ Lorraine G. LoPresti
	  	
	Printed Name:	 	Lorraine G. LoPresti	  	
	Title:	 	VP – Finance & Admin, CFO	  	
	Date:	 	10/20/2010	  	

  
 

 

			
	

  

 Exhibit A4 

Commercial Quotation 
 For
BioNanomatrix, Inc.’s Alpha3.0 Technology 
  

			
	 START DATE: 10-15-2010
	 	DURATION: One (1) Year

 SVTC proposes the date above on which SVTC will begin providing the following services under the Master
Services Agreement (“Start Date”). Project Duration is the period of time for the project described in this Quotation. 
 1.0
DESCRIPTION OF SERVICES: 
 SVTC shall provide research and development services in support
of BioNanomatrix, lnc.’s Alpha3.0 Technology. SVTC will start with semiconductor processes that exist or are being developed by BioNanomatrix, Inc., and will provide such research and development services, as well as other support as described
herein (collectively, “Services”). SVTC shall use its best efforts, which shall be no less than commercially reasonable efforts, to perform the Services requested by BioNanomatrix, Inc.,in accordance with this Exhibit A4 subject to the
ability of SVTC to perform these Services on SVTC’s existing equipment and using standard materials and process recipes that are compatible with the equipment and resources of SVTC. 

2.0 SUMMARY OF SERVICES THAT MAY BE PROVIDED:

  

	 	•	 	Fab Services 

  

	 	•	 	Engineering Services 

  

	 	•	 	Process Library Licenses 

 3.0 SVTC SERVICE DEFINITIONS: 

Fab Access Services: 
 1. [...***...] 

2. [...***...] 
 3. [...***...] 

4. [...***...] 
 5. [...***...] 

6. [...***...] 
 7. [...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

  

 Engineering Services: (Defined in the Agreement) 

1. Contracted engineering time may be utilized for the following development tasks 
  

	 	a.	[...***...] 

  

	 	b	[...***...] 

  

	 	c.	[...***...] 

  

	 	d.	[...***...] 

  

	 	e.	[...***...] 

  

	 	f.	[...***...] 

 2. These services are to be executed in collaboration with customers direction and
management 
 Library License Fee: 
  

	1.	[...***...] 

 4.0 ADDITIONAL SERVICES**: 

 

					
	Additional Training Services	 	[***]	 	
	Additional Cubicles & Lockable Office Space	 	Subject to availability priced upon request	 	
	Reticles	 	[***]	 	
	Analytical Services	 	Full service capabilities available priced upon request	 	

  

	**	Additional Services subject to availability 

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

  

 5.0 SVTC SERVICE FEE SCHEDULE: 

 

							
	 	 	 Development Contract
	  	 Fees
	  	 Frequency

	a)	 	Fab Services	  		  	
				
		 	        [...***...]	  		  	
				
		 	Development Activity unit pricing	  	[...***...]	  	per activity
				
		 	Yield Engineering Activity unit pricing	  	[...***...]	  	per activity
				
	d)	 	Engineering Services - Process Engineering Support	  		  	
				
		 	 •   Duration for 4 quarters
	  		  	
				
		 	Engineering Services hours exceeding Included Hours	  	[...***...]	  	hourly
				
	f)	 	Library License Fee	  	[...***...]	  	quarterly
				
		 	 •   IP License Fee waived with 1 year contract commitment
	  		  	
				
	g)	 	Analytical Services	  	[...***...]	  	
				
		 	 •   [...***...]
	  		  	
				
	g)	 	Reticles	  	[...***...]	  	
				
		 	        Flexible spending with quarterly Financial Commitment	  	[...***...]	  	Quarterly

  

	*	Actual spend rate is expected to exceed the minimum financial commit. Predicted run rate based on scope of work is between $175 and $225K per quarter 

6.0 PILOT / LOW VOLUME PRODUCTION: 

 

			
	Wafers per year	  	Activity Pricing
	 100 – 1,200
	  	[...***...]
	 12,000 – 3,000
	  	[...***...]
	 > 3,000
	  	[...***...]

  

	 	•	 	[...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 7.0 SCOPE OF WORK: 

 

	•	 	Alpha2.0 Chip Development Requirements 

  

	 	•	 	Remaining technical challenges: 

  

	 	•	 	None; baseline process exists 

  

	 	•	 	Estimated Scope: 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	•	 	Alpha3.0 Chip Development Requirements: 

  

	 	•	 	Remaining technical challenges 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	Estimated Scope: 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	-	[...***...] 

  

	 	•	 	[...***...] 

  

	•	 	Total Scope Estimate: [...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 

 
 9.0     TERMS: 

 

	1)	Actual usage shall be invoiced at the end of each SVTC fiscal month for actual activities or engineering hours used, due NET30 days. It is anticipated that actual spend rate will exceed the monthly minimum financial
commitment. Minimum financial commitment shall be [...***...], with a minimum of [...***...]. Any adjustments to fulfill the contracted fee requirements shall be invoiced at the end
of every six (6) month duration. 

  

	2)	Product wafers will be ordered under this agreement, and will be invoiced upon shipment, and shall be included in the minimum financial commitment. 

 

	3)	The first and last billing cycle fees and service quantities other than set up shall be prorated to the actual start date and then continue in accordance with SVTC’s fiscal calendar such that all invoicing shall
follow SVTC fiscal month start and end dates. 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 10.0 PRODUCT WAFER SPECIFICATIONS: 

 

	 	•	 	Production Wafer Specifications 

  

	 	•	 	SVTC and BNM agree that at the conclusion of process verification of the Alpha2.0 chip, a robust, in-line test specification will be established to determine “good
wafers”. It is expected that this specification will include top-down CD, profilometry for depth verification, and visual defect inspect. Actual criteria to be mutually agreed by SVTC and BNM.

  

	 	•	 	SVTC and BNM agree that at the conclusion of the Alpha3.0 technology development and process verification, a robust, in-line test specification will be established to determine
“good wafers”. Specification requirements are yet to be determined, and will be mutually agreed by SVTC and BNM. 

  

	 	•	 	It is the intent of SVTC and BNM to integrate the TSV module into the Alpha2.0 flow and eliminate the back-grind process. Once the TSV module is fully developed and the existing Alpha2.0 flow has been released, it is
expected that the development required to integrate the two will be minimal. SVTC cannot predict the absolute effort required, as there is currently no data on which to base this conclusion. However, SVTC anticipates at least 2 lots of 6 wafers will
be required for validation. SVTC will commit to complete this specific development at pilot production activity pricing, and at the least number of validation lots reasonable to mitigate the cost. 

11.0 SUPPLY CHAIN MANAGEMENT: 
  

	 	•	 	Supply Chain 

  

	 	•	 	Incoming Material: SVTC will by the end of the second quarter of this contract, assume control of incoming supply chain, specifically silicon substrates and glass lid wafers. These materials will be added to monthly
invoices with SVTC standard [...***...] applied 

  

	 	•	 	Packaging: SVTC will engage prospective packaging suppliers to develop an integrated solution for BNM. Once a viable technology demonstrator has been produced, SVTC will manage it as part of the integrated supply chain
solution with a standard [...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 12.0 STANDARD ANALYTICAL SERVICES PRICE
LIST: 
 Note: Pricing listed is typical pricing per technique. Actual price will be determined following review of
customer specific material and objectives and is subject to change 
  

					
	SVTC Analytical Services	  	Price	  	Unit
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
			
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  	Quote	  	Each
			
	 [...***...]
	  	[...***...]	  	1st Wafer
	 [...***...]
	  	[...***...]	  	Additional Wafer
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...] Lot	  	
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

					
	 [...***...]
	  		  	
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Lot
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Lot
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Lot
			
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  		  	
			
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  	[...***...]	  	Hour

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

					
	 [...***... ]
	  	[...***...]	  	Hour
	 [...***...]
	  		  	
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Sample
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Sample
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  	[...***...]	  	1st Wafer
	 [...***...]
	  	[...***...]	  	Additional Wafer
			
	 [...***...]
	  	[...***...]	  	Sample w/prep
	 [...***...]
	  	[...***...]	  	Sample w-out prep

  

	**	Expedite Pricing Options Available for ALL Services Listed** 

  
 ***Confidential
Treatment Requested 
  
 

 

			
	

  

 TERMS AND CONDITIONS FOR ANALYTICAL SERVICES 

SVTC, LLC 3901 North First Street, San Jose, CA 95134 

1. Except as otherwise agreed in writing by the parties, these Terms and Conditions shall govern analytical services provided to Customer by
SVTC. These Terms and Conditions supersede all previous communications, representations, or agreements, either verbal or written, between the parties. The Parties also agree that these Terms and Conditions shall supersede additional, inconsistent or
conflicting terms, whether printed or otherwise set forth in any purchase order or other documents provided by Customer to SVTC. 
 2.
Services. SVTC agrees to perform the services described in the proposal/quotation to which these Terms and Conditions are attached. Unless specifically agreed, completion times are not assured. Unless otherwise agreed, SVTC will electronically
transmit the results of the analytical services which constitute full performance of SVTC’s obligations. 
 3. Legal. This agreement
shall be interpreted under the laws of the State of California. The invalidity or unenforceability, in whole or in part of any provision shall not affect the validity or enforceability of the remainder of the Terms and Conditions. Wavier by
SVTC of any provision or of any breach by or obligation of the Customer shall not constitute a waiver of such provision on any other occasion or a waiver of any other breach by or obligation of the Customer. Modifications to this Agreement must be
in writing and approved by authorities of the Parties. 
 4. Methodology. Customer acknowledges that unless otherwise agreed in
writing, analytical services may be outsourced to subcontractors of SVTC at SVTC’s sole discretion. Industry standard methodologies will normally be used; however, SVTC reserves the right if necessary to deviate from standard
methodologies. Customer shall provide a prior written disclosure of known or suspected hazards of toxicity and shall provide written instructions concerning handling. Customer warrants that all submissions will be packaged, labeled, transported and
delivered in accordance with applicable laws. Customer will be responsible for disposal. 
 5. Warranty. SVTC warrants only that it will
perform analytical services and prepare reports consistent with current generally accepted analytical laboratory principles and practices. No specific results are guaranteed. Preliminary results may be given in advance of a final report. If provided
to Customer, preliminary results are subject to change and final review by SVTC and Customer’s use of preliminary results shall be at Customer’s risk. SVTC DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED. 

6. Liability. Customer’s exclusive remedy in the event of a breach of this Agreement shall be that SVTC will repeat the services at its
own expense, and SVTC shall have no other liability whatsoever. All claims shall be deemed waived unless made in writing and received by SVTC within sixty (60) days following completion of services. Results are provided only for the use of SVTC
Customers. Customer shall indemnify SVTC from any claims by third parties arising out of or related to the services provided under this agreement. IN NO EVENT SHALL SVTC BE LIABLE TO CUSTOMER OR TO ANY THIRD PARTY CLAIMING THROUGH OR UNDER
CUSTOMER FOR INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, EVEN IF ADVISED OF THE POSSIBILITY THEREOF IN THE EVENT THAT ANY LIABILITY IS IMPOSED ON SVTC HEREUNDER. AWARDED DAMAGES SHALL NOT EXCEED THE AMOUNT PAID OR PAYABLE BY
CUSTOMER TO SVTC FOR THE SERVICE TO WHICH SUCH LIABILITY RELATES. Each party acknowledges that the foregoing limitations are an essential element of the Agreement and that in the absence of such limitations the pricing and other terms set forth
in this Agreement would be substantially different. 
 7. Handling. SVTC shall have no responsibility or liability for the actions of any
carrier or for delivery problems to or from SVTC. All shipment arrangements will be at Customer’s expense. If not picked up, submissions will be held for a limited time after which they will be destroyed unless otherwise agreed in writing.
Disposal of hazardous materials is the responsibility of the Customer. SVTC reserves the right to refuse accept any submission if SVTC determines in its sole discretion, that a submission is of insufficient volume, or that it poses a risk due
to health, safety, environmental or other factors, even if not a hazardous substance or notice was made by Customer. 
 8. Compensation.
Services performed will be billed in the amounts quoted or as stated on applicable SVTC Fee Schedules. If Customer notified SVTC to terminate services prior to completion. Customer shall remain liable for all services performed prior to receipt of
notice. Payment terms are stated on SVTC’s invoice. Unless stated, charges do not include any sales, use or other taxes that will be added to invoice prices if required. SVTC reserves the right to require payment prior to commencing services or
release of data. Forensic testimony or other services not stated on the quotation are not included the services to be provided. 
 9.
Intellectual Property. Customer’s proprietary data or information submitted by SVTC shall remain the Customer’s property. Upon satisfactory payment to SVTC for services provided, data or information generated by SVTC for the Customer shall
be deemed the Customer’s property. SVTC or its subcontractors shall retain ownership of all analytical methods, protocols, and equipment. Without SVTC’s prior written consent, Customer shall not use SVTC’s or its
subcontractor’s names or trademarks in any marketing or reporting materials, press releases or in any other manner and shall not attribute to SVTC any test result tolerance or specification derived from SVTC’s data. 

  
 

 

 

 
  

 AMENDMENT 5 

This Amendment 5, (“Amendment”), dated September 26, 2011 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between SVTC Technologies, LLC (“SVTC”), and BioNanomatrix, Inc. (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The Agreement is here by amended to include attached Exhibit A5 describing services that will be provided by SVTC for Customer starting on the effective Date. SVTC will provide to Customer the services described in
Exhibit A5 for the fees set forth therein, subject to any additional terms and conditions set forth therein. Starting on September 26, 2011, attached Exhibit A5, including the service and fee provisions herein, shall replace and supersede the
provisions of prior Exhibit A4 to the Agreement in its entirety. 

  

	 	2)	SVTC and Customer also agree to extend the expiration of the Agreement itself from its current expiration date of March 02, 2012, so that the Agreement shall now expire on September 25, 2012 to coincide with the
expiration of the Duration in Exhibit A5. 

 Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment,
this Amendment shall control. Except as amended or otherwise set forth in this Amendment, all terms and conditions of the agreement remain in full force and effect and shall apply to this Amendment and the interpretation thereof. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provisions referencing the Agreement and must be executed by all parties. 

 

Exhibit A5 - Commercial Terms 

 With due
authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 
  

			
		 	SVTC Technologies, LLC
		
	Signature:	 	 /s/ Kevin Kassekert

	Printed Name:	 	Kevin Kassekert
	Title:	 	General Manager
	Date:	 	9/22/11
		
	Customer;	 	BioNanomatrix, Inc.
		
	Signature:	 	 /s/ R. Erik Holmlin

	Printed Name:	 	R. Erik Holmlin
	Title:	 	CEO
	Date:	 	9/22/2011

  
 

 

 

 
  

 Exhibit A5 

Commercial Terms 
 For
BioNanomatrix, Inc.’s Fluidics Chip Technology 
  

			
	 START DATE: 09-26-2011
	  	 DURATION: One (1) Year

 SVTC proposes the dale above on which SVTC will begin providing the
following services under the Master Services Agreement (“Start Date”). Project Duration is the period of time for the project described in this Amendment. 

1.0    DESCRIPTION OF SERVICES: 

SVTC shall provide research and development services in support of Customer’s Fluidics Chip Technology. SVTC will start with semiconductor processes that
exist or are being developed by Customer. and will provide other support as described herein (“Services”). SVTC shall use commercially reasonable efforts to perform the Services requested by BioNanomatrix. Inc., subject to the ability of
SVTC to perform these Services on SVTC’s existing equipment and using standard materials and process recipes that are compatible with the equipment and resources of SVTC. 

2.0    SUMMARY OF SERVICES THAT MAY BE
PROVIDED: 
  

	 	•	 	Fab Services 

  

	 	•	 	Engineering Services 

  

	 	•	 	Process Library Licenses 

 3.0    SVTC SERVICE
DEFINITIONS: 
 Fab Services: 
  

	1.	[...***...] 

  

	2.	[...***...] 

  

	3.	[...***...] 

  

	4.	[...***...] 

  

	5.	[...***...] 

  

	6.	[...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 Engineering Services: (Defined in the Agreement) 

 

	1.	Contracted engineering services may be utilized for the following developmental tasks 

  

	 	a.	[...***...] 

  

	 	b.	[...***...] 

  

	 	c.	[...***...] 

  

	 	d.	[...***...] 

  

	 	e.	[...***...] 

  

	 	f.	[...***...] 

 Library License Fee: 

 

	1.	[...***...] 

 4.0    ADDITIONAL SERVICES** : 

 

			
	Reticles	  	[...***...]
	Analytical Services	  	[...***...]

  

	**	Additional Services subject to availability 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 5.0    SVTC SERVICE FEE SCHEDULE:

  

							
	 	  	 Development Contract Fees Frequency
	  	Fees	  	Frequency
	a)	  	Fab Services	  		  	
				
		  	[...***...]	  		  	
				
		  	Development Activities unit pricing	  	[...***...]	  	per activity
				
	b)	  	Engineering Services - Process Engineering Support	  		  	
				
		  	 •  [...***...]
	  		  	
				
		  		  	[...***...]	  	hourly
				
		  	Engineering Services hours exceeding Included Hours	  		  	
				
		  		  	[...***...]	  	quarterly
				
	c)	  	Library License Fee	  		  	
				
		  	 •  [...***...]
	  		  	
				
		  		  	[...***...]	  	
				
	d)	  	Analytical Services	  		  	
				
		  	 •  [...***...]
	  		  	
				
	e)	  	Reticles	  	Quoted upon request	  	
				
		  	[...***...] 	  	[...***...] 	  	Annual

 6.0    PILOT / LOW VOLUME PRODUCTION:

  

			
	Wafers per year	  	Activity Pricing
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 9.0 TERMS: 
  

	 	1)	Actual usage shall be invoiced at the end of each SVTC fiscal month for actual activities or engineering hours used, due NET 30 days. Minimum Financial Commitment (MFC) shall be
[...***...]. 

  

	 	2)	Product wafers will be ordered under this agreement, and will be invoiced upon shipment, and shall be included in the quarterly minimum financial commitment. 

 

	 	3)	The first and last billing cycle fees and service quantities other than set up shall be prorated to the actual start date and then continue in accordance with SVTC’s fiscal calendar such that all invoicing shall
follow SVTC fiscal month start and end dates. 

  

	 	4)	[...***...] 

 10.0 PRODUCT WAFER SPECIFICATIONS: 

(BNM refers to BioNanomatrix, Inc.) 

Production Wafer Specifications 

SVTC and BNM agree that at the collision of process verification of the alpha 2.0 chip, a robust,
in-line test specification will be established to determine “good wafers”. It is expected that this specification will include top-down CD, profilometry for
depth verification, and visual defect inspect. Actual criteria to be mutually agreed 
 by SVTC and BNM. 

SVTC and BNM agree that at the conclusion of the Alpha 3.0 technology development and process verification, a robust, in-line test specification will be established to determine “good wafers”. Specification requirements are yet to be determined, and will be mutually agreed by SVTC and BNM. 

It is the intention of SVTC and BNM to integrate the TSV module into the Alpha 2.0 flow and eliminate the back-grind process. Once the TSV
module is fully developed and the existing Alpha 2.0 flow has been released, it is expected that the development required to integrate the two will be minimal. SVTC cannot predict the absolute the absolute effort required, as there is currently no
data on which to base this conclusion. However, SVTC anticipates at least 2 lots of 6 wafers will be required for validation. SVTC will commit to complete this specific development at pilot production activity pricing, and the least number of
validation lots reasonable to mitigate the cost. 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 12.0 STANDARD ANALYTICAL SERVICES PRICE
LIST: 
 Note: Pricing listed is typical pricing per technique. Actual price will be determined following review of
customer specific material and objectives and is subject to change 
  

					
	SVTC Analytical Services	  	Price	  	Unit
	 [...***...]
	  	[...***...]	  	 Sample

	 [...***...]
	  	[...***...]	  	 Sample

			
	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  	[...***...]	  	 1st Wafer

	 [...***...]
	  	[...***...]	  	 Additional Wafer

			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	
	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  	[...***...]	  	 Hour

			
	 [...***...]
	  	[...***...]	  	 Hour

	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

					
	 [...***...]
	  		  	
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

	 [...***...]
	  	[...***...]	  	 Each

			
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Lot
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Lot
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Lot
			
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
			
	 [...***...]
	  	[...***...]	  	 Hour

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

					
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  		  	
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Hour
			
	 [...***...]
	  	[...***...]	  	Sample
			
	 [...***...]
	  		  	
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Hour
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Sample
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Sample
		  		  	
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  	[...***...]	  	Each
	 [...***...]
	  		  	
			
	 [...***...]
	  	[...***...]	  	1st Wafer
	 [...***...]
	  	[...***...]	  	Additional Wafer
			
	 [...***...]
	  	[...***...]	  	Sample w/prep
	 [...***...]
	  	[...***...]	  	Sample w-out prep

  

	**	Expedite Pricing Options Available for ALL Services Listed** 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 AMENDMENT 6 

This Amendment 6, (“Amendment”), dated September 26, 2011 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between SVTC Technologies, LLC (“SVTC”), and BioNanomatrix, Inc. (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
 The
Agreement is hereby amended to include attached Exhibit C1, Insurance Requirements for SVTC Customers. Starting on September 26, 2011, attached Exhibit C1, including the insurance requirements therein, shall replace and supersede the provisions
of prior Exhibit C to the Agreement in its entirety. 
 Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment,
this Amendment shall control. Except as amended or otherwise set forth in this Amendment, all terms and conditions of the agreement remain in full force and effect and shall apply to this Amendment and the interpretation thereof. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
  

	
	Exhibit C1 – Insurance Requirements for SVTC Customers

 With due authority from our respective companies, we hereby signify our consent to this Agreement by signing
below. 
  

			
		 	SVTC Technologies, LLC
		
	Signature:	 	 /s/ Kevin Kassekert

	Printed Name:	 	Kevin Kassekert
	Title:	 	General Manager
	Date:	 	9/23/11
		
	Customer;	 	BioNanomatrix, Inc.
		
	Signature:	 	 /s/ Lorraine LoPresti

	Printed Name:	 	Lorraine LoPresti
	Title:	 	CFO
	Date:	 	9/23/2011

  
  
 

 

 

 
  

 Exhibit C1 

Insurance Requirements 
  

					
	BioNanomatrix	 		  	September 26, 2011

 Insurance Requirements for SVTC Customers 

Within the timeframe specified in the Agreement stating insurance requirements or when requested by SVTC, Customer must provide Certificates
of insurance verifying it has the following types of insurance (including an attachment specifying additional or named insureds and any waiver endorsements). If the Agreement requires limits other than those below, the limits stated in the Agreement
shall supersede those below. Customer agrees to maintain all such applicable insurance during its operations at SVTC. 
 Note that the
following insurance requirements apply only to Customers working on SVTC premises using SVTC equipment. If there will be no use of SVTC equipment, the below insurance requirements do not apply. If the nature of Customer’s work on STC premises
changes during the term of the Agreement, the insurance requirement below may be imposed, waived or re-imposed. By way of example, if a customer desires access to the fabs but does not actually use the
equipment, a lesser value of insurance may be acceptable, subject to the level being increased if the customer later starts directly using SVTC equipment. 

Commercial General Liability Coverage: Policy must name SVTC, Technologies LLC., (“SVTC”), as an additional insured and include a waiver of
subrogation in favor of SVTC; include Broad Form Property Damage, Blanket Contractual Liability (covering liability assumed by Supplier), Premises/Operations, and products/Completed Operations. 

$ [...***...] General Aggregate 

$ [...***...] Products-Completed Operations Aggregate (as needed) 

$ [...***...] Personal 7 Advertising Injury 

$ [...***...] Each Occurrence 

$ [...***...] Fire Damage (Any one fire) 

$ [...***...] Medical Expense (any one person) 

Excess/Umbrella Coverage: This policy must be in force in addition to the underlying coverage required above without any gaps and subject to all of the
same requirements as the underlying coverage so that the total amount of insurance coverage (underlying plus umbrella) equals the following: 

$ [...***...] Each occurrence and general aggregate 

SVTC and BioNanomatrix agree that under no circumstances will BioNanomatrix personnel enter SVTC’s facilities unescorted, nor will Bionanomatrix
personnel operate SVTC equipment. 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 AMENDMENT 7 

This Amendment 7, (“Amendment”), dated March 26, 2012 (“Effective Date”) is to the Master Services Agreement dated
March 2, 2009, as amended, (collectively, the “Agreement”) between SVTC Technologies, LLC (“SVTC”), and BioNanomatrix, now known as BioNano Genomics, (“Customer”). The Agreement mandates that all changes must be in
a writing signed by the parties. Except as provided below, all the provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 

 

	 	1)	The Agreement is hereby amended to include attached Exhibit A7 describing services that will be provided by SVTC for Customer starting on the Effective Date. SVTC will provide to Customer the services described in
Exhibit A7 for the fees set forth therein, subject to any additional terms and conditions set forth therein. Starting on March 26, 2012, attached Exhibit A7, including the service and fee provisions therein, shall replace and supersede the
provisions of prior Exhibit A5 to the Agreement in its entirety. 

  

	 	2)	SVTC and Customer also agree to amend the Agreement to include attached Exhibit D. 

  

	 	3)	SVTC and Customer also hereby agree to extend the expiration of the Agreement from its current expiration date of September 25, 2012, to March 24, 2013. 

Effect of this Amendment. IN THE EVENT OF ANY CONFLICT BETWEEN THE AGREEMENT AND THIS AMENDMENT, THIS AMENDMENT SHALL CONTROL.
Except as amended or otherwise set forth in this Amendment, all terms and conditions of the Agreement remain in full force and effect and shall apply to this Amendment and the interpretation thereof. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment
must include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 Exhibit A7 - Commercial Terms

 Exhibit D — Process Controls and Metrics 

  
 

 

 

 
  

 With due authority from our respective companies, we hereby signify our consent to this
Agreement by signing below, 
  

			
		 	 SVTC Technologies, LLC

		
	Signature:	 	
                     

	Printed Name:	 	Kevin Kassekert
	Title:	 	Vice President, Silicon Services
	Date:	 	
                     

		
	Customer:	 	BioNano Genomics
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	CEO
	Date:	 	May 3, 2012

  
 

 

 

 
  

 Exhibit A7 

Commercial Terms 
 For
BioNano Genomics’s [...***...] Validation Phase 
  

			
	
 START DATE: 03-26-2012
	  	DURATION: Twelve (12) Fiscal Months

 SVTC proposes the date above on which SVTC will begin providing the following services under the Master
Services Agreement (“Start Date”). Project Duration is the period of time for the project described in this Amendment. 
 1.0
    DESCRIPTION OF SERVICES: 
 SVTC shall provide
research and development services in support of Customer’s [...***...]. SVTC will start with [...***...], as well as other support as described herein (“Services”). SVTC shall use commercially reasonable efforts to perform
the Services requested by Customer, subject to the ability of SVTC to perform these Services on SVTC’s existing equipment and using standard materials and process recipes that are compatible with the equipment and resources of SVTC. 

2.0     SUMMARY OF SERVICES THAT MAY
BE PROVIDED: 
  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

 3.0     SVTC SERVICE
DEFINITIONS 
 Fab Services: 
  

	1.	[...***...] 

  

	2.	[...***...] 

  

	3.	[...***...] 

  

	4.	[...***...] 

  

	5.	[...***...] 

  

	6.	[...***...] 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 Engineering Services: (Defined in the Agreement) 

 

	1.	Contracted engineering services may be utilized for the following development tasks 

  

	 	a.	[...***...] 

  

	 	b.	[...***...] 

  

	 	c.	[...***...] 

  

	 	d.	[...***...] 

  

	 	e.	[...***...] 

  

	 	f.	[...***...] 

  

	2.	These services are to be executed in collaboration with customers direction and management 

Library License Fee: 
  

	1.	Library access, use, and license is limited to recipes available on the SVTC equipment list (MSA Exhibit B) at the time of contract closure. 

4.0     ADDITIONAL SERVICES*: 

 

			
	  Reticles
	  	[...***...]
	  Analytical Services
	  	[...***...]

  

	**	Additional Services subject to availability 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 5.0 SERVICE FEE SCHEDULE: ONGOING
DEVELOPMENT: [...***...] OPTIMIZATION & NEXT GEN PRODUCT 
  

									
			
	 Item
	  	Fees	 	  	Frequency	 
	 a)  Tier 1 Pricing

•  [...***...]
  

– [...***...]
	  	 	[...***...	] 	  	 	[...***...	] 
			
	 Engineering Services - Process Engineering Support
	  	 	[...***...	] 	  	 	[...***...	] 
			
	 Analytical Services
	  	 	[...***...	] 	  	 	[...***...	] 
			
	Tier 1 Minimum Financial Commitment	  	 	[...***...	] 	  	 	[...***...	] 
			
	 b)  Tier 2 Pricing (Baseline Commitment)

•  [...***...]
  

– [...***...]
	  	  
	 [...***...
	 ] 
	  	 	[...***...	] 
			
	 Engineering Services - Process Engineering Support
	  	 	[...***...	] 	  	 	[...***...	] 
			
	 Analytical Services
	  	 	[...***...	] 	  	 	[...***...	] 
			
	Tier 2 Minimum Financial Commitment	  	 	[...***...	] 	  	 	[...***...	] 
			
	 c)  Tier 3 Pricing

 
 – [...***...]
	  	 	[...***...	] 	  	 	[...***...	] 
			
	 Engineering Services - Process Engineering Support
	  	 	[...***...	] 	  	 	[...***...	] 
			
	 Analytical Services
	  	 	[...***...	] 	  	 	[...***...	] 
			
	Tier 3 Minimum Financial Commitment	  	 	[...***...	] 	  	 	[...***...	] 
			
	 d)  Hot Lot Fee
	  	 	[...***...	] 	  	 	[...***...	] 
			
	 e)  Baseline Minimum Financial Commitment (Tier 2 Above)
	  	 	[...***...	] 	  	 	[...***...	] 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 6.0 SERVICE FEE SCHEDULE: [...***...]
CHARACTERIZATION & VALIDATION - DURATION – 9 FISCAL MONTHS 
  

							
			
	Phase	  	Deliverables: Turnkey Project	  	Total	 
			
	 6.1 Phase 1
	  	 Complete Process Characterization for Validation
	  	 	[...***...]	 
			
		  	 [...***...]
	  			
			
		  	 [...***...]
	  			
			
		  	 [...***...]
	  			
			
		  	 [...***...]
	  			
			
		  	 [...***...]
	  			
			
		  	 [...***...]
	  			
			
		  	Milestones:	  			
			
		  	 [...***...]
	  	 	[...***...]	 
			
		  	 [...***...]
	  	 	[...***...]	 
			
		  	 [...***...]
	  	 	[...***...]	 
			
		  	 [...***...]
	  	 	[...***...]	 
			
		  	 [...***...]
	  	 	[...***...]	 
			
		  	 [...***...]
	  	 	[...***...]	 
			
		  	 [...***...]
	  	 	[...***...]	 
			
		  	 [...***...]
	  	 	[...***...]	 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

					
			
	Phase	  	Deliverables: Turnkey Project	  	Total
			
	6.2 Phase 2	  	Validate Process for Specialty Production	  	[...***...]
			
		  	 [...***...] 
	  	
			
		  	 [...***...] 
	  	
			
		  	 [...***...]
	  	
			
		  	 Milestones:
	  	
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]
			
		  	 [...***...]
	  	[...***...]

 Change in the scope of work: If Customer, during the course of the project execution, materially changes the scope of work
such that the SVTC’s engineering resources are increased or if the costs to SVTC increase to perform the work as per the changes, Customer will be notified in order to reconvene to re-negotiate the
agreement. In case the parties do not agree regarding the changes, Customer is responsible for the payments according to the Early Termination clause, below. 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 7.0 TERMS: 
  

	1)	Section 5.0 (above) Actual usage shall be invoiced at the end of each SVTC fiscal month for actual services provided, due NET30 days. At the end of SVTC’s fiscal year, [...***...].

  

	2)	Customer must provide SVTC with advanced written notice of its election of the pricing tier, section 5 above, twice a year, at least [...***...] prior to the start of the first and third SVTC fiscal quarters.
If no written notice is received [...***...] prior to the beginning of any quarter, the pricing tier [...***...]. In the event [...***...] is selected by Customer, the price structure for that tier will be applied to
[...***...]. In the event a [...***...]. 

  

	3)	These commercial terms may be terminated with 90 days prior written notice of project termination. 

  

	4)	Product/sample wafers will be ordered under this agreement, and will be invoiced upon shipment, and shall be included in the quarterly financial commitment. 

 

	5)	The first and last billing cycle fees and service quantities other than set up shall be prorated to the actual start date and then continue in accordance with SVTC’s fiscal calendar such that all invoicing shall
follow SVTC fiscal month start and end dates. 

  

	6)	Section 6.0 (above): SVTC shall invoice Customer upon completion of each milestone as defined in sub-sections 6.1 and 6.2 above, and payment shall be due 30 days from date
of invoice. 

  

	7)	Upon execution, this proposal will supersede the existing agreement between Customer and SVTC, and that agreement (AMEND462693-006) will become null and void with no penalty to
Customer. 

  

	8)	The parties agree that the final outcome of the [...***...] cannot be known at the time of this agreement. Therefore it is agreed that in the event [...***...], then the parties will agree to convene and
decide on next steps. In such case, BioNano Genomics would be under no obligation to [...***...]. In the event that [...***...], then [...***...] will be the responsibility of SVTC. 

8.0 LICENSED TECHNOLOGY: 

The Services listed above and SVTC’s process technology, including recipes and steps, used in the performance of services shall be provided and licensed
to Customer under the terms, conditions and limitations of the Master Services Agreement, which shall override and supersede any terms and conditions in any customer provided documents. 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 9.0 ASSUMPTIONS, RISKS & MITIGATIONS: 

Cornerstone Assumptions 

[...***...] process flow as developed will not require major changes in process integration. 

[...***...] will provide hardware for new wetting quality checks. 
  

			
	Risks	  	Risk Mitigation Plan
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 Exhibit D 

Process Controls and Metrics 

To be defined at a future date 

  
 

 

 

 
  

 AMENDMENT 8 

This Amendment 8, (“Amendment”), dated October 29, 2012 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The parties acknowledge the successful assignment of the Agreement by SVTC Technologies, LLC to Novati Technologies, Inc. (“Novati”) effective as of October 15, 2012. 

 

	 	2)	The parties agree to amend the Agreement describing services that Novati will perform for Customer starting on the Effective Date. 

  

	 	3)	Starting on October 19, 2012 and ending on December 31, 2012, Novati will continue the ongoing Development of the [...***...]. Accordingly, the parties agree to use the Tier 2 pricing in Section 5
of Exhibit A7. The proposed estimated volume is [...***...] over this time period. 

  

	 	4)	Customer agrees to prepay the charges for the activities and engineering hours in item 2) above, for a total amount of [...***...] which is the estimated November and December spend. Novati shall invoice the
November prepayment of [...***...] upon execution of this Amendment, and Customer agrees to pay on or before November 16, 2012. Furthermore, Customer agrees to prepay [...***...] on or before December 1, 2012 which is the
estimated spend for December. 

  

	 	5)	The Wafer minimum Lot size for all activities under this agreement shall be 6. 

  

	 	6)	Any pre-paid funds which are unutilized as of December 31, 2012 shall be carried forward as a credit balance. Any activities, engineering hour charges, or other billable
services in excess of the pre-paid amount shall be reconciled and billed as of December 31, 2012 at the unit cost consistent with that specified in 3) above and are due Net 30. 

 

	 	7)	The parties may extend the term of the Agreement by mutual agreement in writing on a quarterly basis. 

  

	 	8)	Novati’s address for notices, set forth in section 12.8 of the Agreement is hereby replaced with: 2706 Montopolis Drive, Austin, TX 78741, ATTN: Legal Department. 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as
amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 With due authority from our respective companies, we hereby signify our consent to this
Agreement by signing below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	  

	Printed Name:	 	David B. Anderson
	Title:	 	CEO
	Date:	 	  

		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	Chief Executive Officer
	Date:	 	11/14/12

  
 

 

 

 
  

 AMENDMENT 9 

This Amendment 9, (“Amendment”), dated December 31, 2012 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). Novati is the legal successor in interest to SVTC Technologies, LLC on the Agreement. The Agreement mandates that
all changes must be in a writing signed by the parties. Except as provided below, all the provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 

 

	 	1)	The parties agree to amend the Agreement to describe services that will be provided by Novati for Customer on the effective date. Novati will continue to provide to Customer the services described in Amendment 7 for the
fees set forth therein using the Tier 2 pricing in Section 5.0, subject to any additional terms and conditions set forth therein. 

  

	 	2)	The parties hereby agree to amend paragraph 3 of Amendment 7 to revise the expiration date from March 24, 2013 to March 31, 2013 to align with the Novati fiscal quarter. 

 

	 	3)	The parties agree to delete in its entirety Section 6.2 – Phase 2, described in Amendment 7. 

  

	 	4)	The parties agree that section 12.1 of the Agreement is hereby amended to state that the laws of the State of Texas, without regard to the conflict of laws provisions, shall govern this Agreement. 

Effect of this Amendment: In the, event of any conflict between the Agreement and this
Amendment, this Amendment shall control. Except as amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

With due authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 

 

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	Chief Executive Officer
	Date:	 	1-31-13
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	Chief Executive Officer
	Date:	 	Jan 30, 2013

  
 

 

 

 
  

 AMENDMENT 10 

This Amendment 10, (“Amendment”), dated April 1, 2013 (“Effective Date”) is to the Master Services Agreement dated March 2, 2009
(“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The parties agree to amend the Agreement describing services that will be provided by Novati for Customer starting on the Effective Date. Novati will provide to Customer the services described in Exhibit A10 for the
fees set forth therein subject to any additional terms and conditions set forth therein. 

 Effect of this Amendment: In the
event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its
terms. 
 LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future
added attachment must include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
  

	
	 Exhibit A10

 With due authority from our respective companies, we hereby signify our consent to this Agreement by signing
below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	March 18, 2013
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	Chief Executive Officer
	Date:	 	March 15, 2013

  
 

 

 

 
  

 Exhibit A 

Commercial Quotation 
 For
BioNano Genomics’s Alpha Chip Continued Development - Q2’13 - Q1’14 
  

			
	START DATE: 04-01-20139	  	DURATION: Four Fiscal (4) Quarters

 Novati proposes the date above on which Novati will begin providing the following services under the Master Services Agreement
(“Start Date”). Project Duration is the period of time for the project described in this Quotation. 

1.0    DESCRIPTION OF SERVICES: 

Novati shall provide research and development services in support of BioNano Genomics’s Alpha Chip Continued Development Q2’13 -
Q1’14. Novati will start with semiconductor processes that exist or are being developed by BioNano Genomics, and will provide other support as described herein (“Services”). Novati shall use commercially reasonable efforts to perform
the Services requested by BioNano Genomics, subject to the ability of Novati to perform these Services on Novati’s existing equipment and using standard materials and process recipes that are compatible with the equipment and resources of
Novati. 
 2.0    SUMMARY OF SERVICES THAT MAY
BE PROVIDED: 
  

	 	•	 	Fab Services 

  

	 	•	 	Engineering Services 

 3.0    NOVATI SERVICE
DEFINITIONS: 
 Fab Services: 
  

	1.	[...***...] 

  

	2.	[...***...] 

  

	3.	[...***...] 

  

	4.	[...***...] 

  

	5.	[...***...] 

  

	6.	[...***...] 

  

	7.	[...***...] 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 Engineering Services: (Defined in the Agreement) 

 

	 	1.	[...***...] 

  

	2.	These services are to be executed in collaboration with customers direction and management 

4.0    ADDITIONAL SERVICES**: 

 

			
	Additional Training Services	  	[...***...]
	Additional Cubicles & Lockable Office Space	  	[...***...]
	Reticles	  	[...***...]
	Analytical Services	  	[...***...]

  

	**	Additional Services subject to availability 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 5.0    NOVATI SERVICE FEE
SCHEDULE: 
  

											
	 	  	 	  	 Item
	  	Fees	 	 	Frequency
	 a)
	  		  	 Tier 1 Pricing 
	  	 	[...***...	] 	 	Per activity
					
		  		  	 [...***...]
	  	 	[...***...	] 	 	per hour
					
		  		  	 [...***...]
	  				 	per standard price list
					
		  		  	 Tier 1 Minimum Financial Commitment 
	  	 	[...***...	] 	 	Quarterly
					
	 b)
	  		  	 Tier 2 Pricing (Baseline Minimum Financial Commitment) 
	  	 	[...***...	] 	 	Per activity
					
		  		  	 [...***...]
	  	 	[...***...	] 	 	per hour
					
		  		  	 [...***...]
	  				 	per standard price list
					
		  		  	 Tier 2 Minimum Financial Commitment 
	  	 	[...***...	] 	 	Quarterly
					
	c)	  		  	 Tier 3 Pricing
	  	 	[...***...	] 	 	Per activity
					
		  		  	 [...***...]
	  	 	[...***...	] 	 	per hour
					
		  		  	 [...***...]
	  				 	per standard price list
					
		  		  	 Tier 3 Minimum Financial Commitment 
	  	 	[...***...	] 	 	Quarterly
					
	d)	  		  	 Tier 4 Pricing 
	  	 	[...***...	] 	 	Per activity
					
		  		  	 [...***...]
	  	 	[...***...	] 	 	per hour
					
		  		  	 [...***...]
	  				 	per standard price list
					
		  		  	 Tier 4 Minimum Financial Commitment 
	  	 	[...***...	] 	 	Quarterly
					
	 e)
	  		  	 Hot Lot Fee
	  	 	[...***...	] 	 	Per request
					
	 f)
	  		  	 Baseline Minimum Financial Commitment (Tier 2 above)
	  	 	[...***...	] 	 	Quarterly

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 6.0     TERMS: 

 

	1)	The Minimum Financial Commitment (MFG) for Fab Services and Engineering Services shall be per the selected Tier in Section 5. At the signing of contract, the Minimum Financial Commitment will be
set at the Tier 2 Baseline. Novati will invoice Customer [...***...] 15 days prior to the start of the fiscal quarter and each subsequent fiscal month thereafter. All prepayments are due immediately upon receipt of
invoice. Actual usage shall be invoiced at the end of each Novati fiscal month for actual services provided and is due within 30 days from date of invoice. At the end of Novati’s fiscal quarter, the actual usage will be ‘trued-up” against the designated MFC tier, and any under usage shall be invoiced and is due within 30 days from date of invoice. Other than the foregoing, Novati shall invoice Customer when services are
rendered, products shipped and/or deliverables are provided in the Novati fiscal month that they occur. Payments shall be due within 30 days from date of Invoice. 

 

	2)	Customer may change the election of the pricing tier on a quarterly basis by providing 20 days advanced written notice prior to each Novati fiscal quarter. If no written notice is received 20 days prior to the
beginning of any quarter, the pricing tier will automatically be set to Tier 2. 

  

	3)	The first and last billing cycle fees and service quantities other than set up shall be prorated to the actual start date and then continue in accordance with Novati’s fiscal calendar such that all invoicing
shall follow Novati fiscal month start and end dates. 

  

	4)	Additional Activities, Engineering Hours, Additional Tool Training, access to additional equipment and resources, and other Extraordinary Expenses (“Additional Services”) shall be made available at
Novati’s sole discretion and shall be agreed to in writing prior to being performed by Novati BioNano Genomics shall pay for all Additional Services per the terms of the Master Services Agreement. 

7.0     LICENSED TECHNOLOGY: 

The Services listed above and Novati’s process technology, including recipes and steps, used in the performance of services shall be provided and licensed
to Customer under the terms, conditions and limitations of the Master Services Agreement, which shall override and supersede any terms and conditions in any customer provided documents. 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 AMENDMENT 11 

This Amendment 11, (“Amendment”), dated April 29, 2013 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The parties agree to amend the Agreement describing services that will be provided by Novati for Customer starting on the Effective Date. Novati will provide to Customer the services described for the fees set forth
therein subject to any additional terms and conditions set forth therein. 

  

	 	2)	The following activity has occurred against Amendment 10 to date: Novati invoiced Customer the April prepayment against invoice 616 on 3/18/13 for [...***...] and has been paid by Customer. Novati invoiced
Customer the May prepayment against invoice 800 on 4/15/13 for [...***...]. Novati agrees to credit Customer for the invoice amount. 

  

	 	3)	Starting on April 29, 2013 Section 6, item 1 in Amendment 10 shall be replaced and superseded in its entirety with the following. 

 

	 	4)	The Minimum Financial Commitment (MFC) for Fab Services and Engineering Services shall be per the selected Tier in Section 5. At the signing of contract, the Minimum Financial Commitment will be set at the Tier 2
Baseline. Novati will invoice Customer actual usage bi-weekly for actual services provided and will be due immediately upon receipt of invoice. At the end of Novati’s fiscal quarter, the actual usage will
be “trued-up” against the designated MFC tier, and any under usage shall be invoiced and is due immediately upon receipt of invoice. Other than the foregoing, Novati shall invoice Customer when
services are rendered, products shipped and/or deliverables are provided in the Novati fiscal month that they occur. Payments shall be due Net 0 from date of invoice. 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as
amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added
attachment must include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 With due authority from our respective companies, we hereby signify our consent to this
Agreement by signing below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	April 24, 2013
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ R. Erik Holmlin

	Printed Name:	 	R. Erik Holmlin
	Title:	 	President CEO
	Date:	 	24-Apr-2013

  
 

 

 

 
  

 AMENDMENT 12 

This Amendment 12, (“Amendment”), dated December 15, 2013 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The parties agree to amend the Agreement describing services that will be provided by Novati for Customer starting on the Effective date. Novati will provide to Customer the services described for the fees set forth
therein subject to any additional terms and conditions set forth therein. 

  

	 	2)	Starting on December 15th, 2013 Section 4 in Amendment 11 shall be replaced and superseded in its entirety with the original language stated Section 6.0, paragraph (1) in Amendment 10 to reinstate the
prepayment provisions for Q1 2014. 

 Effect of this Amendment: In the event of any conflict between the Agreement and this
Amendment, this Amendment shall control. Except as amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

With due authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 

 

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	DEC 17, 2013
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Lynne R. Rollins

	Printed Name:	 	Lynne R. Rollins
	Title:	 	CFO
	Date:	 	Dec 16 2013

  
 

 

 

 
  

 AMENDMENT 13 

This Amendment 13, (“Amendment”), dated March 7, 2014 (“Effective Date”) is to the Master Services Agreement dated March 2, 2009
(“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	Both parties agree to extend the expiration date of the Agreement from April 1, 2014 to March 31, 2015. 

  

	 	2)	Effective April 1, 2014 item 4 in Amendment 11 shall be replaced and superseded with the following paragraph which was originally set forth in Section 6, item 1 in Amendment 10: 

The Minimum Financial Commitment (MFC) for Fab Services and Engineering Services shall be per the selected Tier in Section 5. At the
signing of contract, the Minimum Financial Commitment will be set at the Tier 2 Baseline. Novati will invoice Customer 1/3 of the quarterly commitment 15 days prior to the start of the fiscal quarter and each subsequent fiscal month thereafter. All
prepayments are due immediately upon receipt of invoice. Actual usage shall be invoiced at the end of each Novati fiscal month for actual services provided and is due within 30 days from date of invoice. At the end of Novati’s fiscal quarter,
the actual usage will be “trued-up” against the designated MFC tier, and any under usage shall be invoiced and is due within 30 days from date of invoice. Other than the foregoing, Novati shall
invoice Customer when services are rendered, products shipped and/or deliverables are provided in the Novati fiscal month that they occur. Payments shall be due within 30 days from date ofinvoice. 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as
amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 

  
 

 

 

 
  

 With due authority from our respective companies, we hereby signify our consent to this
Agreement by signing below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	3/13/2014
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	CEO
	Date:	 	3/13/14

  
 

 

 

 
  

 AMENDMENT 14 

This Amendment 14, (“Amendment”), dated June 10, 2014 (“Effective Date”) is to the Master Services Agreement dated March 2, 2009
(“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The parties agree that the unspent portion of Customer’s MFC for 2Q2014, shall carry forward into the next calendar quarter, 3Q2014. 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as
amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 With due authority from our
respective companies, we hereby signify our consent to this Agreement by signing below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	June 10 2014
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Joel R. Jung

	Printed Name:	 	Joel R. Jung
	Title:	 	CFO
	Date:	 	June 11, 2014

  
 

 

 

 
  

 AMENDMENT 15 

This Amendment 15, (“Amendment”), dated September 18, 2014 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The parties agree that the unspent portion of Customer’s MFC for 3Q2014, shall carry forward into the next calendar quarter, 4Q2014. 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as
amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 With due authority from our
respective companies, we hereby signify our consent to this Agreement by signing below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	25 Sep. 2014
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ R. Erik Holmlin

	Printed Name:	 	R. Erik Holmlin
	Title:	 	President & CEO
	Date:	 	26 Sept 2014

  
 

 

 

 
  

 AMENDMENT 16 

This Amendment 16, (“Amendment”), dated October 7, 2014 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	Pricing for the [...***...] is [...***...] per wafer. Min lot size = [...***...] wafers which is consistent with the current commercial terms. 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as
amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 With due authority from our
respective companies, we hereby signify our consent to this Agreement by signing below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	2014-10-22
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ R. Erik Holmlin

	Printed Name:	 	  

	Title:	 	  

	Date:	 	  

  
 ***Confidential
Treatment Requested 
  
 

 

 

 
  

 AMENDMENT 17 

This Amendment 17, (“Amendment”), dated April 1, 2015 (“Effective Date”) is to the Master Services Agreement dated March 2, 2009
(“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	Both parties agree to extend the expiration date of the Agreement from March 31, 2015 to May 31, 2015. 

Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as
amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added
attachment must include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 With due authority
from our respective companies, we hereby signify our consent to this Agreement by signing below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	4/5/2015
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Mark Borodkin

	Printed Name:	 	Mark Borodkin
	Title:	 	VP, Systems Development
	Date:	 	4/2/2015

  
 

 

 

 
  

 AMENDMENT 18 

This Amendment 18, (“Amendment”), dated June 1, 2015 (“Effective Date”) is to the Master Services Agreement dated March 2, 2009
(“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The parties agree to amend the Agreement describing services that will be provided by Novati for Customer starting on the Effective Date. Novati will provide to Customer the services described in Exhibit A for the fees
set forth therein subject to any additional terms and conditions set forth therein. 

 Effect of this Amendment: In the event of any conflict
between the Agreement and this Amendment, this Amendment shall control. Except as amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added
attachment must include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
  

	
	 Exhibit
A

 With due authority from our respective companies, we hereby signify our consent to this Agreement by signing
below, 
  

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ David B. Anderson

	Printed Name:	 	David B. Anderson
	Title:	 	President and CEO
	Date:	 	6-2-2015
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	Chief Executive Officer
	Date:	 	29 May 2015

  
 

 

 

 
  

 Exhibit A 

Commercial Quotation 
 For
BioNano Genomics’s Alpha Chip Development & Production 
  

			
	
START DATE: 06-01-2015
	  	DURATION: 05-31-2016

 Novati proposes the date above on which Novati will begin providing the following services under the Master Services Agreement
(“Start Date”). Project Duration is the period of time for the project described in this Quotation. 

1.0    DESCRIPTION OF SERVICES: 

Novati shall provide development and pilot production services in support of BioNano Genomics’ Alpha Chip requirements. Novati will start
with semiconductor processes that exist or are being developed by BioNano Genomics, and will provide other support as described herein (“Services”). Novati shall use commercially reasonable efforts to perform the Services requested by
BioNano Genomics, subject to the ability of Novati to perform these Services on Novati’s existing equipment and using standard materials and process recipes that are compatible with the equipment and resources of Novati. 

2.0    SUMMARY OF SERVICES THAT MAY BE
PROVIDED: 
  

	 	•	 	Fab Services 

  

	 	•	 	Engineering Services 

 3.0    NOVATI SERVICE
DEFINITIONS: 
 Fab Services: 
 1.
    [...***...] 
 2.     [...***...] 

3.     [...***...] 

4.     [...***...] 
 5.
    [...***...] 
 6.     [...***...] 
  

	*	or as available per Novati’s then-current standard operating schedule 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 Engineering Services: (Defined in the Agreement) 

 

	 	1.	[...***...] 

  

	2.	These services are to be executed in collaboration with customers direction and management 

4.0    ADDITIONAL SERVICES**: 

 

			
	Additional Training Services	  	[...***...]
		
	Additional Cubicles & Lockable Office Space	  	[...***...]
		
	Reticles	  	[...***...]
		
	Analytical Services	  	[...***...]

  

	**	Additional Services subject to availability 

 5.0    TABLE-1–MOVE PRICING: 
  

																									
	 Tool Type /Area
	  	Category	 	 	Development (6-wfr min lot)	 	 	Fixed Flow 
(25-wfr min lot)	 	 	Fixed Flow 
(25-wfr min lot)	 
	  	 	Tier 1	 	 	Tier 2	 	 	Tier 3	 	 	 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 
	[...***...]	  	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 	 	 	[...***...	] 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 6.0    NOVATI SERVICE FEE
SCHEDULE: 
  

									
	 	  	 	  	 Item
	  	Fees	 	Frequency
	a)	  	Tier 1 Pricing	  		 	
					
		  	    •	  	         [...***...]	  	Per Table 1	 	Per move
				
		  	Engineering Services — Process Engineering Support	  	[...***...]	 	per hour
					
		  		  	 Tier 1 Minimum Financial Commitment
	  	[...***...]	 	Quarterly
				
	b)	  	Tier 2 Pricing (Baseline Minimum Financial Commitment)	  		 	
					
		  	    •	  	         [...***...]	  	Per Table 1	 	Per move
				
		  	Engineering Services — Process Engineering Support	  	[...***...]	 	per hour
					
		  		  	 Tier 2 Minimum Financial Commitment
	  	[...***...]	 	Quarterly
				
	c)	  	Tier 3 Pricing	  		 	
					
		  	    •	  	         [...***...]	  	Per Table 1	 	Per move
				
		  	Engineering Services — Process Engineering Support	  	[...***...]	 	per hour
					
		  		  	 Tier 3 Minimum Financial Commitment
	  	[...***...]	 	Quarterly
				
	d)	  	Expedite Fees	  		 	
				
		  	    [...***...]	  	[...***...]	 	Per request
				
		  	    [...***...]	  	[...***...]	 	CoO approval
				
		  	    [...***...]	  	[...***...]	 	CoO approval

 ADDITIONAL NOTES: 
  

	1.	[...***...] 

	2.	[...***...]. 

	3.	[...***...]. 

	4.	Wafers can be processed through any portion of the process Flow that is designated as “Fixed Flow”, at the Fixed Flow pricing per Table-1, provided minimum lot size
criteria are met. These wafers can be staged for further development / small lot size processing through subsequent processes including TSV and bond. These “child” lots will be billed for all subsequent steps at the appropriate development
pricing tier and minimum lot size. Fixed Flow is defined as any part of the process flow that is mutually agreed as not requiring engineering development or support to be processed in line. 

	5.	Novati and Customer will mutually agree upon production FMEA criteria and risks, based upon completion of TDP (Technology Development Process) criteria to move from POC to a “validated” flow. Once established
and agreed upon with risks effectively mitigated, Novati will commit to deliver wafers against those criteria, and wafers that fail to meet those criteria will be reimbursable or replaced at Novati expense. Prior to TDP completion and established
FMEA criteria, reimbursable events will be limited to those in which a mis-process occurs at fault of Novati, or where a failed Novati tool qualification/spec causes a scrap event. In the event of Novati mis-process / tool-related event causing scrap, if a replacement lot is started it will be elevated to “Hot” status at no additional charge to customer, or “Rocket” status at [...***...] up-charge. Customer may at their discretion apply this status to a lot already in line. If Customer requests expedited status prior to assignment of root cause, Customer agrees to bear potential expenses in the
event root cause is determined not to be a Novati mis-process or 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

	 	 
tool-related issue. Expenses will be totalled and invoiced after the final failure analysis report has been presented to Customer. 

	6.	The next lot to arrive at a step where the previous lot incurred a scrap event will be processed as follows: A single wafer will be sent ahead through the tool to verify correct operation before the rest of the lot is
cleared to process. The lot will then be merged back into a single lot immediately after this operation. No min-lot or split-lot charge shall be assessed for this
activity. 

	7.	Novati shall furnish to Customer a list of current qualification/specs for each tool in Customer’s process flow, and shall update Customer when specifications are revised. 

7.0     TERMS: 
  

	1)	The Minimum Financial Commitment (MFC) for Fab Services and Engineering Services shall be per the selected Tier in Section 5. At the signing of contract unless otherwise specified, the Minimum
Financial Commitment will be set at the Tier 1 Baseline. Novati will invoice Customer [...***...] 15 days prior to the start of the fiscal quarter and each subsequent fiscal month thereafter. All prepayments shall
be due NET15 days from invoice. Actual usage shall be “trued up” at the end of each Novati fiscal month for actual services provided and is due NET15 days from invoice. In the event the designated MFC is not fully consumed through no fault
of Customer, up to [...***...] of the MFC value can be carried forward to the next quarter. The carry-forward amount must be consumed in the subsequent quarter or it shall be forfeited. In the event that extended
tool down events cause the MFC not to be fully consumed, the [...***...] cap shall not apply, and the carry-forward period shall be extended to up to 6 months from the time the tool is
re-qualified to meet specification. 

  

	2)	Customer may change the election of the pricing tier on a quarterly basis by providing 2 weeks advanced written notice prior to each Novati fiscal quarter. If no written notice is received 2 weeks prior to the
beginning of any quarter, the pricing tier will automatically be set to Tier 1. 

  

	3)	The first and last billing cycle fees and service quantities shall be prorated to the actual start date and then continue in accordance with Novati’s fiscal calendar such that all invoicing shall follow Novati
fiscal month start and end dates. 

  

	4)	Additional Activities, Engineering Hours, Additional Tool Training, access to additional equipment and resources, and other Extraordinary Expenses (‘Additional Services”) shall be made available at
Novati’s sole discretion. BioNano Genomics shall pay for all Additional Services per the terms of the Master Services Agreement. 

8.0     LICENSED TECHNOLOGY: 

The Services listed above and Novati’s process technology, including recipes and steps, used in the performance of services shall be provided and
licensed to Customer under the terms, conditions and limitations of the Master Services Agreement, which shall override and supersede any terms and conditions in any customer provided documents. 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 AMENDMENT 19 

This Amendment 19, (“Amendment”), dated July 25 2016 (“Effective Date”) is to the Master Services Agreement dated March 2, 2009
(“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	The parties agree to amend the Agreement to incorporate Exhibit A, describing development services, which will be provided by Novati for Customer starting on the Effective Date for the fees set forth therein.

  

	 	2)	The parties agree to amend the Agreement to extend the expiration date to March 31, 2017. 

 Effect of this
Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in
accordance with its terms. 
 LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any
future added attachment must include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 

Exhibit A – Development Services 
 With due
authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 
  

					
		  	 Novati Technologies, Inc.
	  	
			
	Signature:	  	 /s/ Rod Langley (on behalf of John Behnke)
	  	
	Printed Name:	  	John Behnke	  	
	Title:	  	President	  	
	Date:	  	7-18-2016	  	
			
	Customer:	  	BioNano Genomics	  	
			
	Signature:	  	 /s/ Erik Holmlin
	  	
	Printed Name:	  	Erik Holmlin	  	
	Title:	  	Chief Executive Officer	  	
	Date:	  	7/14/16	  	

  
 

 

 

 
  

 Exhibit A 

Commercial Quotation – Development Services 
  

			
	START DATE: 07-01-2016	  	END DATE: 03-31-2017

 Novati proposes the date above on which Novati will begin providing the following services under the Master Services Agreement
(“Start Date”). Project Duration is the period of time for the project described in this quotation. 

1.0    DESCRIPTION OF SERVICES: 

Novati shall provide development and pilot production services in support of BioNano Genomics’ Alpha Chip requirements. Novati will start
with semiconductor processes that exist or are being developed by BioNano Genomics, and will provide other support as described herein (“Services”). Novati shall use commercially reasonable efforts to perform the Services requested by
BioNano Genomics, subject to the ability of Novati to perform these Services on Novati’s existing equipment and using standard materials and process recipes that are compatible with the equipment and resources of Novati. 

2.0    SUMMARY OF SERVICES THAT MAY BE
PROVIDED: 
  

	 	•	 	Fab Services 

  

	 	•	 	Engineering Services 

  
 

 

 

 
  

 3.0 NOVATI SERVICE DEFINITIONS: 

 

					
	Fab Services:	  			
		
	 1.  [...***...]
	  			
		
	 2.  [...***...]
	  			
		
	 3.  [...***...]
	  			
		
	 4.  [...***...]
	  			
		
	 5.  [...***...]
	  			
		
	 6.  [...***...]
	  			

  

	*	or as available per Novati’s then-current standard operating schedule 

 Engineering Services: (Defined
in the Agreement) 
  

					
	 1.  [...***...]
	  			
		
	 2.  [...***...]
	  			

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 4.0 ADDITIONAL SERVICES**: 

 

			
	Additional Training Services	  	[...***...]
		
	Additional Cubicles & Lockable Office Space	  	[...***...]
		
	Reticles	  	[...***...]
		
	Analytical Services	  	[...***...]

  

	**	Additional Services subject to availability 

 5.0
TABLE-1–MOVE PRICING: 
  

																													
	 Tool Type /Area
	  	Category	 	  	Development
(6-wfr min lot)	 	  	Fixed Flow
(25-wfr min
lot)	 	  	Fixed Flow
(25-wfr min
lot)	 
	  	  	Tier 0	 	  	Tier 1	 	  	Tier 2	 	  	Tier 3	 	  	  
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
								
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
								
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
								
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
								
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
								
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
								
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
								
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 
								
	 [...***...]
	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 	  	 	[...***...]	 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 6.0 NOVATI SERVICE FEE SCHEDULE: 

 

					
	 Item
	  	 Fees
	  	 Frequency

	 a)  Tier 0 Pricing (no MFC)
	  	Per Table 1	  	Per move
			
	 b)  Tier 1 Pricing
	  		  	
			
	 • [...***...]
	  	Per Table 1	  	Per move
			
	 Engineering Services — Process Engineering Support
	  	[...***...]	  	per hour
			
	Tier 1 Minimum Financial Commitment	  	[...***...]	  	Quarterly
			
	 c)  Tier 2 Pricing (Baseline Minimum Financial Commitment)

 
 • [...***...]
	  	Per Table 1	  	Per move
			
	 Engineering Services — Process Engineering Support
	  	[...***...]	  	per hour
			
	Tier 2 Minimum Financial Commitment	  	[...***...]	  	Quarterly
			
	 d)  Tier 3 Pricing

 
 • [...***...]
	  	Per Table 1	  	Per move
			
	 Engineering Services — Process Engineering Support
	  	[...***...]	  	per hour
			
	Tier 3 Minimum Financial Commitment	  	[...***...]	  	Quarterly
			
	 e)  Expedite Fees
	  		  	
			
	 [...***...]
	  	[...***...]	  	Per request
			
	 [...***...]
	  	[...***...]	  	CoO approval
			
	 [...***...]
	  	[...***...]	  	CoO approval

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 ADDITIONAL NOTES: 

1.    Deep silicon etch will have a [...***...] move multiplier applied. [...***...]. 

2.    [...***...]. 

3.    Wafers can be processed through any portion of the process flow that is designated as “Fixed Flow”, at the Fixed Flow
pricing per Table-1, provided minimum lot size criteria are met. These wafers can be staged for further development / small lot size processing through subsequent processes including TSV and bond. These
“child” lots will be billed for all subsequent steps at the appropriate development pricing tier and minimum lot size. Fixed Flow is defined as any part of the process flow that is mutually agreed as not requiring engineering development
or support to be processed in line. 
 4.    The next lot to arrive at a step where the previous lot incurred a scrap event will be
processed as follows: A single wafer will be sent ahead through the tool to verify correct operation before the rest of the lot is cleared to process. The lot will then be merged back into a single lot immediately after this operation. No min-lot or split-lot charge shall be assessed for this activity. In the event of a Novati mis-process / tool-related event causing
scrap, if a replacement lot is started it will be elevated to “Hot” status at no additional charge to customer, or “Rocket” status at [...***...] up-charge. Customer may at their
discretion apply this status to a lot already in line. If Customer requests expedited status prior to assignment of root cause, Customer agrees to bear potential expenses in the event root cause is determined not to be a Novati mis-process or tool-related issue. Expenses will be totaled and invoiced after the final failure analysis report has been presented to Customer. 

5.    Novati shall furnish to Customer a list of current qualification/specs for each tool in Customer’s process flow, and shall
update Customer when specifications are revised. 
 7.0     TERMS: 

 

	1)	The Minimum Financial Commitment (MFC) for Fab Services and Engineering Services shall be per the selected Tier in Section 5. At the signing of contract unless otherwise specified, the Minimum
Financial Commitment will be set at the Tier 1 Baseline. Novati will invoice Customer [...***...] 15 days prior to the start of the fiscal quarter and each subsequent fiscal month thereafter. All prepayments shall
be due NET15 days from invoice. Actual usage shall be “trued up” at the end of each Novati fiscal month for actual services provided and is due NET15 days from invoice. In the event the designated MFC is not fully consumed through no fault
of Customer, up to [...***...] of the MFC value can be carried forward to the next quarter. The carry-forward amount must be consumed in the subsequent quarter or it shall be forfeited. In the event that extended
tool down events cause the MFC not to be fully consumed, the [...***...] cap shall not apply, and the carry-forward period shall be extended to up to 6 months from the time the tool is
re-qualified to meet specification. 

  

	2)	Customer may change the election of the pricing tier on a quarterly basis by providing 2 weeks advanced written notice prior to each Novati fiscal quarter. If no written notice is received 2 weeks prior to the
beginning of any quarter, the pricing tier will automatically be set to Tier 1. 

  

	3)	The first and last billing cycle fees and service quantities shall be prorated to the actual start date and then continue in accordance with Novati’s fiscal calendar such that all invoicing shall follow Novati
fiscal month start and end dates. 

  

	4)	Additional Activities, Engineering Hours, Additional Tool Training, access to additional equipment and resources, and other Extraordinary Expenses (‘Additional Services”) shall be made available at
Novati’s sole discretion. BioNano Genomics shall pay for all Additional Services per the terms of the Master Services Agreement. 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

	5)	This Agreement can be canceled by either party giving 90 days written notice in accordance with the terms of the MSA. 

8.0 LICENSED TECHNOLOGY: 

The Services listed above and Novati’s process technology, including recipes and steps, used in the performance of services shall be provided and licensed
to Customer under the terms, conditions and limitations of the Master Services Agreement, which shall override and supersede any terms and conditions in any customer provided documents. 

  
 

 

 

 
  

 AMENDMENT 20 

This Amendment 20, (“Amendment”), dated August 1, 2016 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, Inc. (“Novati”), and BioNano Genomics (“Customer”). The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all the
provisions of the Agreement shall remain in effect and apply to the amended language. Accordingly, the parties agree to the following: 
  

	 	1)	Novati agrees to provide the production services set forth in Exhibit A in accordance with the provisions of the Production Services Schedule both of which are incorporated into the Agreement by this Amendment.

  

	 	2)	The parties set July 31, 2017 expiration date of Amendment 20 of the Agreement. 

 Effect of this
Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in
accordance with its terms. 
 LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any
future added attachment must include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 Exhibit
A – Production Services 
 Production Service Schedule 

With due authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 

 

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ Rod Langley (on behalf of John Behnke)

	Printed Name:	 	John Behnke
	Title:	 	President
	Date:	 	7/18/16
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	Chief Executive Officer
	Date:	 	7/14/16

  
 

 

 

 
  

 Exhibit A 

Commercial Quotation – Production Services 
  

			
	START DATE: 08-01-2016	  	END DATE: 07-31-2017

 Novati proposes the date above on which Novati will begin providing the following services under the Master Services Agreement
(“Start Date”). Project Duration is the period of time for the project described in this quotation. 

1.0    DESCRIPTION OF SERVICES: 

Novati shall provide production services in support of BioNano Genomics’ Alpha-9 Chip requirements. Novati will
manage the production line to meet the committed production forecast as provided by BioNano Genomics. 

2.0    SUMMARY OF SERVICES THAT MAY BE
PROVIDED: 
  

	 	•	 	Product Wafers 

 3.0    NOVATI SERVICE
DEFINITIONS: 
 Fab Services: 
  

	1.	[...***...] 

  

	2.	[...***...] 

  

	3.	[...***...] 

  

	4.	[...***...] 

  

	5.	[...***...] 

  

	6.	[...***...] 

  

	*	or as available per Novati’s then-current standard operating schedule 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 Engineering Services: (Defined in the Agreement) 

1.    Contracted engineering services may be available to Customer upon request as deemed necessary by Customer, subject to Novati
approval. 
 2.    Engineering support for production wafers shall be provided to perform the agreed production services for Customer in
accordance with the terms of the Production Services Schedule. Any additional engineering support that is requested by Customer, subject to Novati approval, shall be charged engineering hourly rates per Section 6 in Exhibit A to this Amendment.

 4.0    ADDITIONAL SERVICES**: 

 

			
	Additional Training Services	 	[...***...]
		
	Additional Cubicles & Lockable Office Space	 	[...***...]
		
	Reticles	 	[...***...]
		
	Analytical Services	 	[...***...]

  

	**	Additional Services subject to availability 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

5.0    TABLE-2–PRODUCT WAFER
PRICING: 
  
 

 
 For all wafers, the [...***...]. 

A Production Control and Inventory Management fee of [...***...] of the price will be added to each lot shipped. 

Note: Initial default contract value for the first three months is: [...***...]. Customer is to specify in writing at time of execution of this
Amendment if other values are required. Wafer volume and requirements for subsequent months can be adjusted based on Customers’ written adjusted monthly forecast. 

6.0    TERMS: 

 

1)    Customer shall provide a rolling 12 month forecast for product wafers on
a monthly basis. The immediate [...***...] of said forecast shall be considered a binding Take-or-Pay commitment. The minimum monthly forecast shall be
[...***...]. Production deliveries will start in the third month after execution of this Amendment. Example: Amendment start date is August 1, 2016. The first three (3) months committed production forecast would be for November,
December, January respectively. Unless approved by Customer in writing, Novati will limit actual lot sizes in WIP to no more than [...***...]. 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 2)    Customer shall place purchase orders for wafers in minimum lot sizes and pricing
indicated in Table 2 — Product Wafer Pricing — and in accordance with the rolling forecast provided by Customer. Novati shall deliver wafers per individual purchase order subject to the terms of the Agreement. Novati shall ship wafers
within 4 weeks of order placement, and shall maintain any buffer inventory as necessary to meet this lead time commitment. Novati reserves the right, in its sole discretion, to decline purchase orders In excess of the committed forecast, or to
require other than the committed lead time to fulfill such orders. For all orders for which Novati has a lead time of 4 weeks or longer, if Novati is responsible for delivery delays of more than seven (7) days after the committed delivery date,
customer will receive a [...***...] discount for each additional week of delay up to 3 weeks. 
 3)    An Initial Deposit
of 6 weeks of the agreed upon minimum product shipments [...***...] shall be invoiced to customer and due upon execution of this Amendment, in order to reserve future capacity. Customer shall indicate the minimum monthly production quantity in
writing to Novati at the time of execution of this Amendment. Novati shall build buffer inventory and maintain said inventory in the line in order to meet <4 week Cycle Time from order placement in support of Customer’s committed product
requirements. 
 4)    The initial term of this Exhibit A is one (1) year. Production services under this Exhibit A may be
terminated on 90 days written notice. Work in progress and any buffer inventory held in the line at the time of notice of termination shall be used to fulfill the final three months of production forecast. Upon termination, in addition to any
pending charges for services rendered and product deliveries, Customer will be charged liquidated damages to cover Novati’s costs, including without limitation charges for the partially processed buffer inventory in the line at the time of
notice. Buffer inventory and WIP covered in liquidated damages shall be no more than the # of wafers to satisfy the forecast for the 3 months following the termination date. For example, if the forecast for each of months 1, 2, 3 is 6 wafers per
month at time of termination, Customer is liable for liquidated damages of the actual number of wafers in WIP and buffer inventory up to 18 wafers. The Initial Deposit shall be applied to the final invoice for services and liquidated damages, with
any remaining balance being due from Customer within 30 days of the date of the final invoice. In the event of expiration, work may continue after the expiration date only if both parties explicitly allow this in writing. 

5)    All product wafers shipped will conform to the specifications for [...***...] associated with the selected wafer price and
measured at the indicated operations outlined in Table 2. Additionally, all shipped wafers will have an average [...***...]. These measurements will be made inline and In accordance with the following Novati specifications: [...***...].

 6)    A wafer that does not meet the above conditions will be classified as nonconforming material. Nonconformity will be
determined by inline data. In cases of customer returns failure analysis techniques such as SEM and TEM can be used to verify nonconformity. 

7)    Product wafers shall be invoiced upon completion and arrival at Novati’s shipping dock. All wafers are Ex-Works Novati and Customer shall directly arrange shipping and insurance. Payments shall be due NET-30 days from Invoice. 

8)    Borofloat glass lid wafers shall be procured by customer and drop-shipped to Novati in sufficient quantity and lead time as to
support the production requirements. Novati will provide Customer with an update of their glass lid wafer Inventory and 3 month demand forecast within 2 weeks of the Customer submitting the monthly wafer forecast. Novati is not responsible for
shortages resulting from incoming defective glass lid wafers. Customer is responsible for managing the right supply level of glass lid wafers at Novak including a buffer to account for incoming defective lids. 

  
 

 
 ***Confidential Treatment Requested 

 

 
  

 7.0     LICENSED TECHNOLOGY: 

The Services listed above and Novati’s process technology, including recipes and steps, used in the performance of services shall be provided and licensed
to Customer under the terms, conditions and limitations of the Master Services Agreement, which shall override and supersede any terms and conditions in any customer provided documents. 

  
 

 

 

 
  

 PRODUCTION SERVICE SCHEDULE 

This Production Service Schedule (the “Schedule”) is entered into effective as of August 1, 2016, (“Effective
Date”) between NOVATI TECHNOLOGIES, INC., and BioNano Genomics, (“Customer”) as an attachment to the Master Services Agreement (“Agreement”), between
the parties, dated March 2, 2009. Capitalized terms used but not defined herein have the meanings ascribed to them in the Agreement. All terms and conditions in this Schedule are in addition to the terms and conditions set forth in the
Agreement. In the event of any conflict between the provisions of this Schedule and the Agreement, the Agreement shall govern unless explicitly superseded in this Schedule. 

Customer desires that Novati provide manufacturing services to produce certain agreed items for use in Customer’s business or end product
(“Production Services”). This Schedule shall apply only to such production services; other services provided by Novati shall be pursuant to other schedules for such services. 

1. DEFINITIONS 
 1.1. Allowed Delivery
Tolerance means the mutually agreed amount of deviation in the number of units of Product from the exact amount of units of Product Customer has released in a given Product Start Release that may be delivered and be considered to have to have
fulfilled the Product Start Release order. 
 1.2. Critical Step Specification means a mutually agreed specification requested by
Customer and agreed by Novati to be needed for the manufacturing of a Product. The critical step specification is based upon the FMEA approved by the parties and the SPC data available to substantiate the performance levels and expectations of
customer technology. 
 I.3. Delivery Date means the date the Products desired by Customer for delivery to the Delivery Location, as
specified on a Release, or as otherwise agreed to by the parties in writing. 
 1.4. Delivery Location means the location to which
the Products are requested to be delivered, as specified in a Release or through other ordering mechanism. 
 1.5. Engineering Samples
means finished substrate or the Product generated from a finished substrate delivered prior to completion of the Product Production Release Plan that may be provided to Customer’s customer for evaluation purposes. 

1.6. Excess In-Process Loss means any In-Process Loss
during a Novati fiscal quarter in excess the amount allowed by the Mechanical Yield. 
 1.7. FMEA means Failure Mode Effect Analysis,
and is a document used to describe process maturity at the critical steps within the product flow. The FMEA is a living document that will evolve through mutual agreement of the parties throughout the term of this Schedule. 

1.8. In-Process Loss means any loss of partially completed Product substrates on a Production
Line. 
 1.9. In-Process Loss Rate means the rate loss of partially completed Product
substrates on a Production Line as defined by total number of Product substrates lost in a Novati fiscal quarter divided by the total number of Product substrates started in the same Novati Fiscal quarter. 

1.10. Lead Time means the period of time, as may be specified by Novati, between the date a Release is received by Novati and the date
Novati shall ship the Products to the Delivery Location. 
 1.11 Mechanical Yield means the allowable
In-Process Loss Rate of partially completed Product substrates on a Production Line as mutually agreed in this Agreement. 

1.12. Minimum Product Volume Commit means the minimum total amount of dollars of Product defined in the Agreement. 

1.13. Production Line means the process flow sequence, route, recipes, equipment and specifications that have been utilized and
mutually accepted as having had completed a Production Release Plan for one or more Products. 
 1.14. Product or Products mean
finished substrate or substrates (usually wafers) requested of Novati by Customer. 
 1.15. Product Lot means a group of Product
substrates started on the Production Line to be possessed together. 
 1.16. Production Release Plan means a plan that is mutually
agreed between Novati and Customer defining the conditions required for release of a Product from development status to Production. 

  
 

 

 

 
  

 1.17. Prototype or Prototype Product means any Product delivered prior to completion
of the Production Release Plan. 
 1.18. Proven Product means a Product manufactured using a process that has verified functionality
and yield and otherwise meets, and continues to meet, the Production Release Plan as demonstrated in one or more Production Release Lots. 

1.19. Production Release Lot means a group of substrates that are processed together to validate that a Product can go into regular
production pursuant to a Production Release Plan. 
 1.20. Product Start Release means a written order requesting and authorizing
Novati to deliver a specified quantity of Products covered by a contractual commitment, on a specified Delivery Date. 
 1.21. SPC
means Statistical Process Control and is a means for ensuring tools used in the product flow are maintained within an allowable specification range. 

2. Customer Materials: Customer may be obligated to provide certain materials to Novati to enable it to manufacture Products, including
but not limited to process flow, reticles/masks, Product reticle GDSII data, recipes, recipe characterization data, special equipment configurations, and non-Novati standard raw materials as specified in
detail elsewhere in this Agreement. 
 2.1. If specific raw materials are required for the substrates to be processed for Customer,
then it shall be mutually agreed who shall be responsible for procuring and setting stocking levels of such materials. If Novati purchases such materials, and they are such that they cannot be used by Novati for other customers, and if quantities of
such materials are remaining after completion of orders or due to cancellations of orders, Customer agrees to pay Novati for such materials. Depending upon the nature of these materials and only if Customer pays for all packaging, transportation,
and delivery charges, Novati may, in its sole discretion, determine whether such materials will be delivered to Customer. 
 2.2. In-Process Loss Claim Limitations: Unless mutually agreed in writing, Novati will not be liable for the costs of Customer supplier materials in the event of In-Process
Loss. 
 3. Forecasts: Fifteen (15) days prior to the start of each month during the term of this Schedule, Customer shall
provide a rolling forecast for the next 12 months of its desired production quantities. The forecast shall include the number of Products required each month for 12 months. The first 3 months of each 12 month forecast are firm contractual
commitments such that Customer shall be obligated to pay each month to Novati the dollar commitment for each of’ those 3 months notwithstanding any subsequent changes requested by Customer. The remaining 9 months of the forecast may be changed
by Customer from the numbers for the corresponding months in previous monthly forecasts, provided however, that if any materials are procured by Novati solely for the services for Customer in anticipation of a forecast, Customer shall, if requested
by Novati, reimburse Novati for such materials. 
 4. Periodic Management Business Review: Periodically depending on need, but at
least semi-annually, the parties agree to meet to review mutually agreed key metrics for Production Line used for Customer’s Product. 

5. Product Scheduling: Consistent with previously provided forecasts, Customer shall provide Novati regularly, in a format to be
mutually agreed, with an order detail tentatively titled “Product Start Release,” setting forth the dates and quantities of Product it desires to be delivered. Product Releases will be, at a minimum, set by the Minimum Product Volume
Commit. Novati shall review such submitted Product Start Release schedules and shall acknowledge in writing to Customer that all of the information is acceptable; provided, however, if portions of the Product Start Release schedule cannot be
accommodated or met, Novati shall notify Customer and negotiate mutually acceptable changes. 
 6. Product Delivery: Novati will use
commercially reasonable efforts to deliver the Novati-acknowledged volume of Product requested byCustomer within the mutually agreed Lead Time, subject to the Allowed Delivery Tolerance. Customer will be invoiced for the actual amount of Product
delivered or for the charges associated with the Minimum Product Volume Commit, whichever is greater. 
 7. Expedited Product
Schedules: Customer may request Delivery Dates with a Lead Time shorter than the normal Novati-defined Lead Time, which if accepted by Novati, may require additional fees. Customer acknowledges that Novati’s obligations to its other
customers may affect Novati’s ability to agree to Customer’s desired scheduling and agrees that Novati shall have sole discretion with respect to managing the scheduling of Novati resources. 

8. Customer Cancellation Policies: In the event that Customer desires to cancel or delay all or portions of previously scheduled
deliveries, Customer shall notify Novati in writing with specific details of its desired changes. Customer shall remain obligated to pay fees contractually committed, the Minimum Product Volume Commit, and charges owed by Customer under the terms of
this Schedule, including without limitation material expenses due pursuant to Section 2.1. To the extent that minimum commitments are exceeded, cancellation of other orders shall incur a cancellation charge equal to fees incurred for actual
processing performed prior to receipt of the cancellation notice. 
 9. Capacity Constraints and Allocation: At all times during the
Agreement, Novati will allocate manufacturing capacity, components, raw 

  
 

 

 

 
  

 
materials and parts, for manufacture of Products on an equitable basis consistent with its capabilities and prior contractual commitments. If Customer’s forecast exceeds Novati’s then
current ability to supply Customer’s Product, Novati and Customer will negotiate in good faith the terms to, if feasible, add the necessary capacity to meet the forecast at Customer’s cost. Customer acknowledges that clean room space,
equipment availability, purchase lead time and installation lead time may limit Novati’s ability to support Customer’s forecast. Customer acknowledges that Novati’s obligations to other customers may affect Novati’s ability to
agree to Customer’s capacity requests. 
 10. Customer Equipment: In the event Customer desires to install equipment at Novati
premises for use in processing Customer Products, the parties shall separately negotiate and agree to such installation terms and conditions, including but not limited to the cost, timing, and logistics of the installation, as well as related
ongoing costs, maintenance fees, rights, and responsibilities, limitations of use, liabilities and responsibilities for such Customer equipment, Depending upon the volume of production, Customer may be required to pay an additional Equipment Hosting
fee. At Customer’s expense, Customer equipment must be promptly removed and the premises restored to pre-use condition by the effective date of the termination, expiration, or cancellation of this
Agreement. Hosting fees shall apply from the date work begins to install Customer equipment and shall continue until all the equipment is full removed and the space is restored so that other usage of the space may occur. Fees for installation or
removal of Customer equipment will be determined by quote from licensed subcontractors of Novati’s choosing along with a commercially reasonable project management fee. 

11. Warranty: For a period of one year from the date of shipment, Novati warrants that Products shall be processed in compliance with
mutually agreed procedures, the FMEA, and Critical Step Specifications; free of any defect in materials or workmanship above levels demonstrated in the Production Release Plan; and that Product shall be processed in a commercially reasonable manner
consistent with industry standards. Expressly excluded is any warranty that Products shall meet other specifications, goals or requirements of Customer unless mutually agreed. Also expressly excluded is any warranty of Product wafer level test
yield, Product packaged unit electrical yield, Product package unit physical yield or Product reliability unless mutually agreed. NOVATI HEREBY EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED
WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 12.
Warranty Exclusions: The above warranty shall not apply to any Products which, by someone other than Novati, have been subject to (1) accident, abuse, misuse, neglect, improper installation or packaging, repair or alteration,
(2) improper testing or use contrary to any instructions given by Novati, (3) placement in an unsuitable physical or operating environment or improper storage or maintenance improperly by Customer or the Customer’s end customer,
(4) or caused to fail solely or in part as a result of any component, material, product or service supplied by Customer; or (5) any Products with a defect solely or in part caused by the defective Customer proprietary design or other fault
in any property provided by Customer. The above warranty is also not applicable to Prototype or Engineering Sample Product or Products that are not Proven Products. 

13. Warranty Claim Limitations: Under no circumstances will Novati be liable for warranty compensation greater than the fees paid to
Novati for the Product returned. Novati will at it sole option; 1) process replacement Product and deliver to Customer, or 2) pay Customer the fees paid by Customer to Novati for the Product or portion thereof which is the subject of the claim. 

14. Shipment: Title to Products provided by Novati passes to Customer upon receipt by Customer or its carrier at Novati’s shipping
dock, EXW (Incoterms 2010); At Customer’s request, Novati will arrange for transportation at Customer’s expense in accordance with standard industry practices. Novati shall have no responsibility or liability for the actions of any carrier
or for delivery problems to or from Novati. Novati will package substrates for shipment and storage in accordance with standard industry commercial practice at no additional cost to Customer, however, Customer may specify additional packaging
instructions subject to agreement by Novati, with Customer paying for such additional packaging. Nan-substrate deliverables are shipped in a format deemed most appropriate by Novati. 

15. Product Inspection Rights: Customer will be deemed to have waived its rejection rights for nonconformity unless Customer notifies
Novati in writing of any nonconformity within thirty (30) days after receipt (“Inspection Period”). During the Inspection Period, Customer may reject and return to Novati any Products that do not conform to mutually agreed procedures.
Customer’s written notification must specifically identify how the nonconforming Products vary or do not conform. Customer will make transportation arrangements pursuant to standard industry practice, and Novati will reimburse Customer for
reasonable return expenses unless Novati in good faith contests the validity of Customer’s rejection. Customer’s sole and exclusive remedies for Products that fail to conform, unless Novati in good faith contests the validity of
Customer’s rejection, shall be at Novati’s sole discretion: (I) Novati will retain the non-conforming Products and will refund to Customer any amounts that Customer paid to Novati for such
nonconforming Products; (2) Novati will rework the nonconforming Products once and will submit such reworked Products to Customer per the delivery dates agreed upon by the parties; or (3) Novati will replace the non-conforming Products; or (4) Customer accepts the wafers notwithstanding their nonconformity and pays Novati a mutually agreed upon percentage of the amount that Customer would have paid the Novati according
to the order had such wafers conformed to the specifications. If the parties elect option two as a remedy and the Products do not meet specifications the second time they are delivered, Customer may reject and return them to Novati unless Novati in
good faith contests the validity of Customer’s rejection. If not contested, upon receipt Novati will 

  
 

 

 

 
  

 
retain the Products and Novati will refund any money Customer has paid for the non-conforming Products or replace the Products, at Novati’s sole
discretion. 
 16. New Product Introduction: Customer may request priority support for validation of a new Product on an existing
Production Line or at Novati’s sole option, for Prototype Product or Engineering Sample Product. Customer acknowledges that this support shall be subject to non-reoccurring engineering charges and
expedite fees as defined in this Agreement. 
 17. Limitation on Experimentation and Development Holds: Customer may not plan nor
execute experiments, nor development holds on Product Lots started on the Production Line. At customer request, limited by Customer otherwise meeting the Minimum Product Volume Commit, Customer may request Novati to convert in its entirety a Product
Lot to development status. All previously completed steps as well as any yet to be completed steps will be invoiced to the Novati standard development terms defined in this Agreement or other applicable agreements between Customer and Novati. Any
experimentation or development holds done on Product Lots by Customer without prior authorized by Novati will be subject, at Novati’s sole discretion, to conversion to development status with the consequences noted above. 

18. Limitations on Problem Lot Issues: If a Customer’s Product Lot on a Production Line goes on Problem Lot hold three times as
defined in Novati’s standard operating procedure, after the 3rd hold, the Product Lot, at Novati sole option, may be scrapped at Novati’s sole expense. 

19. CHANGE PROCEDURES 

19.1. Novati Requested Change Procedure: Where Novati wishes to make a change to the Production Line (a “Process Change”)
which potentially impacts form, fit, or function, Novati shall issue a process change notice (PCN), which PCN shall include sufficient details regarding the nature of the proposed change, the reason for the proposed change, details regarding its
implementation, the impact of the change (including but not limited to scheduling and Fees) on any contractual commitment or releases, and the proposed implementation date of the engineering change. 

19.2. Promptly after issuing the foregoing PCN, Novati shall, at its expense, provide Customer with a mutually agreed number of
evaluation samples of the affected Product and other information requested by Customer to enable Customer to evaluate the change. Customer may, acting in its reasonable discretion, reject any Process Change Notification and shalt notify Novati in
writing of such rejection within thirty (30) days of time from its receipt of such Product samples and other information. While Customer is considering a Process Change or if Customer rejects a Process Change, Novati shall continue to
manufacture and supply the Product, in accordance with the terms of this Agreement, without the requested Process Change, however Novati may refuse to accept additional Product orders beyond the existing order at the time Novati delivers the PCN to
Customer. Where Customer provides its written approval of the Process Change, Novati shall implement the change on a mutually agreed schedule. 

20. Customer Requested Changes: Customer may, at Customer’s expense, by written notice to Novati, amend Customer drawings or
designs, Production Line details or the Specifications, at any time prior to the manufacture of the affected Products and provided Customer pays to Novati any reasonable non-recurring charges, if any, and/or
revised Fees for such Products, as mutually agreed by the parties in writing, Novati shall implement such amendment within a period of time as mutually agreed by the parties upon validation through a Production Release Plan if necessary. 

21. Additional Indemnity of Novati by Customer: Since the Products that are provided by Novati to Customer will by their nature, be
further processed, transformed, tested, and integrated into Customer’s products without the involvement or control of Novati, it is expressly agreed that Customer shall indemnify, defend, and held Novati harmless from all third party claims of
death, personal injury, costs, or damages of any description, irrespective of any theory of liability including but not limited to negligence, strict or products liability, and whether or not third parties are customers of Customer, where such
claims arise out of or are related to the Products provided to Customer by Novati pursuant to this Agreement. This indemnity is in addition to and is not in lieu of any other indemnity obligations in this Agreement and this indemnity shall be
excluded from and not be subject to any limitation or cap on liability that may be elsewhere in this Agreement. The parties agree that this contractual indemnity shall apply notwithstanding any liability legally attributable to Novati and that this
indemnity is intended to extend to all third party claims of any kind or character, whether fixed or contingent, known or unknown. The parties agree that this indemnity shall survive the completion, expiration and/or termination of the Agreement.
The parties acknowledge that this indemnity was an essential element in this Agreement and that in the absence of this indemnity the pricing and other terms set forth in this Agreement would be substantially different. 

22. Quality & Quality Assurance: Novati shall use commercially reasonable effort to manufacture the Products in
accordance with the then-current, written manufacturing specifications, Novati’s then-current Global Quality Management procedure, and any other mutually agreed quality requirements including, without limitation those in the FMEA. 

23. CAR: Where a non-conformance is identified, Customer may issue a corrective action requests
(“CAR”) to Novati. Novati shall notify Customer as soon as non-conformance identified in a CAR is corrected. Customer will use a CAR process to notify Novati of defective Products

  
 

 

 

 
  

 
(i.e., those not conforming to applicable specifications) or degradation of established quality requirements. Novati will initiate appropriate actions to minimize the possibility that additional
defective Products will be delivered to Customer. Within a commercially reasonable amount of time of CAR notification, Novati will notify Customer in writing of its initial analysis on the cause for the defect and the interim actions being taken to
continue delivery of defect-free Products conforming to applicable specifications while analysis continues to determine root cause and a final corrective action plan. Novati will deliver a formal written response to the CAR (or a request for an
extension) to Customer within 30 (thirty) business days after notice of the CAR from Customer. CAR responses must include (a) a root cause or methodology to arrive at root cause, (b) a containment plan, (c) a corrective action
implementation date, and (d) any follow-on preventive action plans. Upon Customer’s request, Novati will use commercially reasonable efforts to provide such additional support as needed to achieve
full corrective action. All costs incurred for such additional support and other correction action shall be borne by Novati provided that the defect is one for which Novati is responsible under the warranty terms under Section 1L The above
remedy will be in addition to any other rights and remedies Customer may have under this Agreement. 
 24. Production Line Control:
Novati will manage the control of the Product on the Production Line used for Customer’s Product as defined in Novati standard operating procedures. 

25. Data Retention: Product traceability information will be retained by Novati per Novati’s record retention policy but is at a
minimum for 2 years. 
 26. Attachments: 

The Schedule includes the following attachments which are incorporated by this reference: the initial FMEA, the SPC controls, the measurement
plan, and the full customer process flow with agreed to performance specifications. [NOTE: This Schedule and the attachments are to be added to an existing Customer MSA by formal written amendment.] 

  
 

 

 

 
  

 AMENDMENT 21 

This Amendment 21, (“Amendment”), dated March 31, 2017 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, LLC (“Novati”), and BioNano Genomics (“Customer”)• The Agreement mandates that all changes must be in a writing signed by the parties. Except as provided below, all
the provisions of the Agreement shall remain in effect and apply to the amended language, Accordingly, the parties agree to the following: 
  

	 	1)	Both parties agree to extend the expiration date of the Amendment 19 and the End Date of the Exhibit A, Commercial Quotation — Development Services from March 31, 2017 to March 31, 2018.

 Effect of this Amendment: In the event of any conflict between the Agreement and this Amendment, this Amendment shall control. Except as
amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 None. 

With due authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 

 

			
		 	Novati Technologies, Inc.
		
	Signature:	 	 /s/ John R. Behnke

	Printed Name:	 	John R. Behnke
	Title:	 	CEO and President
	Date:	 	4-26-2017
		
	Customer:	 	BioNano Genomics
		
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	CEO
	Date:	 	April 25, 2017

  
 

 

 

 
  

 AMENDMENT 22 

This Amendment 22, (“Amendment”), dated March 31, 2018 (“Effective Date”) is to the Master Services Agreement dated March 2,
2009 (“Agreement”) between Novati Technologies, LLC (“Formerly Novati, now Skorpios”), and BioNano Genomics (“Customer”)• The Agreement mandates that all changes must be in a writing signed by the parties. Except
as provided below, all the provisions of the Agreement shall remain in effect and apply to the amended language, Accordingly, the parties agree to the following: 
  

	 	1)	Both parties agree to extend the expiration date of the Amendment 19 and the End Date of the Exhibit A, Commercial Quotation — Development Services from March 31, 2018 to the earlier of March 31, 2019 or
the execution of a [...***...] between the parties for [...***...]. 

 Effect of this Amendment: In the event of any conflict
between the Agreement and this Amendment, this Amendment shall control. Except as amended or as otherwise set forth in this Amendment, the Agreement shall continue unchanged and in full force and effect in accordance with its terms. 

LIST OF ATTACHMENTS: Following is a list of attachments to this Amendment, including all Schedules and Exhibits. Any future added attachment must
include a dated Amendment or provision referencing the Agreement and must be executed by all parties. 
 None. 

With due authority from our respective companies, we hereby signify our consent to this Agreement by signing below, 

 

			
		 	Skorpios Technologies, Inc. (f/k/a
		 	Novati Technologies, LLC)
		
	Signature:	 	 /s/ John Hamma

	Printed Name:	 	John Hamma
	Title:	 	SVP Foundry Services
	Date:	 	March 31, 2018
		
	Customer:	 	Bionano Genomics
		
	Signature:	 	 /s/ Erik Holmlin

	Printed Name:	 	Erik Holmlin
	Title:	 	CEO
	Date:	 	March 31, 2018

  
 ***Confidential
Treatment RequestedEX-10.25

 Exhibit 10.25 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 LICENSE
AGREEMENT 
 BETWEEN PRINCETON UNIVERSITY AND 

BIONANOMATRIX LLC 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
			
	1.	 	 Definitions
	  	 	1	 
			
	2.	 	 Grant of License
	  	 	4	 
				
		 	2.1	  	 Grant of License
	  	 	4	 
				
		 	2.2	  	 Limitation
	  	 	4	 
				
		 	2.3	  	 Covenant not to Sue
	  	 	4	 
				
		 	2.4	  	 Notice Provision
	  	 	4	 
			
	3.	 	 Sublicensing
	  	 	4	 
				
		 	3.1	  	 Sublicense Grant
	  	 	4	 
				
		 	3.2	  	 Notice
	  	 	5	 
				
		 	3.3	  	 Continuation of Sublicenses
	  	 	5	 
			
	4.	 	 Ownership
	  	 	5	 
				
		 	4.1	  	 Princeton Improvements
	  	 	5	 
				
		 	4.2	  	 Joint Improvements
	  	 	5	 
				
		 	4.3	  	 BioNanomatrix Improvements
	  	 	5	 
			
	5.	 	 Due Diligence
	  	 	5	 
				
		 	5.1	  	 Commercially Reasonable Efforts
	  	 	5	 
				
		 	5.2	  	 Judgment
	  	 	5	 
				
		 	5.3	  	 Governmental Approvals
	  	 	5	 
				
		 	5.4	  	 Milestones
	  	 	5	 
			
	6.	 	 Payment Terms
	  	 	6	 
				
		 	6.1	  	 License Payment
	  	 	6	 
				
		 	6.2	  	 License Maintenance Fee
	  	 	6	 
				
		 	6.3	  	 Sublicense Income
	  	 	6	 
				
		 	6.4	  	 Royalties on Licensed Products
	  	 	6	 
				
		 	6.5	  	 Royalties for Services
	  	 	7	 
				
		 	6.6	  	 Third Party Payments
	  	 	7	 
				
		 	6.7	  	 Sales to the United States Government
	  	 	7	 
				
		 	6.8	  	 Payment
	  	 	7	 
				
		 	6.9	  	 Written Statement
	  	 	8	 
				
		 	6.10	  	 Books and Records; Audits
	  	 	8	 

  
 i 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	  	 	  	Page	 
				
		 	6.11	  	 Taxes
	  	 	8	 
				
		 	6.12	  	 Reports
	  	 	9	 
			
	7.	 	 Confidentiality
	  	 	9	 
				
		 	7.1	  	 Confidential Information
	  	 	9	 
				
		 	7.2	  	 Disclosure of Confidential Information
	  	 	9	 
				
		 	7.3	  	 Exceptions
	  	 	9	 
				
		 	7.4	  	 Survival
	  	 	10	 
			
	8.	 	 Use of Names
	  	 	10	 
				
		 	8.1	  	 Use of Names
	  	 	10	 
			
	9.	 	 Patent Prosecution and Maintenance
	  	 	10	 
				
		 	9.1	  	 Patent Filings for Inventions
	  	 	10	 
				
		 	9.2	  	 Amendments
	  	 	10	 
				
		 	9.3	  	 BioNanomatrix Improvements
	  	 	10	 
				
		 	9.4	  	 Initial Costs
	  	 	11	 
				
		 	9.5	  	 Foreign Applications
	  	 	11	 
				
		 	9.6	  	 Discontinuance
	  	 	11	 
				
		 	9.7	  	 Recordation
	  	 	11	 
				
		 	9.8	  	 Cooperation
	  	 	11	 
			
	10.	 	 Patent Marking
	  	 	12	 
				
		 	10.1	  	 Patent Marking
	  	 	12	 
			
	11.	 	 Patent Infringement
	  	 	12	 
				
		 	11.1	  	 Infringement of Invention
	  	 	12	 
				
		 	11.2	  	 Infringement of Third Party Rights
	  	 	13	 
				
		 	11.3	  	 Cooperation
	  	 	13	 
			
	12.	 	 Limited Warranty
	  	 	14	 
				
		 	12.1	  	 Princeton Representations and Warranties
	  	 	14	 
				
		 	12.2	  	 Disclaimer of Warranties
	  	 	14	 
				
		 	12.3	  	 Limitation of Liability
	  	 	14	 
				
		 	12.4	  	 Further Disclaimer of Warranties
	  	 	14	 
			
	13.	 	 Term and Termination
	  	 	15	 

  
 ii 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	  	 	  	Page	 
				
		 	13.1	  	 Term
	  	 	15	 
				
		 	13.2	  	 Termination by BioNanomatrix
	  	 	15	 
				
		 	13.3	  	 Termination by Princeton
	  	 	15	 
				
		 	13.4	  	 Survival of Obligations
	  	 	15	 
				
		 	13.5	  	 Section 365(n)
	  	 	15	 
			
	14.	 	 Indemnification; Insurance
	  	 	16	 
				
		 	14.1	  	 Indemnification by BioNanomatrix
	  	 	16	 
				
		 	14.2	  	 Insurance
	  	 	16	 
			
	15.	 	 Miscellaneous Provisions
	  	 	16	 
				
		 	15.1	  	 Assignment
	  	 	16	 
				
		 	15.2	  	 Export Controls
	  	 	16	 
				
		 	15.3	  	 Payment, Notices and Other Communications
	  	 	17	 
				
		 	15.4	  	 Governing Law
	  	 	17	 
				
		 	15.5	  	 Entire Agreement
	  	 	17	 
				
		 	15.6	  	 Further Actions
	  	 	17	 
				
		 	15.7	  	 Severability
	  	 	18	 
				
		 	15.8	  	 No Waiver
	  	 	18	 
				
		 	15.9	  	 Binding Effect
	  	 	18	 
				
		 	15.10	  	 Amendment
	  	 	18	 
				
		 	15.11	  	 Headings
	  	 	18	 
				
		 	15.12	  	 Force Majeure
	  	 	18	 
				
		 	15.13	  	 Independent Contractors
	  	 	18	 
				
		 	15.14	  	 Counterparts
	  	 	18	 

  
 iii 

 LICENSE AGREEMENT 

BETWEEN PRINCETON UNIVERSITY AND 

BIONANOMATRIX LLC 
 THIS LICENSE
AGREEMENT (this “Agreement”) is made as of the 7th day of January, 2004 (the “Effective Date”) by and between the Trustees of PRINCETON UNIVERSITY, a
not-for-profit corporation duly organized and existing under the laws of the State of New Jersey, U.S.A. (“Princeton”), and BIONANOMATRIX LLC, a limited
liability company duly organized and existing under the laws of the State of Delaware (“BioNanomatrix”). 
 BACKGROUND 

WHEREAS, certain inventions disclosed under [...***...], generally characterized as [...***...], [...***...],
[...***...], and [...***...] (collectively, the “Inventions”) were made in the course of research at Princeton by the inventors listed on Exhibit A (the “Inventors”); 

WHEREAS, BioNanomatrix wishes to obtain certain rights from Princeton for the commercial development, manufacture, use and sale of the
Inventions; 
 WHEREAS, Princeton is willing to grant certain rights and licenses with respect to the Inventions in accordance with the
terms and conditions of this Agreement; and 
 WHEREAS, Princeton is desirous that the Inventions be developed and utilized to the fullest
extent so that the benefits can be enjoyed by the general public. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants
contained herein, and intending to be legally bound hereby, the parties hereto agree as follows: 
 1. Definitions. 

1.1 “Affiliate” means (i) any corporation or business entity that directly or indirectly controls, is controlled by, or
is under common control with BioNanomatrix to the extent of at least 50% of the outstanding stock or other measure of voting rights with respect to the management of the corporation or business entity and (ii) any joint venture in which
BioNanomatrix or an Affiliate participates that markets Licensed Products or Services. 
 1.2 “BioNanomatrix Improvement”
shall mean any modification, enhancement or other improvement developed solely by BioNanomatrix, its employees, consultants or [...***...], unless (a) all or part of the cost thereof is paid from Princeton funds or from funds administered
by Princeton, (b) such modification, enhancement or improvement is made as a direct result of Princeton duties, or (c) 

  
 ***Confidential
Treatment Requested 
  
 1 

 
such modification, enhancement or improvement has been developed in whole or in part through the utilization of Princeton resources (except as otherwise set forth in a written agreement between
BioNanomatrix and Princeton or one of its facilities relating to the use of Princeton resources) in which case, such modification, enhancement or improvement shall be considered a Joint Improvement. 

1.3 “Federal Government Interest” shall mean the rights of the United States Government and agencies thereof under Public
Laws 96-517, 97-256 and 98-620, codified at 35 U.S.C. §§200-212, and any
regulations issued thereunder, as such statute or regulations may be amended from time to time hereafter. 
 1.4 “Field of
Use” shall mean all fields of use except for any claimed methods of creating or fabricating nano or microstructures by means of [...***...]. 

1.5 “Inventions” shall mean the inventions covered by claims of the Princeton Patent Rights that are owned or controlled by
Princeton and are listed on Exhibit A, and that are contained within the Field of Use. 
 1.6 “Joint Improvement”
shall mean any modification, enhancement or other improvement relating to the Inventions developed jointly by both Princeton and BioNanomatrix inventors, as determined by U.S. patent law. 

1.7 “Licensed Method” shall mean any process or method that is covered by the Princeton Patent Rights whose use or practice
would constitute, but for the license granted to BioNanomatrix pursuant to this Agreement, an infringement of a Valid Claim of the Princeton Patent Rights. 

1.8 “Licensed Product” shall mean any material or product or kit, or any process, or procedure that (1) would
constitute, but for the license granted to BioNanomatrix pursuant to this Agreement, an infringement of a Valid Claim of the Princeton Patent Rights or (2) is developed, made, sold, registered, or practiced using Licensed Method or which may be
used to practice the Licensed Method, in whole or in part. 
 1.9 “Net Sales” shall mean the total of [...***...].

 1.10 “Princeton Improvement” shall mean any modification, enhancement or other improvement to the Inventions developed
solely by Princeton. 
 1.11 “Princeton Patent Rights” shall mean all rights embodied in PCT patent applications bearing
serial nos. [...***...], and U.S. patent 

  
 ***Confidential
Treatment Requested 
  
 2 

 
application bearing serial no. [...***...], corresponding U.S. and foreign patent applications or issued patents, including any provisionals, divisionals, continuations, reissues and
extensions derived therefrom, such as patent term restorations, supplementary protection certificates, etc., to the foregoing that may be filed by or granted to Princeton during the term of this Agreement, to the fullest extent that Princeton
currently has, or in the future is adjudicated by a court of competent jurisdiction to have, rights in the aforementioned PCT and U.S. patent applications. 

1.12 “Services” means the use of the Licensed Product or Licensed Method to provide a service to an independent third party.

 1.13 “Service Income” means the total of [...***...]. 

1.14 “Sublicensee Income” means all [...***...]; provided, that, Sublicensee Income shall not include:
[...***...]. 
 1.15 “Territory” shall mean all countries of the world. 

1.16 “Valid Claim” shall mean (i) a claim of an issued and unexpired patent included within the Princeton Patent Rights
which has not been held invalid in a final decision of a court of competent jurisdiction from which no appeal may be taken, and which has not been disclaimed or admitted to be invalid or unenforceable through reissue or otherwise, or (ii) a
claim of a pending patent application within the Princeton Patent Rights and for which not more than five (5) years has elapsed from the filing date to which the claim is entitled. 

  
 ***Confidential
Treatment Requested 
  
 3 

 2. Grant of License. 

2.1 Grant of License. Subject to Section 12.1 and the other limitations set forth in this Agreement and subject to the Federal
Government Interest, if any, Princeton hereby grants to BioNanomatrix in the Territory a worldwide, exclusive right and license in the Field of Use under the Princeton Patent Rights to make, have made, use, have used, reproduce, sublicense, create
and implement improvements, distribute, import, export, market, promote, offer to sell, sell, have sold, rent, and lease Licensed Products and Services, including, without limitation, the right to make, have made, further develop; improve, use, sell
and distribute the Licensed Products and Services for all commercial, military and other applications and to practice the Licensed Method. For purposes of clarification, nothing contained in this Agreement shall prevent BioNanomatrix from utilizing
any intellectual property of third parties, or any intellectual property developed by BioNanomatrix after the date hereof, relating to [...***...], alone or in combination with the intellectual property rights granted under this Agreement.

 It being expressly understood and acknowledged by BioNanomatrix that in so utilizing such intellectual property, it may be necessary to acquire rights to
other Princeton patents or claims, including but not limited to those claiming [...***...], that are not licensed herein. No implied license to such other Princeton patents, or claims, including but not limited to those claiming
[...***...], is implied, or conferred in this Section 2.1. 
 2.2 Limitation. Princeton agrees not to license, assign or
otherwise transfer any portion of the Inventions in the Field of Use, except that Princeton retains the rights to use the Inventions for educational and internal research and development activities throughout Princeton, including the right to
develop Princeton Improvements to the Inventions and apply for government grants relating thereto. For the avoidance of doubt, noting contained herein shall prevent Princeton from licensing to any third party any Princeton Patent Rights outside of
the Field of Use. 
 2.3 Covenant not to Sue. BioNanomatrix hereby grants, and will cause its Affiliates, licensees and sub-licensees to grant, a limited covenant not to sue under the Princeton Patent Rights to one Princeton designee. The scope of the covenant not to sue granted under the Princeton Patent Rights shall be limited to
the use, manufacture, sell or offer for sale of [...***...] machines, parts and accessories, and improvements to any of the preceding, that are covered by a Valid Claim of the Princeton Patent Rights. The parties agree that the initial
Princeton designee shall be the [...***...]. Princeton reserves the right to change the Princeton designee from time to time. 
 2.4
Notice Provision. Provided BioNanomatrix is in compliance with all of the terms under this Agreement and where Princeton is legally able, for a period of [...***...] from the Effective Date, Princeton shall make a good faith effort to
disclose to BioNanomatrix on a non-exclusive basis, non-confidential information of any Princeton Improvements to the Inventions within the Field of Use, made to
Princeton within a reasonable time after it has been disclosed to Princeton. 
 3. Sublicensing. 

3.1 Sublicense Grant. Princeton grants to BioNanomatrix the right to grant sublicenses to 

third parties and Affiliates under the licenses granted in Sections 2.1 and 2.2. To the extent applicable, such sublicenses shall include all of the rights of
and obligations due to Princeton (and, if applicable, to the United States Government) that are contained in this Agreement. 

  
 ***Confidential
Treatment Requested 
  
 4 

 3.2 Notice. Within [...***...] after execution thereof, BioNanomatrix shall provide
Princeton with a copy of each sublicense issued hereunder, subject to any confidentiality obligations. 
 3.3 Continuation of
Sublicenses. Upon termination of this Agreement for any reason and within [...***...] of such termination, any sublicensee not then in default shall have the right to request in writing that its sublicense be assigned to Princeton. Such
assignment shall be subject to Princeton’s approval, such approval not to be unreasonably withheld. Additionally, Princeton shall in good-faith consider any reasonable request by a sublicensee for a modification of its obligations under the
sublicense 
 4. Ownership. Subject to Section 12.1, Princeton shall have and retain all right, title and interest to the Inventions, subject to
the license rights and Federal Government Interest set forth in Section 2. 
 4.1 Princeton Improvements. Princeton Improvements
shall be owned by Princeton. 
 4.2 Joint Improvements. Joint Improvements shall be owned jointly by Princeton and BioNanomatrix and
[...***...]. 
 4.3 BioNanomatrix Improvements. BioNanomatrix Improvements shall be owned by BioNanomatrix. 

5. Due Diligence. 
 5.1 Commercially
Reasonable Efforts. BioNanomatrix shall use commercially reasonable efforts to develop, test, obtain regulatory approval, manufacture, market and sell Licensed Products and shall earnestly and diligently endeavor to market the same within a
reasonable time after execution of this Agreement and in quantities sufficient to meet the market demands therefore. 
 5.2 Judgment.
BioNanomatrix shall be entitled to exercise prudent and reasonable business judgment in meeting its diligence obligations hereunder. 
 5.3
Governmental Approvals. BioNanomatrix shall use commercially reasonable efforts to obtain all necessary governmental approvals for the manufacture, use and sale of Licensed Products or Services. 

5.4 Milestones. 
 (a)
BioNanomatrix shall raise at least [...***...] on or before [...***...]. 
 (b) BioNanomatrix shall have raised at least
[...***...] prior to [...***...]. 

  
 ***Confidential
Treatment Requested 
  
 5 

 (c) BioNanomatrix shall prepare a full business plan suitable for distribution to additional
investors by [...***...]. 
 (d) BioNanomatrix shall develop a [...***...] incorporating at least a portion of the Princeton
Patent Rights by [...***...]. 
 (e) BioNanomatrix shall identify a [...***...] by [...***...]. 

(f) BioNanomatrix shall achieve a first commercial sale of Licensed Products or Licensed Methods by [...***...]. 

(g) BioNanomatrix shall achieve total sales of [...***...] of at least [...***...] during the calendar year ending
[...***...]. 
 6. Payment Terms. 

6.1 License Payment. BioNanomatrix agrees to pay to Princeton a license fee of [...***...] (the “License Fee”). The
License Fee shall be payable by BioNanomatrix in [...***...]. In the event this Agreement is terminated by BioNanomatrix for any reason before [...***...], then BioNanomatrix shall not be obligated to [...***...]. The License Fee
is [...***...]. After payment of these amounts, there shall be no further payment obligations of BioNanomatrix except as set for the Sections 6.2 through 6.8. 

6.2 License Maintenance Fee. BioNanomatrix agrees to pay to Princeton a license maintenance fee of [...***...] beginning three
years after the Effective Date, and continuing annually on the anniversary of the Effective Date each subsequent year (the “License Maintenance Fee”); provided that, beginning with the first commercial sale of a
Licensed Product or Service, the License Maintenance Fee payable on any due date shall be reduced by the amount of any earned royalty paid to Princeton on sales of Licensed Product or Services during the preceding 12 month period. The License
Maintenance Fee is [...***...]. 
 6.3 Sublicense Income. BioNanomatrix shall pay to Princeton [...***...] of all
Sublicense Income, to be paid in accordance with the schedule and conditions in Sections 6.5, 6.6(b), 6.7 and 6.8. 
 6.4 Royalties on
Licensed Products. BioNanomatrix shall pay to Princeton a royalty of [...***...] of Net Sales of Licensed Products, during the term of this Agreement. Sales among BioNanomatrix, its Affiliates and its sublicensees for ultimate third party
use shall be disregarded for purposes of computing royalties. Royalties shall be payable only upon sales 

  
 ***Confidential
Treatment Requested 
  
 6 

 
or transfers between unrelated third parties and shall be based on arms length consideration. Notwithstanding anything to the contrary contained herein, in the event that a Licensed Product is
also covered by valid claim of a patent right or is also developed, made, sold, registered or practiced using a method licensed from Princeton pursuant to a separate agreement, then BioNanomatrix shall only be required to pay to Princeton
[...***...]. 
 6.5 Royalties for Services. BioNanomatrix shall pay to Princeton a royalty of [...***...] of Service
Income, during the term of this Agreement. Sales among BioNanomatrix, its Affiliates and its sublicensees for ultimate third party use shall be disregarded for purposes of computing royalties. Royalties shall be payable only upon sales or transfers
between unrelated third parties and shall be based on arms length consideration. Notwithstanding anything to the contrary contained herein, in the event that a Service is also covered by valid claim of a patent right or is also developed, made,
sold, registered or practiced using a method licensed from Princeton pursuant to a separate agreement, then BioNanomatrix shall only be required to pay to Princeton [...***...]. 

6.6 Third Party Payments. 

(a) If BioNanomatrix, in order to make, use, sell or otherwise dispose of Licensed Products or Services in any jurisdiction, reasonably
determines that it must make payments (“Third Party Payments”) to one or more independent third parties to obtain license or similar rights to make, use, sell or otherwise dispose of Licensed Products or Services in said
jurisdiction, BioNanomatrix may reduce the future royalties due Princeton pursuant to Section 6.4 or 6.5 by the amount of [...***...]. 

(b) In the event that any patent or any claim thereof included within the Princeton Patent Rights shall be held invalid in a final decision by
a court of competent jurisdiction and last resort in any country and from which no appeal has or can be taken, all obligation to make Payments based on such patent or claim shall cease as of the date of such final decision with respect to such
country. BioNanomatrix shall not, however, be relieved from paying any royalties that accrued before such claim was asserted or that are based on another patent or claim not involved in such decision. 

6.7 Sales to the United States Government. If a license to the Invention has been granted to the United States Government, no royalties
shall be payable hereunder on Licensed Products or Services sold to the United States Government. BioNanomatrix and its sublicensees shall [...***...]. 

6.8 Payment. 

  
 ***Confidential
Treatment Requested 
  
 7 

 (a) After [...***...], the royalties payable to Princeton shall be made by BioNanomatrix to
Princeton within [...***...] during the term of this Agreement. After termination or expiration of this Agreement, a final payment shall be made by BioNanomatrix covering the whole or partial calendar quarter. Each quarterly payment shall be
accompanied by a written statement of royalties as described in Section 6.9 hereunder. 
 (b) All payments shall be payable in United
States Dollars in Princeton, New Jersey. When Licensed Products or Services are sold for monies other than United States Dollars, such amounts shall first be determined in the foreign currency of the country in which such Licensed Products or
Services were sold and then converted into equivalent United States Dollars. The exchange rate will be the United States Dollar buying rate quoted in the Wall Street Journal on the last day of the applicable reporting period. 

(c) In the event any amounts due Princeton hereunder, including [...***...], are not received when due, BioNanomatrix shall pay to
Princeton interest charges at a rate of [...***...] per annum. Such interest shall be calculated from the date payment was due until actually received by Princeton. 

6.9 Written Statement. Along with each remittance of payments to Princeton, BioNanomatrix shall include a report covering
BioNanomatrix’s most recently completed calendar quarter and will show the payments in U.S. Dollars with respect to Net Sales and sublicensing revenue. If no sales of Licensed Products or Services have been made during any reporting period, a
statement to this effect shall be made by BioNanomatrix. 
 6.10 Books and Records; Audits. BioNanomatrix agrees to maintain and
retain, in accordance with generally accepted accounting practices, complete and accurate records showing all transactions and information relating to this Agreement for a period of three years from the date of entry to which they pertain. Upon the
written request of Princeton and not more than once in each calendar year, BioNanomatrix shall permit an independent certified public accounting firm (other than on a contingency fee basis) selected by Princeton and acceptable to BioNanomatrix
(which acceptance by BioNanomatrix shall not be unreasonably withheld), to have access during normal business hours to such records of BioNanomatrix as may be reasonably necessary to verify BioNanomatrix’s compliance with the payment terms of
Section 6. The accounting firm shall enter into an acceptable and customary confidentiality agreement with BioNanomatrix obligating the accounting firm to retain in confidence all information of BioNanomatrix which it obtains in performing such
audits hereunder, and such audit shall be subject to BioNanomatrix’s third party confidentiality obligations. Any audit under this Section 6.10 shall be at the expense of Princeton, provided, however, if such audit reveals an underpayment
by BioNanomatrix of more than [...***...], the cost of such audit shall be paid by BioNanomatrix. 
 6.11 Taxes. BioNanomatrix
shall be responsible for any and all taxes, fees, or other charges imposed by the government of any country outside the United States on the remittance 

  
 ***Confidential
Treatment Requested 
  
 8 

 
of royalty income for sales occurring in any such country other than income taxes due from Princeton. BioNanomatrix shall also be responsible for all bank transfer charges. 

6.12 Reports. Beginning [...***...], and annually thereafter, BioNanomatrix shall submit to Princeton a progress report covering
BioNanomatrix’s activities related to the development of all Licensed Products and Services. Such reports shall include sufficient information to enable Princeton to determine BioNanomatrix’s progress in fulfilling its obligations under
Section 5 hereunder. 
 7. Confidentiality. 

7.1 Confidential Information. The parties understand and agree that in the performance of this Agreement each party may have access to
proprietary or confidential data or information of the other party, including, but not limited to, trade secrets, intellectual property, services and/or the business, finances, or affairs of either party (“Confidential
Information”). Confidential Information may be communicated orally, visually, in writing or in any other recorded or tangible form. All data and information shall be considered to be Confidential Information hereunder (i) if either
party has marked them as such, (ii) if either party, orally or in writing, has advised the other party of their confidential nature, or (iii) if, due to their character or nature, a reasonable person in a like position and under like
circumstances would treat them as confidential. 
 7.2 Disclosure of Confidential Information. During the term of this Agreement,
either party may disclose certain Confidential Information (the “Disclosing Party”) to the other party (the “Receiving Party”) solely to permit the performance of obligations under this Agreement. The Receiving
Party shall refrain from using, exploiting, or copying any and all Confidential Information for any purposes or activities other than those specifically authorized in this Agreement. The Receiving Party shall not disclose any Confidential
Information to any third party, except to its employees, agents, representatives or sub-distributors as necessary for the performance of its obligations under this Agreement. Each party shall implement
effective security procedures in order to avoid disclosure or misappropriation of the other party’s Confidential Information. Each employee, agent or representative who will have access to any Confidential Information shall execute a reasonable
nondisclosure agreement which prohibits the unauthorized use or disclosure of any of the Disclosing Party’s Confidential Information. The Receiving Party shall immediately notify the Disclosing Party of any unauthorized disclosure or use of any
Confidential Information by the Disclosing Party that comes to Receiving Party’s attention and shall take all action that the Disclosing Party reasonably requests to prevent any further unauthorized use or disclosure thereof. 

7.3 Exceptions. The provisions of this Section 7 will not apply, or will cease to apply, to Confidential Information supplied by
the Disclosing Party that (i) was in the Receiving Party’s possession prior to receipt from the Disclosing Party as shown by files existing at the time of disclosure, (ii) has come into the public domain other than through a breach of
confidentiality by the Receiving Party, (iii) was developed independently by employees of the Receiving Party or by persons who have not had access to the Disclosing Party’s Confidential Information, (iv) was or is lawfully obtained,
directly or indirectly, by the Receiving Party from a third party under no obligation of confidentiality, or (v) is required to be disclosed pursuant to 

  
 ***Confidential
Treatment Requested 
  
 9 

 
any statutory or regulatory provision or court order; provided, however, that the Receiving Party provides notice thereof to the Disclosing Party, together with the statutory or regulatory
provision, or court order, on which such disclosure is based, as soon as practicable prior to such disclosure so that the Disclosing Party has the opportunity to obtain a protective order or take other protective measures as it may deem necessary
with respect to such information. 
 7.4 Survival. The obligations of the parties under this Section 7 shall remain in effect
for five (5) years from the date of termination or expiration of this Agreement. 
 8. Use of Names. 

8.1 Use of Names. Nothing contained in this Agreement shall be construed as granting any right to the parties to use in advertising,
publicity or other promotional activities any name, trade name, trademark or other designation of the other party (including contraction, abbreviation or simulation of any of the foregoing). Unless required by law, the use by one party of the other
party’s name is expressly prohibited, and such party shall not use such names of the other party with such party’s prior written consent. 
 9.
Patent Prosecution and Maintenance. 
 9.1 Patent Filings for Inventions. Princeton shall diligently prosecute and maintain
all United States and foreign patents comprising Princeton Patent Rights using counsel designated by BioNanomatrix, subject to Princeton’s approval, not to be unreasonably withheld. Patent counsel shall take instructions only from Princeton,
unless given permission by Princeton to take advice from BioNanomatrix; provided, however, that BioNanomatrix shall not be prohibited from contacting such patent counsel to participate in and provide comments on the filing, prosecution
and maintenance of patents under Princeton Patent Rights. Princeton shall promptly deliver to BioNanomatrix, or have patent counsel deliver to BioNanomatrix, any communications with the applicable patent office, including without limitation, copies
of all office actions and drafts of all proposed responses and any patentability search reports made by patent counsel, including patents located, a copy of each patent application, and each patent that issues thereon. It is the intent of the
parties that all materials shall be provided to BioNanomatrix with appropriate lead time for BioNanomatrix to review and comment upon such materials prior to their submission to the applicable patent office. 

9.2 Amendments. Princeton shall give due consideration to amending any patent application to include claims reasonably requested by
BioNanomatrix to protect the Licensed Products and Services contemplated to be sold under this Agreement. 
 9.3 BioNanomatrix
Improvements. At BioNanomatrix’s cost and expense, BioNanomatrix shall file and prosecute on its own behalf any applications for patent rights relating to any BioNanomatrix Improvements after the Effective Date, and any patents issued on
the BioNanomatrix Improvements shall be owned by BioNanomatrix and shall be in BioNanomatrix’s name. 
 9.4 Initial Costs.
BioNanomatrix shall pay Princeton [...***...] relating to costs of preparing, filing, prosecuting and maintaining, 

  
 ***Confidential
Treatment Requested 
  
 10 

 
the patent applications contained in the Princeton Patent Rights, including interferences and oppositions, and all corresponding foreign patent applications and patents incurred prior to the
Effective Date (the “Initial Costs”). Such amount for the Initial Costs shall be due within [...***...] of the Effective Date. Costs of preparing, filing, prosecuting, and maintaining all United States patent applications
and/or patents, including interferences and oppositions, and all corresponding foreign patent applications and patents contained in the Princeton Patent Rights incurred after the Effective Date (“Future Costs”) shall be paid by
BioNanomatrix within [...***...] of receipt of the invoice for such Future Costs. Failure to pay these bills in a timely manner is grounds for terminating the Agreement. After BioNanomatrix has been notified two times of failure to pay bills
in a timely manner, Princeton may terminate the Agreement upon written notice to BioNanomatrix. 
 9.5 Foreign Applications.
Princeton shall, at the request of BioNanomatrix, file, prosecute and maintain patent applications and patents covered by Princeton Patent Rights in foreign countries if available. BioNanomatrix consents to the filing of all PCT and foreign patent
applications that have already been filed as of the Effective Date. If Princeton desires to file a patent application in any country or countries in which BioNanomatrix has not elected to secure patent rights, Princeton shall notify BioNanomatrix of
Princeton’s intention to file such application. BioNanomatrix shall have [...***...] from the receipt of such notice to notify Princeton of BioNanomatrix’s desire to have such patent application filed at BioNanomatrix’s expense.
If Princeton does not receive notice from BioNanomatrix within such 15-day period, Princeton may file such applications, at Princeton’s sole cost and expense and the resultant patent applications, and
resulting patents, shall not be subject to the license agreement. 
 9.6 Discontinuance. BioNanomatrix’s obligation to pay
Future Costs shall continue for so long as this Agreement remains in effect, provided, however, that BioNanomatrix may terminate its obligations with respect to any given patent application or patent upon three months’ written notice to
Princeton. Princeton shall use reasonable efforts to curtail Future Costs when such a notice is received from BioNanomatrix. BioNanomatrix shall promptly pay Future Costs that cannot be so curtailed. Commencing on the effective date of such notice,
Princeton may continue prosecution and/or maintenance of such application(s) or patent(s) at its sole discretion and expense, and BioNanomatrix shall have no further right or licenses thereunder. 

9.7 Recordation. If either Princeton or BioNanomatrix so requests in writing, the parties will promptly file and record with the United
States Patent Office, and with any other applicable patent office or authority, a copy or memorandum of this Agreement and any other agreement granting BioNanomatrix rights in the Invention. 

9.8 Cooperation. Each party shall cooperate with the other party to execute all lawful papers and instruments and to make all rightful
oaths and declarations as may be necessary in the preparation and prosecution of all such patents and other applications and protections referred to in this Article. 

10. Patent Marking. 

  
 ***Confidential
Treatment Requested 
  
 11 

 10.1 Patent Marking. BioNanomatrix shall mark all Licensed Products made, used, sold or
otherwise disposed of under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. 
 11. Patent
Infringement. 
 11.1 Infringement of Invention. 

(a) In the event that Princeton or BioNanomatrix becomes aware of infringement of the Princeton Patent Rights, that party shall notify the
other party in writing within thirty (30) days of becoming aware of such infringement. Any Licensee of the Princeton Patent Rights in other Fields of Use (a “Third-Party Licensee”) will also be notified in writing by Princeton,
subject to the exception set forth in Section 11.1(b) of this Agreement. However, in no event will the Third-Party Licensee be notified of any infringement prior to BioNanomatrix being notified of such infringement. Both parties agree that
during the period after notification of infringement and prior to a decision to commence any legal action against the infringement, neither party will notify the infringing entity or person of the infringement of any of Princeton Patent Rights
without first obtaining consent of the other party, which consent shall not be unreasonably denied. Both parties shall use commercially reasonable efforts in cooperation with each other to attempt to terminate such infringement without litigation.
If Princeton is initially made aware of any infringement of the Princeton Patent Rights by a Third-Party Licensee and Princeton notifies BioNanomatrix of such infringement, BioNanomatrix agrees it will not notify the infringing entity or person of
the infringement of any of Princeton Patent Rights and will use commercially reasonable efforts in cooperation with Princeton and any Third-Party Licensee to attempt to terminate such infringement without litigation. 

(b) In the event that the Third-Party Licensee is the infringer or is materially involved in the infringement of the Princeton Patent Rights,
Princeton shall not notify the Third-Party Licensee of the infringement without first obtaining consent of BioNanomatrix, which consent shall not be unreasonably denied. Furthermore, notwithstanding Section 11.1(c) of this Agreement, the
Third-Party Licensee shall not be allowed to join Princeton or BioNanomatrix in any legal action taken against any infringement of the Princeton Patent Rights when the Third-Party Licensee is the infringer or is materially involved in the
infringement of the Princeton Patent Rights. 
 (c) BioNanomatrix may request that Princeton take legal action against any infringement of
Princeton Patent Rights, including, but not limited to, the filing of a temporary restraining order, a preliminary injunction and/or suit. In the event BioNanomatrix request the filing of a temporary restraining order and/or preliminary injunction,
Princeton will make commercially reasonable efforts to evaluate such request within twenty (20) days of receipt. Such request shall be made in writing and shall include reasonable evidence of such infringement and damages to BioNanomatrix. If
the infringing activity has not been abated within one hundred (100) days following the date of such request, Princeton shall have the right to 

(i) commence suit on its own account; or 

(ii) refuse to participate in such suit; 

  
 12 

 and Princeton shall give notice of its election in writing to BioNanomatrix by the end of the one-hundredth (100th) day after receiving notice of such request to take legal action from BioNanomatrix. If and only if Princeton elects not to commence suit for such infringement, BioNanomatrix may thereafter, but
shall not be obligated to, bring suit for such infringement if the infringement occurred during a period and in a jurisdiction and in a Field of Use where BioNanomatrix had exclusive rights under this Agreement. In the event BioNanomatrix elects to
bring suit in accordance with this paragraph, the parties also acknowledge and agree that any Third- Party Licensee may also join in such a suit at its own expense, subject to the exception set forth in Section 11.1(b) of this Agreement, if the
infringement occurred during a period and in a jurisdiction where the Third-Party Licensee had exclusive rights in the Princeton Patent Rights in other Fields of Use under a License Agreement with Princeton. Furthermore, in the event BioNanomatrix
elects to bring suit in accordance with this paragraph, Princeton may thereafter join such suit at its own expense. 
 (d) Such legal action
as is decided upon shall be at the expense of the party on account of whom suit is brought and all recoveries recovered thereby shall belong to such party, provided, however, that recoveries from legal actions brought jointly by Princeton and
BioNanomatrix, or where any Third-Party Licensee is a party to the suit, shall be shared equally, after paying the reasonable legal expenses of the parties to the suit. The net recoveries shall be divided on a
pro-rata basis among BioNanomatrix, Princeton and any Third-Party Licensee of the Princeton Patent Rights in other fields of use, after reimbursing the participating parties for their own respective
reasonable out-of-pocket expenses, reasonable costs and reasonable legal feesIn the event that the suit is settled prior to a court determination or binding arbitration,
Princeton, BioNanomatrix and any Third-Party Licensee shall divide the net recoveries equally, after reimbursing the participating parties for their own respective reasonable
out-of-pocket expenses, reasonable costs and reasonable legal fees. 

(e) Each party agrees to cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party or parties
bringing the litigation proceedings, on account of whom suit is brought. In the absence of a written agreement to the contrary, such litigation proceedings instituted hereunder shall be controlled by the party initiating the litigation proceeding.
Each party may be represented by counsel of its choice at its own expense. 
 11.2 Infringement of Third Party Rights. BioNanomatrix
shall have the right, but not the obligation, to defend against any claim, complaint, suit, proceeding or cause of action, brought against BioNanomatrix, which claims that use of the Inventions infringes any intellectual property right of any third
party. Princeton agrees to (i) notify BioNanomatrix promptly in writing of any such claim, (ii) permit BioNanomatrix to defend, compromise or settle such claim solely at BioNanomatrix’s discretion, and (iii) provide BioNanomatrix
with reasonably available information and assistance regarding such claim. BioNanomatrix agrees to notify Princeton of any claim and reasonably update Princeton regarding the status of any such claim. 

11.3 Cooperation. Each party agrees to cooperate with the other in litigation proceedings instituted hereunder but at the expense of
the party on account of whom suit is brought. Such litigation shall be controlled by the party bringing the suit. Each party may be represented by counsel of its choice. 

  
 13 

 12. Limited Warranty. 

12.1 Princeton Representations and Warranties. BioNanomatrix hereby acknowledges that the Princeton Patent Rights are currently the
subject of litigation between third parties. BioNanomatrix further acknowledges that a third party may be the sole owner or the joint owner of all or certain portions of the Princeton Patent Rights and that Princeton may not have the right or
ability to grant to BioNanomatrix an exclusive right and license in the Field of Use under the Princeton Patent Rights. In the event it is determined that Princeton has no right or ability to grant to BioNanomatrix an exclusive right and license in
the Field of Use under the Princeton Patent Rights, BioNanomatrix’s sole remedy against Princeton is the return by Princeton and any and all consideration, including, but not limited to, Initial Costs, Future Costs and the payments specified in
Sections 5.1 and 5.2, received from BioNanomatrix for the grant of the license herein. BioNanomatrix waives any and all other damage claims against Princeton, its trustees, officers, agents and employees. Subject to foregoing, Princeton hereby
represents and warrants to BioNanomatrix that: 
 (a) Princeton has the right to grant the licenses granted to BioNanomatrix under this
Agreement; 
 (b) upon execution and delivery of this Agreement, BioNanomatrix shall have the exclusive right and license, except as set
forth herein, to make, have made, use, sell, import and offer to sell the Inventions and the Licensed Products and Services under all of the Patent Rights; 

(c) Princeton is the sole owner of the Inventions by assignment from the Inventors of their entire right, title and interest in the
Inventions; and 
 (d) as of the Effective Date there are no known or pending claims or actions in which Princeton is a named party
regarding the Inventions.. 
 12.2 Disclaimer of Warranties. EXCEPT AS SET FORTH IN SECTION 12.1, THIS LICENSE AND THE ASSOCIATED
INVENTIONS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. PRINCETON MAKES NO REPRESENTATION OR WARRANTY THAT A LICENSED PRODUCT OR LICENSED METHOD WILL NOT INFRINGE ANY
PATENT OR OTHER PROPRIETARY RIGHT. 
 12.3 Limitation of Liability. EXCEPT AS PROVIDED FOR IN SECTION 14.1, IN NO EVENT WILL EITHER
PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR MANUFACTURE, SALE, OR USE OF THE INVENTIONS OR LICENSED PRODUCTS OR LICENSED METHOD. 

12.4 Further Disclaimer of Warranties. Nothing in this Agreement shall be construed as: 

(a) a warranty or representation by Princeton as to the scope of any Princeton Patent Rights; or 

  
 14 

 (b) a warranty or representation that anything made, used, sold or otherwise disposed of under
any license granted in this Agreement is or will be free from infringement of patents or other intellectual property of third parties; or 

(c) an obligation to bring or prosecute actions or suits against third parties except as provided in Section 11; or 

(d) conferring by implication, estoppel or otherwise any license or rights under any patents or other intellectual property of Princeton other
than Princeton Patent Rights as defined herein, regardless of whether such patents are dominant or subordinate to Princeton Patent Rights; or 

(e) an obligation to furnish any know-how not provided in the Princeton Patent Rights; it being
understood that BioNanomatrix may use, in the Field of Use on a nonexclusive basis, all know-how owned or controlled by Princeton within the Princeton Patent Rights and within the Field of Use and possessed by
its consultants and employees currently or previously employed by Princeton that is not covered by any other Princeton patent rights or to which Princeton does not owe a third party an exclusive right to use. 

13. Term and Termination. 
 13.1
Term. Unless otherwise terminated by operation of law or by acts of the parties in accordance with the provisions of this Agreement, this Agreement shall be in full force and effect from the Effective Date and shall remain in effect in each
country of the Territory until the later of (a) the last sale of a Licensed Product or Service or (b) the expiration of all of the Princeton Patent Rights. 

13.2 Termination by BioNanomatrix. BioNanomatrix may terminate this Agreement at any time upon sixty (60) days written notice to
Princeton. 
 13.3 Termination by Princeton. The failure by BioNanomatrix to comply with any of the material obligations contained in
this Agreement shall entitle Princeton to give written notice to BioNanomatrix to have the default cured. If such default is not cured within sixty (60) days after the receipt of such notice, or diligent steps are not taken to cure if by its
nature such default could not be cured within sixty (60) days, Princeton shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies that may be available to it, to
terminate this Agreement. 
 13.4 Survival of Obligations. The termination or expiration of this Agreement shall not relieve the
parties of any obligations accruing prior to such termination, and any such termination shall be without prejudice to the rights of either party against the other. The provisions of Sections 4, 6.10, 7, 8, 12, 13, 14 and 15 shall survive any
termination of this Agreement. 
 13.5 Section 365(n). BioNanomatrix and Princeton acknowledge that the rights granted to
BioNanomatrix under this Agreement shall be considered “rights to intellectual property” under Section 365(n) of the United States Bankruptcy Act. 

  
 15 

 14. Indemnification; Insurance. 

14.1 Indemnification by BioNanomatrix. BioNanomatrix will indemnify and hold harmless Princeton, its trustees, officers, agents and
employees (collectively, the “Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense suffered or incurred by the Indemnified Parties (including reasonable attorneys’ fees)
(individually, a “Liability” and collectively, the “Liabilities”) which result from or arise out of the development, use, manufacture, promotion, sale, distribution or other disposition of any Licensed Products or
Services by BioNanomatrix, its Affiliates, assignees, vendors or other third parties, including all claims for personal injury, including death, or property damage arising from any of the foregoing, except to the extent such claims result from the
willful misconduct of the Indemnified Parties. This indemnification shall include, but not be limited to, any and all claims relating to products liability and any and all claims or suits for which either party is found to have been wholly or
partially negligent. 
 14.2 Insurance. Before the first commercial sale of a Licensed Product or Service and thereafter,
BioNanomatrix will maintain general liability insurance covering all claims, including products liability, which policy shall i) be in such form and amount of coverage and written by such company as is reasonable and customary in the industry but in
no case less than $1,000,000 per occurrence, ii) provide that such policy is primary and not excess or contributory with regard to other insurance Princeton may have, iii) provide at least thirty (30) days’ notice to Princeton of
cancellation, and iv) include Princeton and Princeton’s directors, officers and employees, as additional named insureds. BioNanomatrix will furnish Princeton, upon request, written confirmation issued by the insurer or any independent insurance
agent confirming that insurance is maintained in accordance with the above requirements. 
 15. Miscellaneous Provisions. 

15.1 Assignment. No rights under this Agreement may be assigned by either party without the express consent of the other; provided,
however, BioNanomatrix may, upon prior notice to Princeton, sublicense, assign or otherwise transfer this Agreement, without Princeton’s consent, to (i) a purchaser of all or substantially all of BioNanomatrix’s stock or assets or the
line of business to which the agreement relates, provided that such purchaser, agrees in writing to be bound by the terms of this Agreement. 

15.2 Export Controls. It is understood that Princeton is subject to United States laws and regulations controlling the export of
technical data, computer software, laboratory prototypes and other commodities (including the Arms Export Control Act, as amended, and the Export Administration Act of 1979), and that its obligations hereunder are contingent on compliance with
applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by BioNanomatrix that
BioNanomatrix shall not export data or commodities to certain foreign countries without prior approval of such agency. Princeton neither represents that a license shall not be required nor that, if required, it shall be issued. 

  
 16 

 15.3 Payment, Notices and Other Communications. Any notice or payment required to be given
to either party shall be deemed to have been properly given and to be effective (a) on the date of delivery if delivered in person, (b) five (5) business days after mailing if mailed by first-class certified mail, postage paid and
deposited in the United States mail, or (c) the next business day if sent by recognized overnight courier, to the respective addresses given below, or to such other address as it shall designate by written notice given to the other party. 

In the case of Princeton: 

Office of Technology Licensing & Intellectual Property 

Princeton University 
 4 New
South Building, P.O. Box 36 
 Princeton, New Jersey 08544 

Fax: (609) 258-1159 

Phone: (609) 258-1570 

In case of BioNanomatrix: 
 Han
Cao, Ph.D. 
 1131 Great Road (PO Box 75) 

Blawenburg, NJ 08504 
 With a
copy to 
 Unus LLC 
 2800
Highland Court South 
 Birmingham, Alabama 35205 

Fax: (205) 933-9668 

Phone: (205) 933-9137 

or to such other address or addresses as may from time to time be given in writing by either party to the other pursuant to the terms hereof. 

15.4 Governing Law. This Agreement shall be construed, governed, interpreted and applied in accordance with the laws of the State of
New Jersey, without giving effect to its choice of law provisions; except, however, that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent was granted. 

15.5 Entire Agreement. This Agreement and its Exhibits constitute and contain the entire understanding and agreement of the parties
respecting the subject matter of this Agreement and cancels and supersedes any all prior negotiations, correspondence, understandings and agreements between the parties, whether oral or written, regarding such subject matter. 

15.6 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as
may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  
 17 

 15.7 Severability. If any provision of this Agreement becomes or is declared by a court of
competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision, so long as the Agreement, taking into account said voided provision(s), continues to provide the parties with
the same practical economic benefits as the Agreement containing said voided provision(s) did on the date of this Agreement. If, after taking into account said voided provision(s), the parties are unable to realize the practical economic benefit
contemplated on the Effective Date, the parties shall negotiate in good faith to amend this Agreement to reestablish the practical economic benefit provided the parties on the Effective Date. 

15.8 No Waiver. The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this
Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. 

15.9 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs,
successors and assigns, except that Princeton shall not have the right to delegate its obligations hereunder or to assign its rights hereunder or any interest herein without the prior written consent of BioNanomatrix. 

15.10 Amendment. No amendment or modification hereof shall be valid or binding upon the parties unless made in writing and signed on
behalf of each party. 
 15.11 Headings. The captions to the sections in this Agreement are not a part of this Agreement, and are
included merely for convenience of reference only and shall not affect its meaning or interpretation. 
 15.12 Force Majeure. The
failure of a party to perform any obligation under this Agreement by reason of acts of God, acts of governments, riots, wars, strikes, accidents or deficiencies in materials or transportation or other causes of a similar magnitude beyond its control
shall not be deemed to be a breach of this Agreement. 
 15.13 Relationship of the Parties. Nothing contained in this Agreement is
intended nor is to be construed so as to constitute Princeton or BioNanomatrix as partners or joint venturers with respect to any of the transactions or business activities described in this Agreement or to be undertaken by BioNanomatrix. Neither
party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or undertaking with any third party. 

Counterparts. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument,
and any of the parties hereto may execute this Agreement by signing any such counterpart. 
 [SIGNATURE PAGE FOLLOWS] 

  
 18 

 IN WITNESS WHEREOF, the parties hereto have hereunto set their hands and seals and duly executed
this License Agreement as of the Effective Date. 
  

			
	THE TRUSTEES OF PRINCETON UNIVERSITY
		
	By:	 	/s/ Michelle D. Christy
		 	Name: Michelle D. Christy
		 	 Title: Director, Office of Research and Project

          Administration

  

			
	BIONANOMATRIX LLC
		
	By:	 	/s/ Han Cao
		 	Name: Dr. Han Cao, PhD.
		 	Title: CEO

  

			
	READ AND UNDERSTOOD
		
	By:	 	/s/ [...***...]
		 	Name: [...***...]
		 	Title: Inventor

  
 ***Confidential
Treatment Requested 
  
 19 

 EXHIBIT A  

Inventions and Inventors 

Inventions: 
 [...***...],
generally characterized as [...***...], [...***...], [...***...], and [...***...], respectively. 
 Inventors: 

[...***...] 

[...***...] 

[...***...] 

[...***...] 

[...***...] 

  
 ***Confidential
Treatment Requested 
  
 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]